Additional O
iron B-drug
significantly O
inhibited O
the O
absorption O
of O
cobalt B-drug
in O
both O
dietary O
cobalt B-drug
treatments O
. O

It O
is O
not O
clear O
whether O
this O
was O
due O
to O
the O
combination O
of O
therapy O
. O

increased O
creatine O

A O
number O
of O
substances O
affect O
glucose O
metabolism O
and O
may O
require O
insulin B-drug
dose O
adjustment O
and O
particularly O
close O
monitoring O
. O

Beta-adrenergic B-group
receptor I-group
antagonists I-group
( O
beta-blockers B-group
) O
and O
BROVANA B-brand
may O
interfere O
with O
the O
effect O
of O
each O
other O
when O
administered O
concurrently O
. O

Based O
on O
the O
chemical O
resemblance O
of O
itraconazole B-drug
and O
ketoconazole B-drug
, O
coadministration O
of O
astemizole B-drug
with O
itraconazole B-drug
is O
contraindicated O
. O

Unless O
really O
needed O
, O
agents O
which O
may O
enhance O
the O
risk O
of O
hemorrhage O
should O
be O
discontinued O
prior O
to O
initiation O
of O
Lovenox B-brand
Injection O
therapy O
. O

With O
the O
morning O
dose O
of O
ceftibuten B-drug
on O
day O
6 O
, O
each O
volunteer O
received O
a O
single O
intravenous O
infusion O
of O
theophylline B-drug
( O
4 O
mg/kg O
) O
. O

Ways O
of O
improving O
the O
adequacy O
of O
the O
treatment O
of O
psychotic O
patients O
with O
neuroleptics B-group
are O
discussed O
. O

May O
interact O
with O
wthionamide O
( O
Trecator-SC B-brand
) O
and O
isoniazid B-drug
( O
Nydrazid B-brand
) O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

Methadone B-drug
: O
Coadministration O
of O
amprenavir B-drug
and O
methadone B-drug
can O
decrease O
plasma O
levels O
of O
methadone B-drug
. O

N-methyllevallorphan B-drug_n
( O
5 O
mg/kg O
, O
s.c O
. O
) O

Studies O
showed O
that O
diltiazem B-drug
increased O
the O
AUC O
of O
midazolam B-drug
and O
triazolam B-drug
by O
3-4 O
fold O
and O
the O
Cmax O
by O
2-fold O
, O
compared O
to O
placebo O
. O

AMEVIVE B-brand
is O
not O
indicated O
for O
pediatric O
patients O
. O

If O
pregnancy O
occurs O
in O
a O
patient O
or O
partner O
of O
a O
patient O
during O
treatment O
or O
during O
the O
6 O
months O
after O
treatment O
cessation O
, O
such O
cases O
should O
be O
reported O
to O
the O
COPEGUS B-brand
Pregnancy O
Registry O
at O
1-800-526-6367 O
. O

. O

Steady-state O
bosentan B-drug
plasma O
concentrations O
were O
3- O
to O
4-fold O
higher O
than O
in O
the O
absence O
of O
cyclosporine B-drug
A I-drug
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

Therefore O
, O
it O
should O
be O
used O
in O
caution O
in O
patients O
receiving O
such O
agents O
. O

this O
did O
not O
interfere O
with O
its O
effect O
. O

Based O
on O
the O
results O
of O
these O
studies O
, O
it O
is O
concluded O
that O
azithromycin B-drug
may O
be O
safely O
coadministered O
with O
both O
zidovudine B-drug
and O
dideoxyinosine B-drug
. O

Hypotension O
- O
Patients O
on O
Diuretic O
Therapy O
: O
Patients O
on O
diuretics B-group
, O
and O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
PRINIVIL B-brand
. O

Metformin B-drug
: O
In O
a O
single-dose O
interaction O
study O
in O
NIDDM O
subjects O
, O
decreases O
in O
glyburide B-drug
AUC O
and O
Cmax O
were O
observed O
, O
but O
were O
highly O
variable O
. O

. O

The O
bioavailability O
of O
the O
capsule O
formulation O
of O
cefprozil B-drug
was O
not O
affected O
when O
administered O
5 O
minutes O
following O
an O
antacid B-group
. O

Therefore O
, O
when O
using O
these O
blocking O
agents O
to O
treat O
hypertension O
, O
patients O
should O
be O
observed O
carefully O
in O
order O
to O
confirm O
that O
the O
desired O
therapeutic O
effect O
has O
been O
obtained O
. O

This O
interaction O
was O
not O
accompanied O
by O
ECG O
changes O
and O
its O
clinical O
significance O
is O
not O
known O
. O

Veratrum B-group
alkaloids I-group
: O
Amphetamines B-group
inhibit O
the O
hypotensive O
effect O
of O
veratrum B-group
alkaloids I-group
. O

aBased O
on O
reports O
of O
narcotic O
withdrawal O
syndrome O
in O
patients O
treated O
with O
nevirapine B-drug
and O
methadone B-drug
concurrently O
, O
and O
evidence O
of O
decreased O
plasma O
concentrations O
of O
methadone B-drug
. O

The O
administration O
of O
naproxen B-drug
may O
result O
in O
increased O
urinary O
values O
for O
17-ketogenic O
steroids O
because O
of O
an O
interaction O
between O
the O
drug O
and/or O
its O
metabolites O
with O
m-dinitrobenzene O
used O
in O
this O
assay O
. O

these O
enzymes O
would O
therefore O
not O
be O
expected O
to O
be O
inhibited O
in O
clinical O
use O
. O

The O
reduced O
risk O
of O
adverse O
events O
and O
therapeutic O
superiority O
compared O
with O
haloperidol B-drug
and O
risperidone B-drug
in O
the O
treatment O
of O
negative O
and O
depressive O
symptoms O
support O
the O
choice O
of O
olanzapine B-drug
as O
a O
first-line O
option O
in O
the O
management O
of O
schizophrenia O
in O
the O
acute O
phase O
and O
for O
the O
maintenance O
of O
treatment O
response O
. O

In O
a O
study O
of O
12 O
schizophrenic O
patients O
coadministered O
oral O
haloperidol B-drug
and O
rifampin B-drug
, O
plasma O
haloperidol B-drug
levels O
were O
decreased O
by O
a O
mean O
of O
70 O
% O
and O
mean O
scores O
on O
the O
Brief O
Psychiatric O
Rating O
Scale O
were O
increased O
from O
baseline O
. O

Co-administration O
with O
antifungal B-group
agents I-group
such O
as O
ketoconazole B-drug
or O
itraconazole B-drug
is O
not O
recommended O
. O

Leucovorin B-drug
may O
enhance O
the O
toxicity O
of O
5-fluorouracil B-drug
. O

Laboratory O
Tests O
Pregnancy O
Test O
Female O
patients O
of O
childbearing O
potential O
must O
have O
negative O
results O
from O
2 O
urine O
or O
serum O
pregnancy O
tests O
with O
a O
sensitivity O
of O
at O
least O
25 O
mIU/mL O
before O
receiving O
the O
initial O
Accutane B-brand
prescription O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

Mineral B-drug
oil I-drug
interferes O
with O
the O
absorption O
of O
fat-soluble B-group
vitamins I-group
, O
including O
vitamin B-group
D I-group
preparations I-group
. O

Digoxin B-drug
half-life O
of O
elimination O
was O
prolonged O
from O
34 O
+/- O
13 O
to O
40 O
+/- O
16 O
hours O
( O
p O
less O
than O
0.05 O
) O
. O

Therefore O
, O
based O
on O
these O
in O
vitro O
data O
, O
estazolam B-drug
is O
very O
unlikely O
to O
inhibit O
the O
biotransformation O
of O
other O
drugs O
metabolized O
by O
these O
CYP O
isoforms O

The O
biochemical O
toxicology O
of O
1,3-difluoroacetone B-drug_n
, O
a O
known O
metabolite O
of O
the O
major O
ingredient O
of O
the O
pesticide O
Gliftor B-drug_n
( O
1,3-difluoro-2-propanol B-drug_n
) O
, O
was O
investigated O
in O
vivo O
and O
in O
vitro O
. O

No O
pharmacokinetic O
interaction O
was O
identified O
. O

Alprazolam B-drug
: O
When O
fluvoxamine B-drug
maleate I-drug
( O
100 O
mg O
qd O
) O
and O
alprazolam B-drug
( O
1 O
mg O
q.d O
. O
were O
co-administered O
to O
steady O
state O
, O
plasma O
concentration O
and O
other O
pharmacokinetics O
parameters O
( O
AUC O
, O
Cmax O
, O
T1/2 O
, O
) O
of O
alprazolam B-drug
were O
approximately O
twice O
those O
observed O
when O
alprazolam B-drug
was O
administered O
alone O
; O

Drug/Laboratory O
Test O
Interactions O
No O
clinically O
significant O
changes O
in O
the O
results O
of O
clinical O
laboratory O
tests O
have O
been O
observed O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
blood O
glucose O
control O
. O

These O
compounds O
are O
metabolized O
through O
various O
cytochrome O
P450 O
isozymes O
including O
CYP1A2 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
and O
CYP3A O
. O

Efavirenz B-drug

The O
pharmacokinetics O
of O
fenofibric B-drug_n
acid I-drug_n
were O
not O
significantly O
affected O
by O
atorvastatin B-drug

Acebutolol B-drug
, O
atenolol B-drug
, O
and O
nadolol B-drug
( O
low O
hepatic O
clearance O
or O
no O
first-pass O
metabolism O
) O
are O
unlikely O
to O
be O
affected O
. O

The O
drugs O
that O
inhibit O
cytochrome O
P450 O
2D6 O
include O
some O
that O
are O
not O
metabolized O
by O
the O
enzyme O
( O
quinidine B-drug
; O

Drugs O
Demonstrated O
to O
be O
CYP O
3A O
Inhibitors O
of O
Possible O
Clinical O
Significance O
on O
the O
Basis O
of O
Clinical O
Studies O
Involving O
Alprazolam B-drug
( O
caution O
is O
recommended O
during O
coadministration O
with O
alprazolam B-drug
) O
: O
Coadministration O
of O
fluoxetine B-drug
with O
alprazolam B-drug
increased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-drug
by O
46 O
% O
, O
decreased O
clearance O
by O
21 O
% O
, O
increased O
half-life O
by O
17 O
% O
, O
and O
decreased O
measured O
psychomotor O
performance O
. O

The O
serum O
androgen O
concentrations O
of O
estradiol B-drug
+ O
endotoxin-treated B-drug_n
rats O
did O
not O
change O
significantly O
, O
while O
those O
of O
endotoxin-treated B-drug_n
rats O
dropped O
to O
30-40 O
% O

The O
mechanism O
for O
this O
interaction O
is O
unknown O
. O

Sucralfate B-drug
should O
not O
be O
taken O
within O
2 O
hours O
of O
FACTIVE B-brand
. O

Diltiazem B-drug
, O
nifedipine B-drug
, O
verapamil B-drug

In O
contrast O
, O
atropine B-drug
increased O
the O
amplitudes O
of O
components O
P1 O
and O
P2 O
, O
while O
decreasing O
components O
N1 O
, O
N2 O
and O
N3 O
for O
varying O
durations O
of O
time O
. O

Clindamycin B-drug
has O
been O
shown O
to O
have O
neuromuscular O
blocking O
properties O
that O
may O
enhance O
the O
action O
of O
other O
neuromuscular B-group
blocking I-group
agents I-group
. O

No O
drug O
interactions O
of O
clinical O
importance O
have O
been O
identified O
. O

Prior O
administration O
of O
succinylcholine B-drug
has O
no O
clinically O
important O
effect O
on O
the O
neuromuscular O
blocking O
action O
of O
NUROMAX B-brand
. O

Imipramine B-drug
hydrochloride I-drug
may O
potentiate O
the O
effects O
of O
CNS B-group
depressant I-group
drugs I-group
. O

SUSTIVA B-brand
has O
the O
potential O
to O
decrease O
plasma O
concentrations O
of O
itraconazole B-drug
and O
ketoconazole B-drug
. O

Since O
symptoms O
of O
anticholinesterase O
overdose O
( O
cholinergic O
crisis O
) O
may O
mimic O
underdosage O
( O
myasthenic O
weakness O
) O
, O
their O
condition O
may O
be O
worsened O
by O
the O
use O
of O
this O
drug O
. O

Since O
the O
effect O
of O
AMEVIVE B-brand
on O
pregnancy O
and O
fetal O
development O
, O
including O
immune O
system O
development O
, O
is O
not O
known O
, O
health O
care O
providers O
are O
encouraged O
to O
enroll O
patients O
currently O
taking O
AMEVIVE B-brand
who O
become O
pregnant O
into O
the O
Biogen O
Pregnancy O
Registry O
by O
calling O
1-866-AMEVIVE B-brand
( O
1-866-263-8483 O
) O
. O

Myocardial O
injury O
, O
including O
myocardial O
infarction O
, O
myocarditis O
, O
ventricular O
hypokinesia O
, O
and O
severe O
rhabdomyolysis O
appear O
to O
be O
increased O
in O
patients O
receiving O
PROLEUKIN B-brand
and O
interferon-alfa B-drug
concurrently O
. O

In O
comparison O
to O
saline O
values O
, O
all O
three O
agents O
produced O
reliable O
increases O
in O
peak O
latency O
for O
most O
of O
the O
components O
, O
with O
only O
N3 O
showing O
no O
effects O
. O

Understanding O
the O
breadth O
of O
systemic O
antimicrobial B-group
agents I-group
available O
for O
use O
by O
the O
dermatologist O
and O
their O
associated O
side-effect O
profiles O
and O
drug O
interactions O
allows O
the O
clinician O
to O
offer O
patients O
optimal O
care O
in O
the O
management O
of O
cutaneous O
infectious O
disease O
. O

Studies O
in O
humans O
show O
that O
the O
absorption O
of O
chlorothiazide B-drug
as O
reflected O
in O
urinary O
excretion O
is O
markedly O
decreased O
even O
when O
administered O
one O
hour O
before O
colestipol B-drug
hydrochloride I-drug
. O

Anticoagulants B-group
( O
Oral O
) O
: O
The O
hypoprothrombinemic O
effect O
of O
anticoagulants B-group
may O
be O
potentiated O
, O
apparently O
by O
increased O
catabloism O
of O
vitamin O
K-dependent O
clotting O
factors O
. O

Boric B-drug
acid I-drug
may O
interact O
with O
the O
idoxuridine B-drug
preparation O
causing O
a O
gritty O
substance O
to O
form O
or O
may O
interact O
with O
the O
preservative O
in O
the O
idoxuridine B-drug
preparation O
causing O
a O
toxic O
effect O
in O
the O
eye O
. O

Although O
inhibition O
of O
CYP O
3A4/5 O
by O
OXC B-drug
and O
MHD B-drug_n
did O
occur O
at O
high O
concentrations O
, O
it O
is O
not O
likely O
to O
be O
of O
clinical O
significance O
. O

The O
dosage O
of O
these O
drugs O
or O
others O
with O
a O
similar O
metabolism O
may O
need O
to O
be O
modified O
if O
they O
are O
administered O
concomitantly O
with O
nilutamide B-drug
. O

Lastly O
local O
use O
of O
the O
mucocutaneous O
and O
cytoprotective O
properties O
of O
magnesium B-drug
is O
still O
valid O
, O
in O
cardioplegic B-drug
solutions I-drug
and O
for O
preservation O
of O
transplants O
particularly O
. O

Furosemide B-drug
may O
decrease O
arterial O
responsiveness O
to O
norepinephrine B-drug
. O

efavirenz I-drug
concentration O

In O
a O
Phase O
I O
trial O
using O
escalating O
doses O
of O
TAXOL B-brand
( O
110-200 O
mg/m2 O
) O
and O
cisplatin B-drug
( O
50 O
or O
75 O
mg/m2 O
) O
given O
as O
sequential O
infusions O
, O
myelosuppression O
was O
more O
profound O
when O
TAXOL B-brand
was O
given O
after O
cisplatin B-drug
than O
with O
the O
alternate O
sequence O
( O
ie O
, O
TAXOL B-brand
before O
cisplatin B-drug
) O
. O

-adrenergic O
Blockers O
: O
-adrenergic O
blockers O
may O
weaken O
or O
antagonise O
the O
effect O
of O
FORADIL B-brand
. O

The O
key O
to O
maximizing O
therapy O
lies O
in O
individualizing O
it O
as O
much O
as O
possible O
. O

In O
clinical O
studies O
with O
PROPECIA B-brand
( O
finasteride B-drug
, O
1 O
mg O
) O
in O
men O
18-41 O
years O
of O
age O
, O
the O
mean O
value O
of O
serum O
prostate-specific O
antigen O
( O
PSA O
) O
decreased O
from O
0.7 O
ng/mL O
at O
baseline O
to O
0.5 O
ng/mL O
at O
Month O
12 O
. O

The O
patient O
had O
been O
receiving O
simvastatin B-drug
for O
approximately O
six O
months O
. O

Ergot-containing B-group
drugs O
have O
been O
reported O
to O
cause O
prolonged O
vasospastic O
reactions O
. O

Poor O
metabolizers O
have O
higher O
than O
expected O
lasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

The O
concomitant O
use O
of O
alcohol B-drug
or O
other O
central B-group
nervous I-group
system I-group
depressants I-group
may O
have O
an O
additive O
effect O
. O

Antiarrhythmics B-drug
: O
Other O
antiarrhythmic B-drug
drugs O
, O
such O
as O
quinidine B-drug
, O
procainamide B-drug
, O
disopyramide B-drug
, O
and O
phenytoin B-drug
, O
have O
been O
used O
concurrently O
with O
amiodarone B-drug
. O

However O
, O
because O
nafarelin B-drug
acetate I-drug
is O
a O
peptide O
that O
is O
primarily O
degraded O
by O
peptidase O
and O
not O
by O
cytochrome O
P-450 O
enzymes O
, O
and O
the O
drug O
is O
only O
about O
80 O
% O
bound O
to O
plasma O
proteins O
at O
4 O
C O
, O
drug O
interactions O
would O
not O
be O
expected O
to O
occur O
. O

However O
, O
since O
there O
is O
an O
increased O
risk O
of O
bleeding O
with O
Xigris B-brand
, O
caution O
should O
be O
employed O
when O
Xigris B-brand
is O
used O
with O
other O
drugs O
that O
affect O
hemostasis O
. O

In O
addition O
, O
new O
cases O
of O
diabetes O
have O
been O
diagnosed O
during O
retinoid B-group
therapy O
, O
including O
diabetic O
ketoacidosis O
. O

On O
the O
contrary O
, O
neurotensin B-drug_n
and O
tuftsin B-drug_n
were O
agonists O
in O
induction O
of O
analgesia O
. O

A O
chemically O
similar O
drug O
in O
this O
class O
produced O
optic O
nerve O
degeneration O
( O
Wallerian O
degeneration O
of O
retinogeniculate O
fibers O
) O
in O
clinically O
normal O
dogs O
in O
a O
dose-dependent O
fashion O
at O
a O
dose O
that O
produced O
plasma O
drug O
levels O
about O
30 O
times O
higher O
than O
the O
mean O
drug O
level O
in O
humans O
taking O
the O
highest O
recommended O
dose O
. O

- O
Furazolidone B-drug
( O
e.g. O
, O
Furoxone B-brand
) O
or O

Concomitant O
administration O
of O
diltiazem B-drug
with O
carbamazepine B-drug
has O
been O
reported O
to O
result O
in O
elevated O
serum O
levels O
of O
carbamazepine B-drug
( O
40 O
% O
to O
72 O
% O
increase O
) O
, O
resulting O
in O
toxicity O
in O
some O
cases O
. O

In O
single O
and O
multiple O
dose O
studies O
in O
healthy O
subjects O
receiving O
both O
warfarin B-drug
and O
rofecoxib B-drug
, O
prothrombin O
time O
( O
measured O
as O
INR O
) O
was O
increased O
by O
approximately O
8 O
% O
to O
11 O
% O
. O

Pharmacokinetic O
studies O
indicate O
that O
administration O
of O
disulfiram B-drug
or O
diazepam B-drug
does O
not O
affect O
the O
pharmacokinetics O
of O
acamprosate B-drug
. O

Therefore O
, O
agents O
affecting O
sympathetic O
activity O
( O
e.g. O
, O
ganglionic B-group
blocking I-group
agents I-group
or O
adrenergic B-group
neuron I-group
blocking I-group
agents I-group
) O
should O
be O
used O
with O
caution O
. O

Reports O
in O
the O
literature O
suggest O
that O
plasma O
levels O
of O
doxorubicin B-drug
( O
and O
its O
active O
metabolite O
doxorubicinol B-drug_n
) O
may O
be O
increased O
when O
paclitaxel B-drug
and O
doxorubicin B-drug
are O
used O
in O
combination O
. O

The O
concomitant O
use O
of O
H2 B-group
blockers I-group
or O
proton B-group
pump I-group
inhibitors I-group
with O
SPRYCEL B-brand
is O
not O
recommended O
. O

The O
results O
indicate O
that O
a O
statistically O
significant O
difference O
exists O
between O
the O
excreted O
levels O
of O
homocysteine O
in O
the O
urine O
of O
both O
control O
and O
levonorgestrel-treated B-drug
rats O
and O
the O
levels O
shown O
by O
rats O
treated O
with O
ethynyl B-drug
estradiol I-drug
. O

The O
IV O
methylprednisolone B-drug
dose O
should O
be O
reduced O
by O
approximately O
25 O
% O
, O
and O
the O
oral O
methylprednisolone B-drug
dose O
should O
be O
reduced O
by O
approximately O
50 O
% O
when O
coadministered O
with O
Aprepitant B-drug
to O
achieve O
exposures O
of O
methylprednisolone B-drug
similar O
to O
those O
obtained O
when O
it O
is O
given O
without O
Aprepitant B-drug
. O

Simultaneous O
use O
of O
activated B-group
prothrombin I-group
complex I-group
concentrates I-group
or O
prothrombin B-group
complex I-group
concentrates I-group
should O
be O
avoided O
. O

Digoxin B-drug
did O
not O
affect O
BREVIBLOC B-brand
pharmacokinetics O
. O

Urinary B-drug
acidifying I-drug
agents O
decrease O
blood O
levels O
and O
increase O
excretion O
of O
amphetamines B-group
. O

Antibiotics B-group
( O
ampicillin B-drug
, O
tetracycline B-drug
) O
: O
Pregnancy O
has O
been O
reported O
following O
concomitant O
use O
, O
however O
, O
pharmacokinetic O
studies O
have O
not O
shown O
consistent O
effects O
with O
these O
antibiotics B-group
on O
plasma O
concentrations O
of O
synthetic B-group
steroids I-group
. O

The O
second O
pregnancy O
test O
( O
a O
confirmation O
test O
) O
should O
be O
done O
during O
the O
first O
5 O
days O
of O
the O
menstrual O
period O
immediately O
preceding O
the O
beginning O
of O
Accutane B-brand
therapy O
. O

However O
, O
total O
mucosal O
accumulation O
of O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
and O
that O
transferred O
to O
the O
body O
increase O
in O
a O
linear O
logarithmic O
fashion O
from O
0.05 O
to O
5 O
mm O
As B-drug_n
( I-drug_n
V I-drug_n
) I-drug_n
. O

Information O
on O
concurrent O
usage O
of O
atenolol B-drug
and O
aspirin B-brand
is O
limited O
. O

In O
order O
to O
avoid O
the O
occurrence O
of O
severe O
hypersensitivity O
reactions O
, O
all O
patients O
treated O
with O
TAXOL B-brand
should O
be O
premedicated O
with O
corticosteroids B-group
( O
such O
as O
dexamethasone B-drug
) O
, O
diphen-hydramine O
and O
H2 B-group
antagonists I-group
( O
such O
as O
cimetidine B-drug
or O
ranitidine B-drug
) O
. O

Patients O
in O
a O
clinical O
study O
who O
were O
on O
established O
therapy O
with O
sulfasalazine B-drug
, O
to O
which O
ENBREL B-brand
was O
added O
, O
were O
noted O
to O
develop O
a O
mild O
decrease O
in O
mean O
neutrophil O
counts O
in O
comparison O
to O
groups O
treated O
with O
either O
ENBREL B-brand
CI O
or O
sulfasalazine B-drug
alone O
. O

It O
is O
concluded O
from O
these O
results O
that O
the O
modulatory O
effect O
of O
glycine B-drug
is O
evidently O
a O
later O
developmental O
acquisition O
( O
after O
day O
15 O
of O
incubation O
) O
in O
the O
embryogenesis O
of O
NMDA-ergic O
activation O
of O
spontaneous O
motility O
in O
chick O
embryos O
similarly O
as O
glycinergic O
inhibition O
. O

If O
TRANXENE B-brand
is O
to O
be O
combined O
with O
other O
drugs O
acting O
on O
the O
central O
nervous O
system O
, O
careful O
consideration O
should O
be O
given O
to O
the O
pharmacology O
of O
the O
agents O
to O
be O
employed O
. O

Plasma O
concentrations O
of O
cyclosporine B-drug
should O
therefore O
be O
closely O
monitored O
, O
and O
its O
dosage O
reduced O
accordingly O
, O
in O
patients O
treated O
with O
nicardipine B-drug
. O

Excessive O
ethanol B-drug
ingestion O
should O
be O
avoided O
because O
a O
psychotic O
reaction O
has O
been O
reported O
. O

There O
is O
thus O
an O
enhancement O
effect O
of O
PGF2alpha B-drug
upon O
the O
reaction O
of O
placental O
vessels O
to O
oxytocin B-drug
in O
vitro O
. O

Azithromycin B-drug

or O
- O
over-the-counter O
cough O
, O
cold O
, O
allergy O
, O
or O
weight O
loss O
medications O
. O

DESIGN O
: O
Open-label O
, O
three-phase O
, O
sequential O
study O
. O

Adenosine B-drug
effects O
are O
potentiated O
by O
dipyridamole B-drug
. O

Aerosol O
particles O
of O
budesonide B-drug
were O
generated O
from O
an O
ethanol B-drug
solution O
, O
dried O
, O
and O
collected O
by O
a O
cascade O
impactor O
for O
characterization O
or O
by O
a O
liquid O
impinger O
for O
dissolution O
experiments O
. O

Colestipol B-drug

STUDY O
OBJECTIVE O
: O
To O
evaluate O
the O
effect O
of O
fluoxetine B-drug
on O
the O
pharmacokinetics O
and O
cardiovascular O
safety O
of O
cisapride B-drug
at O
steady O
state O
in O
healthy O
men O
. O

However O
, O
current O
evidence O
suggests O
that O
isoniazid B-drug
does O
induce O
P-450IIE1 O
, O
a O
mixed-function O
oxidase O
enzyme O
that O
appears O
to O
generate O
the O
toxic O
metabolites O
, O
in O
the O
liver O
. O

Nelfinavir B-drug
is O
an O
inhibitor O
of O
CYP3A O
( O
cytochrome O
P450 O
3A O
) O
. O

The O
vasodilating O
effects O
of O
nitroglycerin B-drug
may O
be O
additive O
with O
those O
of O
other O
vasodilators B-group
. O

The O
hatching O
of O
miracidia O
from O
eggs O
was O
inhibited O
by O
concentrations O
of O
1000-10000 O
microg/l O
of O
single O
metals O
. O

Phenytoin B-drug
decreases O
serum O
amiodarone O
levels O
. O

The O
effect O
of O
orally O
ingested O
peginterferon B-drug
or O
ribavirin B-drug
from O
breast O
milk O
on O
the O
nursing O
infant O
has O
not O
been O
evaluated O
. O

Vardenafil B-drug
dose O
should O
not O
exceed O
a O
maximum O
of O
2.5 O
mg O
in O
a O
24-hour O
period O
in O
patients O
receiving O
concomitant O
indinavir B-drug
therapy O
. O

therefore O
, O
caution O
should O
be O
used O
when O
administering O
CYP3A4 O
inhibitors O
with O
IRESSA B-brand
. O

Therefore O
, O
the O
simultaneous O
administration O
of O
these O
drugs O
should O
be O
avoided O
. O

Non-selective B-group
MAO I-group
inhibitors I-group
including O
tranylcypromine B-drug
sulfate I-drug
, O
phenelzine B-drug
sulfate I-drug
, O
and O
pargyline B-drug
HC1 O
: O
Concomitant O
use O
of O
L-tyrosine B-drug
and O
non-selective O
MAO B-group
inhibitors I-group
may O
cause O
hypertension O
. O

Acetaminophen B-drug
had O
no O
effect O
on O
plasma O
levels O
of O
diflunisal B-drug
. O

However O
, O
in O
patients O
treated O
with O
oral O
carbonic B-group
anhydrase I-group
inhibitors I-group
, O
rare O
instances O
of O
drug O
interactions O
have O
occurred O
with O
high-dose O
salicylate B-drug
therapy O
. O

Immunosuppressive B-group
Drugs I-group
, O
Fibric B-group
Acid I-group
Derivatives I-group
, O
Niacin B-drug
( O
Nicotinic B-drug
Acid I-drug
, O
Erythromycin B-drug
, O
Azole B-group
Antifungals I-group
: O
Skeletal O
Muscle O
. O

Further O
, O
these O
results O
confirm O
that O
the O
diabetic O
Chinese O
hamster O
's O
alpha O
and O
beta O
cells O
respond O
normally O
to O
theophylline B-drug
, O
but O
are O
relatively O
insensitive O
to O
glucose B-drug
. O

Patients O
treated O
with O
acebutolol B-drug
plus O
catecholamine B-group
depletors I-group
should O
, O
therefore O
, O
be O
observed O
closely O
for O
evidence O
of O
marked O
bradycardia O
or O
hypotension O
which O
may O
present O
as O
vertigo O
, O
syncope/presyncope O
, O
or O
orthostatic O
changes O
in O
blood O
pressure O
without O
compensatory O
tachycardia O
. O

Thus O
, O
the O
hypothesis O
of O
Gibaldi O
et O
al O
. O

This O
has O
been O
observed O
with O
CLINITEST O
reagent O
tablets O

For O
patients O
with O
amenorrhea O
, O
the O
second O
test O
should O
be O
done O
at O
least O
11 O
days O
after O
the O
last O
act O
of O
unprotected O
sexual O
intercourse O
( O
without O
using O
2 O
effective O
forms O
of O
contraception O
) O
. O

No O
interactions O
have O
been O
observed O
with O
beta-receptor B-group
blockers I-group
, O
calcium B-group
antagonists I-group
, O
thiazide O
and O
loop B-group
diuretics I-group
and O
ACE B-group
inhibitors I-group
. O

These O
experiences O
have O
been O
characterized O
by O
flushing O
, O
rash O
, O
peripheral O
edema O
, O
nausea O
, O
and O
headache O
. O

Modification O
of O
toxin B-drug_n
A I-drug_n
with O
diethyl B-drug_n
pyrocarbonate I-drug_n
abolished O
both O
its O
cytotoxic O
activity O
and O
the O
ability O
of O
the O
toxin O
to O
bind O
Zn-Sepharose O
gel O
. O

Flurbiprofen B-drug
pretreatment O
attenuated O
the O
hypotensive O
effect O
of O
a O
single O
dose O
of O
propranolol B-drug
but O
not O
atenolol B-drug
. O

Conclusions O
and O
the O
types O
of O
studies O
which O
support O
these O
conclusions O
are O
given O
for O
each O
major O
section O
. O

Thiazide B-group
Diuretics I-group
: O
The O
reports O
that O
the O
concomitant O
use O
of O
allopurinol B-drug
and O
thiazide B-group
diuretics I-group
may O
contribute O
to O
the O
enhancement O
of O
allopurinol B-drug
toxicity O
in O
some O
patients O
have O
been O
reviewed O
in O
an O
attempt O
to O
establish O
a O
cause-and-effect O
relationship O
and O
a O
mechanism O
of O
causation O
. O

Concurrent O
administration O
of O
vasopressor B-group
drugs I-group
( O
for O
the O
treatment O
of O
hypotension O
related O
to O
obstetric O
blocks O
) O
and O
ergot-type B-group
oxytocic I-group
drugs I-group
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

For O
example O
, O
when O
vitamin B-group
K I-group
antagonists I-group
are O
administered O
concomitantly O
with O
nilutamide B-drug
, O
prothrombin O
time O
should O
be O
carefully O
monitored O
and O
if O
necessary O
, O
the O
dosage O
of O
vitamin B-group
K I-group
antagonists I-group
should O
be O
reduced O
. O

Theophylline B-drug
: O
Grepafloxacin B-drug
is O
a O
competitive O
inhibitor O
of O
the O
metabolism O
of O
theophylline B-drug
. O

However O
, O
the O
absolute O
number O
of O
alcohol-related B-drug
deaths O
is O
far O
greater O
than O
the O
number O
of O
deaths O
in O
amphetamine B-drug
or O
heroin B-drug_n
users O
. O

Phenytoin/Phenobarbital B-drug
: O
The O
coadministration O
of O
phenytoin B-drug
or O
phenobarbital B-drug
will O
not O
affect O
plasma O
concentrations O
of O
vitamin B-group
D I-group
, O
but O
may O
reduce O
endogenous O
plasma O
levels O
of O
calcitriol/ergocalcitriol B-drug
by O
accelerating O
metabolism O
. O

In O
the O
presence O
of O
these O
methylxanthines B-group
, O
larger O
doses O
of O
adenosine B-drug
may O
be O
required O
or O
adenosine B-drug
may O
not O
be O
effective O
. O

Gastrointestinal O
: O
Nausea O
( O
4-12 O
% O
) O
, O
constipation O
( O
2-6 O
% O
) O
; O

If O
a O
diuretic B-group
is O
also O
used O
, O
the O
risk O
of O
lithium O
toxicity O
may O
be O
increased O
. O

The O
administration O
of O
epinephrine B-drug
should O
be O
avoided O
in O
the O
treatment O
of O
drug O
induced O
hypotension O
because O
of O
a O
possible O
reverse O
epinephrine B-drug
effect O
. O

The O
blood O
pressure O
( O
carotid O
cannulation O
) O
decreased O
along O
with O
the O
core O
temperature O
. O

The O
decrease O
in O
temperature O
began O
within O
20 O
minutes O
after O
ethanol B-drug
administration O
, O
reaching O
a O
maximal O
decrease O
between O
60 O
and O
120 O
minutes O
post O
ethanol B-drug
. O

Aripiprazole B-drug
dose O
should O
be O
reduced O
to O
one-half O
of O
its O
normal O
dose O
when O
concomitant O
administration O
of O
quinidine B-drug
with O
aripiprazole B-drug
occurs O
. O

Dose O
adjustment O
is O
not O
recommended.Levetiracetam B-drug
had O
no O
effect O
on O
plasma O
concentrations O
of O
carbamazepine B-drug
, O
valproate B-drug
, O
topiramate B-drug
, O
or O
lamotrigine B-drug
. O

Peripheral O
mononuclear O
cells O
were O
also O
collected O
for O
quantitation O
of O
phosphorylated O
zidovudine B-drug
. O

Dose O
adjustments O
of O
either O
class O
of O
agents O
may O
be O
necessary O
. O

In O
the O
present O
study O
, O
it O
is O
proposed O
that O
the O
opioids B-group
applied O
to O
supraspinal O
brain O
sites O
produced O
their O
analgesic O
effects O
by O
the O
activation O
of O
different O
descending O
pain O
inhibitory O
systems O
. O

Warfarin B-drug
: O
The O
effect O
of O
valdecoxib B-drug
on O
the O
anticoagulant O
effect O
of O
warfarin B-drug
( O
1 O
- O
8 O
mg/day O
) O
was O
studied O
in O
healthy O
subjects O
by O
coadministration O
of O
BEXTRA B-brand
40 O
mg O
BID O
for O
7 O
days O
. O

While O
mean O
INR O
values O
were O
only O
slightly O
increased O
with O
coadministration O
of O
valdecoxib B-drug
, O
the O
day-to-day O
variability O
in O
individual O
INR O
values O
was O
increased O
. O

The O
preservation O
of O
the O
microtubules O
was O
improved O
when O
D2O O
was O
present O
in O
the O
incubation O
medium O
. O

With O
simultaneous O
dosing O
of O
Vardenafil B-drug
10 O
mg O
and O
terazosin B-drug
10 O
mg O
, O
6 O
of O
8 O
subjects O
experienced O
a O
standing O
systolic O
blood O
pressure O
of O
less O
than O
85 O
mm O
Hg O
. O

Lithium B-drug
: O
Inhibition O
of O
renal O
lithium B-drug
clearance O
, O
leading O
to O
an O
increase O
in O
plasma O
lithium B-drug
concentration O
, O
has O
been O
reported O
with O
some O
prostaglandin O
synthesis-inhibiting O
drugs O
. O

Drugs O
that O
reduce O
the O
number O
of O
blood O
platelets O
by O
causing O
bone O
marrow O
depression O
( O
such O
as O
antineoplastic B-group
agents I-group
) O
or O
drugs O
which O
inhibit O
platelet O
function O
( O
eg O
, O
aspirin B-brand
and O
other O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
, O
dipyridamole B-drug
, O
hydrochloroquine B-drug
, O
clofibrate B-drug
, O
dextran B-drug
) O
may O
increase O
the O
bleeding O
tendency O
produced O
by O
anticoagulants B-group
without O
altering O
prothrombin O
time O
determinations O
. O

Monitoring O
for O
amiodarone B-drug
toxicity O
and O
serial O
measurement O
of O
amiodarone B-drug
serum O
concentration O
during O
concomitant O
protease B-group
inhibitor I-group
therapy O
should O
be O
considered O
. O

Interactions O
with O
Fruit O
Juices O
Fruit O
juices O
such O
as O
grapefruit O
, O
orange O
and O
apple O
may O
reduce O
the O
bioavailability O
and O
exposure O
of O
fexofenadine B-drug
. O

The O
effects O
of O
oral O
neomycin B-drug
on O
ACTH B-group
induced O
hypertension O
were O
examined O
in O
conscious O
sheep O
. O

Cardiovascular O
disease O
is O
a O
common O
comorbidity O
and O
a O
major O
cause O
of O
mortality O
in O
patients O
with O
chronic O
renal O
disease O
. O

Patients O
taking O
warfarin B-drug
or O
other O
coumarin-derivative B-group
anticoagulants I-group
should O
be O
monitored O
regularly O
for O
changes O
in O
prothrombin O
time O
or O
INR O

Risk O
of O
Anaphylactic O
Reaction O
: O
Although O
it O
is O
known O
that O
patients O
on O
beta-blockers B-group
may O
be O
refractory O
to O
epinephrine B-drug
in O
the O
treatment O
of O
anaphylactic O
shock O
, O
beta-blockers B-group
can O
, O
in O
addition O
, O
interfere O
with O
the O
modulation O
of O
allergic O
reaction O
and O
lead O
to O
an O
increased O
severity O
and/or O
frequency O
of O
attacks O
. O

- O
Increased O
thyroid-binding O
globulin O
( O
TBG O
) O
leading O
to O
in-creased O
circulating O
total O
thyroid O
hormone O
; O

Serum O
digoxin B-drug
levels O
using O
an O
125I-labelled O
antigen O
: O
Validation O
of O
method O
and O
observations O
on O
cardiac O
patients O
. O

There O
are O
no O
known O
drug O
interactions O
with O
LEUSTATIN B-brand
Injection O
. O

This O
cluster O
of O
metabolic O
abnormalities O
has O
been O
termed O
the O
insulin O
resistance O
or O
cardiovascular O
dysmetabolic O
syndrome O
. O

Deferasirox B-drug
should O
be O
taken O
on O
an O
empty O
stomach O
30 O
minutes O
before O
eating O
. O

As O
DIFFERIN B-brand
Gel O
has O
the O
potential O
to O
produce O
local O
irritation O
in O
some O
patients O
, O
concomitant O
use O
of O
other O
potentially O
irritating O
topical O
products O
( O
medicated O
or O
abrasive O
soaps O
and O
cleansers O
, O
soaps O
and O
cosmetics O
that O
have O
a O
strong O
drying O
effect O
, O
and O
products O
with O
high O
concentrations O
of O
alcohol O
, O
astringents O
, O
spices O
or O
lime O
) O
should O
be O
approached O
with O
caution O
. O

To O
investigate O
the O
effects O
of O
antimicrobial O
combinations O
of O
GL B-drug_n
with O
four O
kinds O
of O
antibiotics B-group
( O
ampicillin B-drug
, O
cefazolin B-drug
, O
oxytetracycline B-drug
and O
chloramphenicol B-drug
) O
, O
the O
fractional O
inhibitory O
concentration O
index O
( O
FICI O
) O
was O
determined O
by O
checkerboard O
assay O
for O
each O
strain O
. O

Effect O
of O
Clonazepam B-drug
on O
the O
Pharmacokinetics O
of O
Other O
Drugs O
: O
Clonazepam B-drug
does O
not O
appear O
to O
alter O
the O
pharmacokinetics O
of O
phenytoin B-drug
, O
carbamazepine B-drug
, O
or O
phenobarbital B-drug
. O

Excystment O
in O
vitro O
was O
only O
significantly O
affected O
by O
cercariae O
exposed O
to O
cadmium/zinc O
mixtures O
whilst O
encysting O
. O

Hypokalemia O
may O
increase O
susceptibility O
to O
cardiac O
arrhythmias O
in O
patients O
treated O
with O
digitalis B-group
. O

Lamivudine B-drug
: O
In O
vitro O
studies O
in O
peripheral O
blood O
mononuclear O
cells O
, O
U937 O
and O
Molt-4 O
cells O
revealed O
that O
lamivudine B-drug
significantly O
inhibited O
zalcitabine B-drug
phosphorylation O
in O
a O
dose O
dependent O
manner O
. O

Therefore O
, O
precaution O
should O
be O
taken O
when O
coadministration O
is O
necessary O
. O

as O
judged O
by O
increased O
serum O
enzyme O
activities O
and O
increased O
incidence O
of O
hepatic O
necrosis O
. O

Caution O
should O
be O
exercised O
if O
an O
HMG-CoA B-group
reductase I-group
inhibitor I-group
is O
administered O
concomitantly O
with O
drugs O
that O
may O
decrease O
the O
levels O
or O
activity O
of O
endogenous O
steroid O
hormones O
, O
such O
as O
ketoconazole B-drug
, O
spironolactone B-drug
, O
and O
cimetidine B-drug
. O

Inhibitors O
of O
CYP2D6 O
: O
Because O
CYP2D6 O
is O
involved O
in O
duloxetine B-drug
metabolism O
, O
concomitant O
use O
of O
duloxetine B-drug
with O
potent O
inhibitors O
of O
CYP2D6 O
may O
result O
in O
higher O
concentrations O
of O
duloxetine B-drug
. O

Ketoconazole B-drug
: O
Co-administration O
of O
200 O
mg O
twice-daily O
ketoconazole B-drug
with O
aliskiren B-drug
resulted O
in O
an O
approximate O
80 O
% O
increase O
in O
plasma O
levels O
of O
aliskiren B-drug
. O

The O
pharmacokinetic O
variables O
for O
digoxin B-drug
were O
determined O
after O
a O
1.0 O
mg O
intravenous O
dose O
of O
digoxin B-drug
in O
each O
subject O
, O
before O
and O
after O
oral O
amiodarone B-drug
, O
400 O
mg O
daily O
for O
3 O
weeks O
. O

Drugs O
That O
Interfere O
With O
Hemostasis O
( O
NSAIDs B-group
, O
Aspirin B-brand
, O
Warfarin B-drug
, O
etc O
. O
) O

Rat O
kidney O
homogenates O
supplemented O
with O
coenzyme O
A O
, O
ATP O
, O
oxaloacetate O
, O
and O
Mg2+ O
converted O
1,3-difluoroacetone B-drug_n
to O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
in O
vitro O
. O

mefenamic B-drug
acid I-drug
; O

Genitourinary O
: O
Urinary O
frequency O
( O
2-6 O
% O
) O
; O

Human O
pharmacokinetics O
data O
indicate O
that O
oral O
ketoconazole B-drug
potently O
inhibits O
the O
metabolism O
of O
cisapride B-drug
resulting O
in O
a O
mean O
eight-fold O
increase O
in O
AUC O
of O
cisapride B-drug
. O

Ketoconazole B-drug
at O
400 O
mg O
daily O
( O
the O
maximum O
approved O
prescription O
dose O
) O
co-administered O
with O
TIKOSYN B-brand
( O
500 O
mcg O
BID O
) O
for O
7 O
days O
has O
been O
shown O
to O
increase O
dofetilide B-drug
Cmax O
by O
53 O
% O
in O
males O
and O
97 O
% O
in O
females O
, O
and O
AUC O
by O
41 O
% O
in O
males O
and O
69 O
% O
in O
females O
. O

Any O
agent O
that O
alters O
thyroid O
hormone O
synthesis O
, O
secretion O
, O
distribution O
, O
effect O
on O
target O
tissues O
, O
metabolism O
, O
or O
elimination O
may O
alter O
the O
optimal O
therapeutic O
dose O
of O
levothyroxine B-drug
sodium O
. O

Cysteine B-drug
conjugation O
at O
3.6 O
, O
5.3 O
and O
7.3 O
% O
( O
m/m O
) O
resulted O
in O
R-values O
of O
1.4 O
, O
1.7 O
and O
1.8 O
, O
respectively O
. O

Monoamine B-group
Oxidase I-group
Inhibitors I-group
: O
Coadministration O
of O
moclobemide B-drug
resulted O
in O
a O
27 O
% O
decrease O
in O
almotriptan B-drug
clearance O
and O
an O
increase O
in O
Cmax O
of O
approximately O
6 O
% O
. O

GI O
Motility O
Agent O
: O
cisapride* B-drug
CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

However O
, O
increasing O
use O
of O
such O
preparations O
to O
control O
symptoms O
indicates O
deterioration O
of O
asthma O
control O
and O
the O
need O
to O
reassess O
the O
patient O
s O
therapy O
. O

Concomitant O
administration O
of O
FACTIVE B-brand
and O
calcium B-drug
carbonate I-drug
, O
cimetidine B-drug
, O
omeprazole B-drug
, O
or O
an O
estrogen/progesterone B-group
oral O
contraceptive B-group
produced O
minor O
changes O
in O
the O
pharmacokinetics O
of O
gemifloxacin B-drug
, O
which O
were O
considered O
to O
be O
without O
clinical O
significance O
. O

Interaction O
with O
Food O
See O
CLINICAL O
PHARMACOLOGY O
, O
Pharmacokinetics O
and O
Metabolism O
. O

5-HT3 B-group
antagonists I-group
: O
In O
clinical O
drug O
interaction O
studies O
, O
aprepitant B-drug
did O
not O
have O
clinically O
important O
effects O
on O
the O
pharmacokinetics O
of O
ondansetron B-drug
or O
granisetron B-drug
. O

Use O
lowest O
possible O
dose O
of O
atorvastatin B-drug
with O
careful O
monitoring O
, O
or O
consider O
HMG-CoA B-group
reductase I-group
inhibitors I-group
that O
are O
not O
primarily O
metabolized O
by O
CYP3A4 O
, O
such O
as O
pravastatin B-drug
, O
fluvastatin B-drug
, O
or O
rosuvastatin B-drug
in O
combination O
with O
CRIXIVAN B-brand
. O

Patients O
who O
have O
been O
treated O
with O
MAO B-group
inhibitors I-group
within O
two O
to O
three O
weeks O
prior O
to O
the O
administration O
of O
dopamine B-drug
HCl I-drug
should O
receive O
initial O
doses O
of O
dopamine B-drug
HCl I-drug
no O
greater O
than O
one-tenth O
( O
1/10 O
) O
of O
the O
usual O
dose O
. O

There O
is O
considerable O
evidence O
suggesting O
that O
histaminergic O
and O
serotoninergic O
central O
pathways O
are O
involved O
in O
nociception O
and O
that O
antihistaminic B-group
drugs O
can O
modulate O
their O
responses O
( O
1 O
) O
. O

Glyburide B-drug
: O
Glyburide B-drug
is O
a O
CYP O
2C9 O
substrate O
. O

The O
concomitant O
use O
of O
nitrofurantoin B-drug
is O
not O
recommended O
since O
nitrofurantoin B-drug
may O
antagonize O
the O
antibacterial O
effect O
of O
Norfloxacin B-drug
in O
the O
urinary O
tract O
. O

Use O
of O
a O
nonhormonal B-group
contraceptive I-group
product I-group
is O
recommended O
. O

The O
hypotensive O
effect O
of O
sodium B-drug
nitroprusside I-drug
is O
augmented O
by O
that O
of O
most O
other O
hypotensive B-group
drugs I-group
, O
including O
ganglionic B-group
blocking I-group
agents I-group
, O
negative O
inotropic O
agents O
, O
and O
inhaled O
anesthetics B-group
. O

GABITRIL B-brand
is O
considered O
to O
be O
a O
non-enzyme O
inducing O
AED B-group
. O

The O
following O
drugs O
have O
been O
coadministered O
with O
Kerlone B-brand
and O
have O
not O
altered O
its O
pharmacokinetics O
: O
cimetidine B-drug
, O
nifedipine B-drug
, O
chlorthalidone B-drug
, O
and O
hydrochlorothiazide B-drug
. O

AUCss O
( O
0-12h O
) O
( O
Extent O
of O
systemic O
exposure O
) O

Although O
concomitant O
use O
of O
Clozapine B-drug
and O
carbamazepine B-drug
is O
not O
recommended O
, O
it O
should O
be O
noted O
that O
discontinuation O
of O
concomitant O
carbamazepine B-drug
administration O
may O
result O
in O
an O
increase O
in O
Clozapine B-drug
plasma O
levels O
. O

Sildenafil B-drug

Therefore O
, O
coagulation O
indices O
should O
be O
monitored O
to O
maintain O
the O
desired O
anticoagulant O
effect O
. O

Data O
from O
studies O
to O
date O
show O
that O
disease O
states O
, O
underlying O
conditions O
, O
and O
concomitantly O
administered O
highly O
protein-bound O
drugs O
have O
essentially O
no O
effect O
on O
etodolac B-drug
pharmacokinetics O
. O

Warfarin B-drug
: O
Increased O
INR O
( O
International O
Normalized O
Ratio O
) O
when O
ARAVA B-brand
and O
warfarin B-drug
were O
co-administered O
has O
been O
rarely O
reported O
. O

The O
mechanism O
for O
this O
interaction O
probably O
is O
adsorption O
of O
nitrofurantoin B-drug
onto O
the O
surface O
of O
magnesium B-drug
trisilicate I-drug
. O

An O
oral O
glucose B-drug
overload O
of O
1 O
ml O
of O
a O
50 O
% O
glucose B-drug
solution O
was O
given O
to O
rats O
and O
blood O
glucose O
was O
determined O
after O
30 O
, O
60 O
and O
90 O
min O
. O

Caution O
should O
be O
exercised O
when O
imipramine B-drug
hydrochloride I-drug
is O
used O
with O
agents O
that O
lower O
blood O
pressure O
. O

Rifampin B-drug

There O
is O
the O
possibility O
of O
precipitating O
anticonvulsant O
drug O
toxicity O
. O

Because O
of O
possible O
additive O
effects O
with O
other O
carbonic B-group
anhydrase I-group
inhibitors I-group
, O
concomitant O
use O
is O
not O
advisable O
. O

certain O
tetracyclic B-group
antidepressants I-group
( O
such O
as O
maprotiline B-drug
) O
; O

Nonsteroidal B-drug
Antiinflammatory I-drug
Agents O
: O
Aspirin B-drug
is O
contraindicated O
in O
patients O
who O
are O
hypersensitive O
to O
nonsteroidal B-drug
anti-inflammatory I-drug
agents O
. O

There O
are O
no O
data O
that O
conclusively O
establish O
whether O
the O
concomitant O
administration O
of O
Mefloquineuine O
and O
the O
above O
listed O
agents O
has O
an O
effect O
on O
cardiac O
function O
. O

especially O
if O
these O
patients O
are O
extensive O
metabolizers O
. O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phenothiazines B-group
, O
thyroid B-group
products I-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimetics B-group
, O
calcium B-group
channel-blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

Thus O
, O
concentrations O
which O
have O
been O
obtained O
in O
vivo O
clinically O
in O
patients O
with O
normal O
renal O
function O
are O
considerably O
lower O
than O
the O
in O
vitro O
concentrations O
found O
to O
induce O
abnormalities O
in O
platelet O
function O
tests O
. O

In O
psoriatic O
arthritis O
clinical O
trials O
, O
concomitant O
medications O
included O
MTX B-drug
in O
approximately O
half O
of O
the O
patients O
as O
well O
as O
nonsteroidal B-group
anti-inflammatory I-group
agents I-group
, O
folic B-drug
acid I-drug
and O
corticosteroids B-group
. O

Coadministration O
with O
valdecoxib B-drug
increased O
exposure O
of O
omeprazole B-drug
( O
AUC O
) O
by O
46 O
% O
. O

Coadministration O
in O
HIV-infected O
individuals O
with O
a O
history O
of O
injection O
drug O
use O
resulted O
in O
decreased O
plasma O
levels O
of O
methadone B-drug
and O
signs O
of O
opiate B-group
withdrawal O
. O

Saquinavir B-drug

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

Dose O
reduction O
of O
CRIXIVAN B-brand
to O
600 O
mg O
every O
8 O
hours O
is O
recommended O
when O
administering O
itraconazole B-drug
concurrently O
. O

Carbamazepine B-drug
: O
Felbatol B-brand
causes O
a O
decrease O
in O
the O
steady-state O
carbamazepine B-drug
plasma O
concentrations O
and O
an O
increase O
in O
the O
steady-state O
carbamazepine B-drug_n
epoxide I-drug_n
plasma O
concentration O
. O

Glucose O
: O
Some O
patients O
receiving O
Accutane B-brand
have O
experienced O
problems O
in O
the O
control O
of O
their O
blood O
sugar O
. O

Products O
containing O
calcium B-drug
and O
other O
multivalent O
cations O
( O
such O
as O
aluminum B-drug
, O
magnesium B-drug
, O
iron B-drug
) O
are O
likely O
to O
interfere O
with O
absorption O
of O
Ibandronate B-drug
. O

Antacids B-group
: O
The O
concomitant O
administration O
of O
antacids B-group
has O
no O
apparent O
effect O
on O
the O
extent O
of O
absorption O
of O
Lodine B-brand
. O

INDOCIN B-brand
and O
triamterene B-drug
should O
not O
be O
administered O
together O
. O

However O
, O
hydrocortisone B-drug
pretreatment O
did O
not O
affect O
any O
of O
the O
physiological O
, O
behavioral O
, O
or O
subjective O
effects O
of O
d-amphetamine B-drug
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8-fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA O
) O
. O

The O
resulting O
increase O
in O
nitrofurantoin B-drug
serum O
levels O
may O
increase O
toxicity O
, O
and O
the O
decreased O
urinary O
levels O
could O
lessen O
its O
efficacy O
as O
a O
urinary O
tract O
antibacterial B-group
. O

In O
pigeons O
, O
naloxone B-drug
did O
not O
systematically O
alter O
the O
effects O
of O
( B-drug_n
- I-drug_n
) I-drug_n
-NANM I-drug_n
, O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
. O

A O
group O
of O
patients O
who O
had O
had O
a O
new O
acute O
episode O
despite O
seemingly O
adequate O
treatment O
were O
selected O
. O

Hypotension O
was O
more O
likely O
to O
occur O
if O
the O
calcium B-group
antagonist I-group
were O
a O
dihydropyridine B-group
derivative I-group
, O
e.g. O
, O
nifedipine B-drug
, O
while O
left O
ventricular O
failure O
and O
AV O
conduction O
disturbances O
, O
including O
complete O
heart O
block O
, O
were O
more O
likely O
to O
occur O
with O
either O
verapamil B-drug
or O
diltiazem B-drug
. O

In O
the O
warfarin B-drug
study O
, O
vardenafil B-drug
had O
no O
effect O
on O
the O
prothrombin O
time O
or O
other O
pharmacodynamic O
parameters O
. O

In O
a O
chronic O
toxicity O
study O
, O
cynomolgus O
monkeys O
were O
dosed O
weekly O
for O
52 O
weeks O
with O
intravenous O
alefacept B-drug
at O
1 O
mg/kg/dose O
or O
20 O
mg/kg/dose O
. O

However O
, O
serious O
opportunistic O
infections O
have O
not O
been O
observed O
, O
and O
no O
complications O
have O
specifically O
been O
attributed O
to O
lymphocytopenia O
. O

Adenosine O
3':5'-cyclic O
phosphate O
in O
turn O
controls O
levels O
of O
free O
calcium O
ions O
in O
platelets O
and O
regulates O
calcium-dependent O
reactions O
. O

Accordingly O
, O
renal O
function O
should O
be O
closely O
monitored O
in O
these O
patients O
and O
, O
in O
the O
event O
of O
relevant O
significant O
changes O
in O
laboratory O
parameters O
, O
bezafibrate B-drug
should O
, O
if O
necessary O
, O
be O
discontinued O

Aspirin B-brand
: O
In O
normal O
volunteers O
, O
a O
small O
decrease O
in O
diflunisal B-drug
levels O
was O
observed O
when O
multiple O
doses O
of O
diflunisal B-drug
and O
aspirin B-brand
were O
administered O
concomitantly O
. O

Clonazepam B-drug
would O
be O
useful O
in O
cases O
with O
potential O
risk O
of O
hypoglycemia O
. O

6 O
. O

In O
vitro O
metabolism O
studies O
have O
demonstrated O
that O
tizoxanide B-drug
has O
no O
significant O
inhibitory O
effect O
on O
cytochrome O
P450 O
enzymes O
. O

This O
may O
indicate O
that O
ibuprofen B-drug
could O
enhance O
the O
toxicity O
of O
methotrexate B-drug
. O

FLEXERIL B-brand
may O
have O
life-threatening O
interactions O
with O
MAO B-group
inhibitors I-group
. O

acanthus O
. O

0.001 O
. O

In O
an O
in O
vitro O
study O
, O
cytochrome O
P450 O
isozymes O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
, O
and O
3A4 O
were O
not O
inhibited O
by O
exposure O
to O
cevimeline B-drug
. O

ZEBETA B-brand
should O
not O
be O
combined O
with O
other O
beta-blocking B-group
agents I-group
. O

The O
safety O
and O
efficacy O
of O
PROLEUKIN B-brand
in O
combination O
with O
any O
antineoplastic B-group
agents I-group
have O
not O
been O
established O
. O

Nevertheless O
, O
the O
effects O
of O
Mefloquine B-drug
on O
travelers O
receiving O
comedication O
, O
particularly O
diabetics O
or O
patients O
using O
anticoagulants B-group
, O
should O
be O
checked O
before O
departure O
. O

In O
contrast O
, O
nucleophosmin/B23 O
in O
serum-deprived O
ras-transformed O
( O
RAS-3T3 O
) O
cells O
was O
as O
stable O
as O
that O
in O
serum-supplemented O
NIH-3T3 O
or O
RAS-3T3 O
cells O
. O

Patients O
using O
CYP3A4 O
metabolized O
statins B-group
should O
have O
cholesterol O
levels O
monitored O
after O
TRACLEER B-brand
is O
initiated O
to O
see O
whether O
the O
statin B-group
dose O
needs O
adjustment O
. O

Due O
to O
its O
nephrotoxicity O
, O
gentamicin B-drug
may O
cause O
abnormal O
renal O
uptake O
to O
be O
seen O
on O
99mTc-MDP B-drug
bone O
scintigraphy O
. O

Paroxetine B-drug
: O
Coadministration O
of O
single O
doses O
of O
eszopiclone B-drug
3 O
mg O
and O
paroxetine B-drug
20 O
mg O
daily O
for O
7 O
days O
produced O
no O
pharmacokinetic O
or O
pharmacodynamic O
interaction O
. O

More O
than O
600 O
Parkinsons O
disease O
patients O
in O
clinical O
trials O
have O
used O
selegiline B-drug
in O
combination O
with O
entacapone B-drug
and O
levodopa/dopa B-drug
decarboxylase B-group
inhibitor I-group
. O

Lincomycin B-drug
has O
been O
shown O
to O
have O
neuromuscular O
blocking O
properties O
that O
may O
enhance O
the O
action O
of O
other O
neuromuscular B-group
blocking I-group
agents I-group
. O

Antacids B-group
, O
Sucralfate B-drug
, O
Metal O
Cations O
, O
Multivitamins B-group
Quinolones I-group
form O
chelates O
with O
alkaline O
earth O
and O
transition O
metal O
cations O
. O

In O
vitro O
mixing O
of O
an O
aminoglycoside B-group
with O
beta-lactamtype O
antibiotics B-group
( O
penicillins B-group
or O
cephalosporins B-group
) O
may O
result O
in O
a O
significant O
mutual O
inactivation O
. O

When O
given O
in O
a O
dose O
of O
50 O
mg/kg O
, O
sandimmune B-brand
produced O
no O
statistically O
significant O
effect O
on O
the O
duration O
of O
hexanal-induced O
sleep O
in O
mice O
. O

Although O
trough O
citalopram B-drug
plasma O
levels O
were O
unaffected O
, O
given O
the O
enzyme-inducing O
properties O
of O
carbamazepine B-drug
, O
the O
possibility O
that O
carbamazepine B-drug
might O
increase O
the O
clearance O
of O
escitalopram B-drug
should O
be O
considered O
if O
the O
two O
drugs O
are O
coadministered O
. O

BREVIBLOC B-brand
concentrations O
were O
equivocally O
higher O
when O
given O
with O
warfarin B-drug
, O
but O
this O
is O
not O
likely O
to O
be O
clinically O
important O
. O

Propranolol B-drug
: O
In O
a O
single O
dose O
study O
in O
normal O
volunteers O
, O
coadministration O
of O
propranolol B-drug
had O
a O
small O
effect O
on O
the O
rate O
but O
no O
effect O
on O
the O
extent O
of O
isradipine B-drug
bioavailability O
. O

Antipsychotic B-group
drugs I-group
such O
as O
phenothiazines B-group
or O
haloperidol B-drug
; O

Sumatriptan B-drug
and O
D.H.E B-brand
. I-brand
45 I-brand
( O
dihydroergotamine B-drug
mesylate I-drug
) O
Injection O
, O
USP O
should O
not O
be O
taken O
within O
24 O
hours O
of O
each O
other.. O

Use O
With O
Ribavirin B-drug
Ribavirin I-drug
is O
genotoxic O
and O
mutagenic O
. O

Corticosteroids B-group
may O
also O
potentiate O
the O
replication O
of O
some O
organisms O
contained O
in O
live B-group
attenuated I-group
vaccines I-group
. O

If O
the O
TARCEVA B-brand
dose O
is O
adjusted O
upward O
, O
the O
dose O
will O
need O
to O
be O
reduced O
upon O
discontinuation O
of O
rifampicin B-drug
or O
other O
inducers O
. O

Dexamethasone B-drug
: O
Steady-state O
trough O
concentrations O
of O
albendazole B-drug
sulfoxide I-drug
were O
about O
56 O
% O
higher O
when O
8 O
mg O
dexamethasone B-drug
was O
coadministered O
with O
each O
dose O
of O
albendazole B-drug
( O
15 O
mg/kg/day O
) O
in O
eight O
neurocysticercosis O
patients O
. O

Dexbrompheniramine B-drug
can O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-group
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-group
) O
. O

COPEGUS B-brand
therapy O
is O
contraindicated O
in O
women O
who O
are O
pregnant O
and O
in O
the O
male O
partners O
of O
women O
who O
are O
pregnant O
. O

A O
similar O
association O
, O
though O
less O
marked O
, O
has O
been O
suggested O
with O
barbiturates B-group
, O
phenylbutazone B-drug
, O
phenytoin B-drug
sodium I-drug
, O
carbamazepine B-drug
, O
griseofulvin B-drug
, O
topiramate B-drug
, O
and O
possibly O
with O
ampicillin B-drug
and O
tetracyclines B-group
72 O
. O

In O
a O
parallel O
group O
drug O
interaction O
study O
comparing O
the O
intravenous O
prodrug O
form O
of O
valdecoxib B-drug
at O
40 O
mg O
BID O
( O
n=10 O
) O
vs O
placebo O
( O
n=9 O
) O
, O
valdecoxib B-drug
had O
no O
effect O
on O
in O
vitro O
aspirin-mediated B-brand
inhibition O
of O
arachidonate- O
or O
collagen-stimulated O
platelet O
aggregation O
. O

Protein O
Binding O
: O
Entacapone B-drug
is O
highly O
protein O
bound O
( O
98 O
% O
) O
. O

Patients O
taking O
warfarin B-drug
should O
be O
monitored O
regularly O
for O
changes O
in O
prothrombin O
time O
or O
INR O
. O

The O
potential O
effects O
of O
INDOCIN B-brand
and O
potassium-sparing B-group
diuretics I-group
on O
potassium O
kinetics O
and O
renal O
function O
should O
be O
considered O
when O
these O
agents O
are O
administered O
concurrently O
. O

Indinavir B-drug

Rifampin B-drug
significantly O
decreased O
the O
AUC O
( O
ss O
) O
of O
amprenavir B-drug
by O
82 O
% O
, O
but O
amprenavir B-drug
had O
no O
effect O
on O
rifampin B-drug
pharmacokinetics O
. O

Similarly O
, O
ethanol B-drug
decreased O
the O
rate O
of O
elimination O
of O
Antizol B-brand
( O
by O
approximately O
50 O
% O
) O
by O
the O
same O
mechanism O
. O

Monoamine B-group
Oxidase I-group
Inhibitors I-group
and O
Tricyclic B-group
Antidepressants I-group
: O
FORADIL B-brand
should O
be O
administered O
with O
extreme O
caution O
in O
patients O
being O
treated O
with O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
because O
the O
action O
of O
formoterol B-drug
on O
the O
cardiovascular O
system O
may O
be O
potentiated O
by O
these O
agents O
. O

1200-2400 O
up O
to O
40 O
% O
increase3 O
[ O
CI O
: O
12 O
% O
increase O
, O
60 O
% O
increase O
] O

Drug O
interaction O
studies O
have O
not O
been O
performed O
with O
Soliris B-brand
. O

Itraconazole B-drug

Organic O
nitrates B-group
- O
L-arginine B-drug
supplements O
theoretically O
may O
potentiate O
the O
effects O
of O
organic O
nitrates B-drug
if O
taken O
concomitantly O
. O

However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-drug
with O
vitamin B-group
D I-group
have O
not O
been O
investigated O
. O

The O
tolerability O
of O
NNRTIs B-group
appears O
generally O
good O
with O
few O
individuals O
discontinuing O
in O
clinical O
studies O
as O
a O
result O
of O
adverse O
drug O
events O
. O

Drug/Laboratory O
Test O
Interactions O
: O
The O
administration O
of O
CEFOTAN B-brand
may O
result O
in O
a O
false O
positive O
reaction O
for O
glucose O
in O
the O
urine O
using O
Clinitest O
, O
Benedicts O
solution O
, O
or O
Fehlings O
solution O
. O

Coadministration O
of O
oral O
contraceptives B-group
increased O
the O
maximum O
plasma O
concentration O
of O
alprazolam B-drug
by O
18 O
% O
, O
decreased O
clearance O
by O
22 O
% O
, O
and O
increased O
half-life O
by O
29 O
% O
. O

The O
therapeutic O
efficacy O
of O
tricyclic B-group
antidepressants I-group
may O
be O
compromised O
in O
these O
patients O
when O
cimetidine B-drug
is O
discontinued O
. O

Drugs O
Metabolized O
by O
CYP2D6 O
: O
Duloxetine B-drug
is O
a O
moderate O
inhibitor O
of O
CYP2D6 O
. O

In O
renal O
and O
cardiac O
transplant O
recipients O
, O
a O
reduction O
of O
cyclosporine B-drug
dose O
ranging O
from O
15 O
% O
to O
48 O
% O
was O
necessary O
to O
maintain O
cyclosporine B-drug
trough O
concentrations O
similar O
to O
those O
seen O
prior O
to O
the O
addition O
of O
diltiazem B-drug
. O

Catecholamine-depleting O
drugs O
( O
e.g. O
, O
reserpine B-drug
) O
may O
have O
an O
additive O
effect O
when O
given O
with O
beta-blocking B-drug
agents O
. O

Morphine B-drug
pharmacokinetic O
parameter O
values O
were O
not O
affected O
by O
administration O
of O
Neurontin B-brand
2 O
hours O
after O
morphine B-drug
. O

Concurrent O
administration O
of O
vasopressor B-group
drugs I-group
and O
of O
ergot-type B-group
oxytocic I-group
drugs I-group
may O
cause O
severe O
, O
persistent O
hypertension O
or O
cerebrovascular O
accidents O
. O

. O

If O
phenytoin B-drug
or O
other O
hepatic O
enzyme O
inducers O
are O
taken O
concurrently O
with O
Norpace B-brand
or O
Norpace B-brand
CR I-brand
, O
lower O
plasma O
levels O
of O
disopyramide B-drug
may O
occur O
. O

Ketoconazole B-drug
( O
200 O
mg O
once O
daily O
) O
produced O
a O
10-fold O
increase O
in O
vardenafil B-drug
AUC O
and O
a O
4-fold O
increase O
in O
Cmax O
when O
co-administered O
with O
Vardenafil B-drug
( O
5 O
mg O
) O
in O
healthy O
volunteers O
. O

As O
most O
entacapone B-drug
excretion O
is O
via O
the O
bile O
, O
caution O
should O
be O
exercised O
when O
drugs O
known O
to O
interfere O
with O
biliary O
excretion O
, O
glucuronidation O
, O
and O
intestinal O
beta-glucuronidase O
are O
given O
concurrently O
with O
entacapone B-drug
. O

Limited O
PK O
and/or O
PD O
studies O
investigating O
possible O
interactions O
between O
anagrelide B-drug
and O
other O
medicinal O
products O
have O
been O
conducted O
. O

Cimetidine B-drug
( O
300 O
mg O
qid O
) O
+103 O
% O
+ O
6 O
% O

Nursing O
Mothers O

Coadministration O
of O
NIZORAL B-brand
Tablets O
and O
drugs O
primarily O
metabolized O
by O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
may O
result O
in O
increased O
plasma O
concentrations O
of O
the O
drugs O
that O
could O
increase O
or O
prolong O
both O
therapeutic O
and O
adverse O
effects O
. O

CYP2D6 O
inhibitors O
- O
Atomoxetine B-drug
is O
primarily O
metabolized O
by O
the O
CYP2D6 O
pathway O
to O
4-hydroxyatomoxetine B-drug_n
. O

Antacid B-group
: O
When O
atorvastatin B-drug
and O
Maalox B-brand
TC I-brand
suspension O
were O
coadministered O
, O
plasma O
concentrations O
of O
atorvastatin B-drug
decreased O
approximately O
35 O
% O
. O

Erythromycin B-drug
and O
clarithromycin B-drug
( O
and O
possibly O
other O
macrolide B-group
antibiotics I-group
) O
and O
tetracycline B-drug
may O
increase O
digoxin B-drug
absorption O
in O
patients O
who O
inactivate O
digoxin B-drug
by O
bacterial O
metabolism O
in O
the O
lower O
intestine O
, O
so O
that O
digitalis B-group
intoxication O
may O
result O
. O

Concurrent O
administration O
of O
a O
TNF B-group
antagonist I-group
with O
ORENCIA B-brand
has O
been O
associated O
with O
an O
increased O
risk O
of O
serious O
infections O
and O
no O
significant O
additional O
efficacy O
over O
use O
of O
the O
TNF B-group
antagonists I-group
alone O
. O

Central B-group
nervous I-group
system I-group
depressant I-group
( O
CNS O
) O
drugs O
including O
alcohol B-drug
, O
antidepressants B-group
, O
antihistamines B-group
, O
antipsychotics B-group
, O
blood O
pressure O
medications O
( O
reserpine B-drug
, O
methyldopa B-drug
, O
beta-blockers B-group
) O
, O
motion O
sickness O
medications O
, O
muscle B-group
relaxants I-group
, O
narcotics B-group
, O
sedatives B-group
, O
sleeping O
pills O
and O
tranquilizers B-group

Magnesium B-drug
: O
Magnesium-containing B-drug
preparations O
( O
eg O
, O
antacids B-group
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-group
D I-group
by O
patients O
on O
chronic O
renal O
dialysis O
. O

Patients O
receiving O
these O
drugs O
concurrently O
should O
be O
monitored O
for O
a O
potential O
drug O
interaction O
. O

Concomitant O
use O
of O
other O
5-HT1B/1D O
agonists O
within O
24 O
hours O
of O
FROVA B-brand
treatment O
is O
not O
recommended O
. O

This O
change O
was O
not O
considered O
clinically O
significant O
and O
no O
dose O
adjustment O
is O
needed O
when O
ketoconazole B-drug
and O
VIRACEPT B-brand
are O
coadministered O
. O

Interactions O
for O
vitamin B-group
D I-group
analogues O
( O
Vitamin B-drug
D2 I-drug
, O
Vitamin B-drug
D3 I-drug
, O
Calcitriol B-drug
, O
and O
Calcidiol B-drug
) O
: O
Cholestyramine B-drug
: O
Cholestyramine B-drug
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
; O

Considering O
that O
the O
involvement O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
has O
been O
implicated O
in O
the O
toxicity O
of O
various O
pesticides O
, O
this O
study O
was O
designed O
to O
investigate O
the O
possibility O
of O
oxidative O
stress O
induction O
by O
cypermethrin B-drug
, O
a O
Type B-drug_n
II I-drug_n
pyrethroid I-drug_n
. O

Digoxin B-drug
: O
Rofecoxib B-drug
75 O
mg O
once O
daily O
for O
11 O
days O
does O
not O
alter O
the O
plasma O
concentration O
profile O
or O
renal O
elimination O
of O
digoxin B-drug
after O
a O
single O
0.5 O
mg O
oral O
dose O
. O

Endocrine O
Function O
HMG-CoA B-group
reductase I-group
inhibitors I-group
interfere O
with O
cholesterol O
synthesis O
and O
theoretically O
might O
blunt O
adrenal O
and/or O
gonadal O
steroid O
production O
. O

Other O
Drugs O
: O
In O
small O
groups O
of O
patients O
( O
7-10/interaction O
study O
) O
, O
the O
concomitant O
administration O
of O
azathioprine B-drug
, O
gold B-group
, O
chloroquine B-drug
, O
D-penicillamine B-drug
, O
prednisolone B-drug
, O
doxycycline B-drug
, O
or O
digitoxin B-drug
did O
not O
significantly O
affect O
the O
peak O
levels O
and O
AUC O
values O
of O
diclofenac B-drug
. O

4 O
. O

In O
clinical O
studies O
, O
coadministration O
of O
WelChol B-brand
with O
atorvastatin B-drug
, O
lovastatin B-drug
, O
or O
simvastatin B-drug
did O
not O
interfere O
with O
the O
lipid-lowering O
activity O
of O
the O
HMG-CoA B-group
reductase I-group
inhibitor I-group
. O

The O
latency O
to O
loss O
of O
the O
righting O
reflex O
and O
duration O
of O
sleep O
time O
were O
recorded O
while O
the O
rats O
were O
kept O
in O
sound-attenuating O
chambers O
. O

The O
concurrent O
use O
of O
these O
drugs O
is O
not O
recommended O
. O

There O
are O
no O
known O
drug/drug O
interactions O
with O
chlorambucil B-drug
. O

In O
the O
first O
study O
, O
concomitant O
administration O
of O
0.2 O
mg O
cerivastatin B-drug
sodium I-drug
and O
12 O
g O
cholestyramine B-drug
resulted O
in O
decreases O
of O
more O
than O
22 O
% O
for O
AUC O
and O
40 O
% O
for O
Cmax O
when O
compared O
to O
dosing O
cerivastatin B-drug
sodium I-drug
alone O
. O

PTX B-drug_n
caused O
the O
release O
of O
norepinephrine O
from O
the O
muscle O
. O

Although O
glucocorticoids B-group
have O
been O
shown O
to O
reduce O
PROLEUKIN-induced B-brand
side O
effects O
including O
fever O
, O
renal O
insufficiency O
, O
hyperbilirubinemia O
, O
confusion O
, O
and O
dyspnea O
, O
concomitant O
administration O
of O
these O
agents O
with O
PROLEUKIN B-brand
may O
reduce O
the O
antitumor O
effectiveness O
of O
PROLEUKIN B-brand
and O
thus O
should O
be O
avoided O
. O
12 O
Beta-blockers B-group
and O
other O
antihypertensives B-group
may O
potentiate O
the O
hypotension O
seen O
with O
PROLEUKIN B-brand
. O

Combination O
therapy O
should O
be O
administered O
with O
caution O
, O
especially O
in O
immunocompromised O
patients O
. O

CPK O
: O
Some O
patients O
undergoing O
vigorous O
physical O
activity O
while O
on O
Accutane B-brand
therapy O
have O
experienced O
elevated O
CPK O
levels O
; O

We O
obtained O
evidence O
that O
increased O
stability O
of O
nucleophosmin/B23 O
is O
involved O
in O
antiapoptotic O
effect O
of O
ras O
during O
serum O
deprivation O
. O

In O
a O
controlled O
clinical O
trial O
, O
a O
20 O
% O
reduction O
of O
the O
phenytoin B-drug
dose O
at O
the O
initiation O
of O
Felbatol B-brand
therapy O
resulted O
in O
phenytoin B-drug
levels O
comparable O
to O
those O
prior O
to O
Felbatol B-brand
administration O
. O

The O
percentage O
of O
drug O
binding O
in O
each O
preparation O
was O
calculated O
. O

Thus O
, O
the O
results O
suggest O
that O
cypermethrin B-drug
exposure O
of O
rats O
results O
in O
free O
radical-mediated O
tissue O
damage O
, O
as O
indicated O
by O
elevated O
cerebral O
and O
hepatic O
lipid O
peroxidation O
, O
which O
was O
prevented O
by O
allopurinol B-drug
and O
Vitamin B-drug
E I-drug
. O

Two O
retrospective O
studies O
were O
conducted O
in O
1992 O
( O
75 O
cases O
) O
and O
in O
1993 O
( O
51 O
cases O
) O
. O

use O
potassium B-drug
supplements O
if O
necessary O
. O

In O
addition O
, O
the O
beneficial O
effects O
of O
levodopa B-drug
in O
Parkinsons O
disease O
have O
been O
reported O
to O
be O
reversed O
by O
phenytoin B-drug
and O
papaverine B-drug
. O

No O
effects O
were O
evident O
on O
excystment O
rates O
of O
cyst-exposed O
parasites O
. O

These O
included O
seven O
cerebrovascular O
accidents O
, O
six O
sudden O
cardiac O
deaths O
, O
three O
cases O
of O
hyperpyrexia O
, O
eight O
poisonings O
of O
uncertain O
mechanism O
and O
seven O
cases O
of O
medical O
complications O
of O
intravenous O
injection O
; O

The O
interval O
between O
the O
administration O
of O
COLESTID B-brand
Tablets O
and O
any O
other O
medication O
should O
be O
as O
long O
as O
possible O
. O

Administration O
of O
diltiazem B-drug
hydrochloride I-drug
with O
digoxin B-drug
in O
24 O
healthy O
male O
subjects O
increased O
plasma O
digoxin B-drug
concentrations O
approximately O
20 O
% O
. O

positive O
antinuclear O

The O
atorvastatin B-drug
Cmax O
values O
were O
not O
significantly O
affected O
by O
fenofibrate B-drug
. O

None O
Reported O

one O
patient O
died O
with O
severe O
hypocalcemia O
. O

DIGOXIN B-drug
: O
Plasma O
digoxin B-drug
levels O
and O
digoxin B-drug
clearance O
at O
steady-state O
were O
not O
affected O
by O
co-administration O
of O
0.2 O
mg O
cerivastatin B-drug
sodium I-drug
. O

Tricyclic B-group
antidepressants I-group
( O
amitriptyline B-drug
, O
imipramine B-drug
, O
nortriptyline B-drug
) O
: O
Metabolism O
may O
be O
inhibited O
by O
combination B-group
hormonal I-group
contraceptives I-group
, O
increasing O
plasma O
levels O
of O
antidepressant B-group
; O

CONTRAINDICATED O
due O
to O
potential O
for O
serious O
and/or O
life-threatening O
reactions O
such O
as O
cardiac O
arrhythmias O
. O

Drugs O
Decreasing O
Heparin B-drug
Effect O
: O
Digitalis B-group
, O
tetracyclines B-group
, O
nicotine B-drug
, O
or O
antihistamines B-group
may O
partially O
counteract O
the O
anticoagulant O
action O
of O
heparin B-drug
sodium I-drug
. O

Lack O
of O
interaction O
between O
levofloxacin B-drug
and O
oxycodone B-drug
: O
pharmacokinetics O
and O
drug O
disposition O
. O

substrates O
, O
in O
vitro O
data O
suggest O
similar O
effects O
of O
grepafloxacin B-drug
in O
CYP3A4 O
mediated O
metabolism O
and O
theophylline B-drug
metabolism O
. O

Development O
and O
pharmacology O
of O
fluvastatin B-drug
. O

Choose O
particular O
low O
doses O
of O
these O
drugs O
. O

Treatment O
of O
both O
parental O
and O
resistant O
MCF-7 O
cells O
with O
TAM B-drug_n
induces O
apoptosis O
and O
clusterin O
. O

Phenothiazines B-group
and O
butyrophenones B-group
may O
reduce O
or O
reverse O
the O
pressor O
effect O
of O
epinephrine B-drug
. O

. O

No O
dose O
adjustment O
of O
bosentan B-drug
is O
necessary O
, O
but O
increased O
effects O
of O
bosentan B-drug
should O
be O
considered O
. O

Urinary O
alkalinizing O
agents O
( O
acetazolamide B-drug
, O
some O
thiazides B-group
) O
increase O
the O
concentration O
of O
the O
non-ionized O
species O
of O
the O
amphetamine B-drug
molecule O
, O
thereby O
decreasing O
urinary O
excretion O
. O

Cyclophosphamide B-drug

It O
is O
suggested O
that O
in O
patients O
receiving O
dopamine B-drug
HCl I-drug
, O
alternatives O
to O
phenytoin B-drug
should O
be O
used O
if O
anticonvulsant B-group
therapy O
is O
needed O
. O

Similarly O
, O
saquinavir B-drug
might O
also O
modify O
the O
pharmacokinetics O
of O
other O
drugs O
that O
are O
substrates O
for O
CYP3A4 O
or O
Pgp O
. O

5 O
. O

Hepatotoxicity O
Asymptomatic O
increases O
in O
liver O
transaminases O
have O
been O
observed O
in O
TARCEVA B-brand
treated O
patients O
; O

On O
the O
other O
hand O
, O
surprisingly O
, O
green B-drug
tea I-drug
gallocatechins I-drug
, O
( O
- O
) O
-epigallocatechin-3-O-gallate O
and O
theasinensin O
A O
, O
potently O
enhanced O
the O
promoter O
activity O
( O
182 O
and O
247 O
% O
activity O
at O
1 O
microM O
, O
respectively O
) O
. O

N=12 O
) O
administration O
. O

Appropriate O
doses O
for O
this O
combination O
arenot O
established O
, O
but O
an O
increase O
in O
thedosage O
of O
saquinavir B-drug
may O
be O
required O
. O

In O
screening O
patients O
suspected O
of O
having O
a O
pheochromocytoma O
and O
being O
treated O
with O
labetalol B-drug
HCl I-drug
, O
a O
specific O
method O
, O
such O
as O
a O
high O
performance O
liquid O
chromatographic O
assay O
with O
solid O
phase O
extraction O
( O
e.g. O
, O
J O
Chromatogr O
385:241,1987 O
) O
should O
be O
employed O
in O
determining O
levels O
of O
catecholamines O
. O

MICs O
of O
vancomycin B-drug
against O
67 O
% O
of O
resistant O
clinical O
isolates O
and O
a O
type O
strain O
of O
enterococci O
were O
lowered O
from O
> O
250 O
microg O
mL O
( O
-1 O
) O
to O
1 O

however O
, O
14-OH O
metabolite O
concentrations O
were O
increased.Because O
clarithromycin B-drug
active O
metabolite O
has O
reduced O
activity O
against O
Mycobacteriumavium-intracellulare O
complex O
, O
overallactivity O
against O
this O
pathogen O
may O
bealtered O
. O

The O
magnitude O
of O
interaction O
at O
other O
doses O
is O
not O
known O
. O

Anastrozole B-drug
did O
not O
alter O
the O
pharmacokinetics O
of O
antipyrine B-drug
. O

The O
results O
of O
a O
study O
of O
coadministration O
of O
ethambutol B-drug
( O
50 O
mg/kg O
) O
with O
an O
aluminum B-drug
hydroxide I-drug
containing O
antacid B-group
to O
13 O
patients O
with O
tuberculosis O
showed O
a O
reduction O
of O
mean O
serum O
concentrations O
and O
urinary O
excretion O
of O
ethambutol B-drug
of O
approximately O
20 O
% O
and O
13 O
% O
, O
respectively O
, O
suggesting O
that O
the O
oral O
absorption O
of O
ethambutol B-drug
may O
be O
reduced O
by O
these O
antacid B-group
products I-group
. O

No O
formal O
studies O
to O
evaluate O
drug O
interactions O
with O
bexarotene B-drug
have O
been O
conducted O
. O

However O
, O
there O
has O
been O
one O
report O
of O
prolonged O
prothrombin O
time O
when O
buspirone B-drug
was O
added O
to O
the O
regimen O
of O
a O
patient O
treated O
with O
warfarin B-drug
. O

Interactions O
for O
vitamin B-group
D I-group
analogues I-group
( O
Vitamin B-drug
D2 I-drug
, O
Vitamin B-drug
D3 I-drug
, O
Calcitriol B-drug
, O
and O
Calcidiol B-drug
) O
: O
Cholestyramine B-drug
: O
Cholestyramine B-drug
has O
been O
reported O
to O
reduce O
intestinal O
absorption O
of O
fat B-group
soluble I-group
vitamins I-group
; O

- O
Drug/Laboratory O
Test O
Interactions O
: O
Thiazides B-group
should O
be O
discontinued O
before O
carrying O
out O
tests O
for O
parathyroid O
function O
. O

Conversion O
could O
be O
affected O
by O
alterations O
in O
the O
level O
of O
phosphatase O
activity O
, O
but O
given O
the O
abundance O
and O
wide O
distribution O
of O
phosphatases O
in O
the O
body O
it O
is O
unlikely O
that O
drugs O
would O
affect O
this O
activity O
enough O
to O
affect O
conversion O
of O
fosphenytoin B-drug
to O
phenytoin B-drug
. O

For O
example O
, O
diuretics B-group
( O
e.g. O
, O
thiazides B-group
) O
may O
activate O
the O
renin-angiotensin-aldosterone O
system O
. O

Corticosteroids B-group
and O
Corticotropin B-drug
( O
ACTH B-group
) O
: O
may O
potentiate O
amphotericin B-drug
B- O
induced O
hypokalemia O
which O
may O
predispose O
the O
patient O
to O
cardiac O
dysfunction O
. O

Sedatives B-group
and O
tranquilizers B-group
( O
e.g. O
, O
diazepam B-drug
) O
. O

If O
these O
drugs O
are O
to O
be O
used O
in O
the O
initial O
treatment O
of O
severe O
malaria O
, O
Mefloquine B-drug
administration O
should O
be O
delayed O
at O
least O
12 O
hours O
after O
the O
last O
dose O
. O

Drug O
Name O

Because O
antacids B-group
may O
interfere O
with O
the O
absorption O
of O
anticholinergic B-group
agents I-group
, O
simultaneous O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

anemia O

Single O
doses O
of O
either O
cholestyramine B-drug
or O
colestipol B-drug
resins B-group
bind O
the O
hydrochlorothiazide B-drug
and O
reduce O
its O
absorption O
from O
the O
gastrointestinal O
tract O
by O
up O
to O
85 O
and O
43 O
percent O
, O
respectively O
. O

Differences O
in O
iron B-drug
balance O
were O
only O
observed O
between O
both O
dietary O
concentrations O
, O
showing O
a O
higher O
absolute O
but O
a O
lower O
relative O
absorption O
as O
well O
as O
retention O
in O
the O
groups O
fed O
further O
Fe B-drug
. O
( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O

Terfenadine B-drug
: O
No O
clinically O
significant O
changes O
occurred O
in O
heart O
rate O
or O
corrected O
QT O
intervals O
, O
or O
in O
terfenadine B-drug
metabolite O
or O
lomefloxacin B-drug
pharmacokinetics O
, O
during O
concurrent O
administration O
of O
lomefloxacin B-drug
and O
terfenadine B-drug
at O
steady-state O
in O
28 O
healthy O
males O
. O

No O
other O
drug O
interactions O
are O
known O
. O

Ketorolac B-drug
is O
highly O
bound O
to O
human O
plasma O
protein O
( O
mean O
99.2 O
% O
) O
. O

Although O
BETAGAN B-brand
used O
alone O
has O
little O
or O
no O
effect O
on O
pupil O
size O
, O
mydriasis O
resulting O
from O
concomitant O
therapy O
with O
BETAGAN B-brand
and O
epinephrine B-drug
may O
occur O
. O

Use O
of O
PRINIVIL B-brand
with O
potassium-sparing B-group
diuretics I-group
( O
e.g. O
, O
spironolactone B-drug
, O
triamterene B-drug
, O
or O
amiloride B-drug
) O
, O
potassium B-drug
supplements O
, O
or O
potassium-containing O
salt O
substitutes O
may O
lead O
to O
significant O
increases O
in O
serum O
potassium O
. O

Ketoconazole I-drug

Blood O
sampling O
for O
the O
pharmacokinetics O
of O
everolimus B-drug
and O
cyclosporine B-drug
was O
performed O
on O
day O
1 O
, O
on O
weeks O
1 O
, O
2 O
, O
3 O
, O
and O
4 O
, O
and O
on O
months O
2 O
, O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
. O

No O
formal O
clinical O
studies O
have O
been O
conducted O
to O
assess O
if O
there O
is O
an O
interactive O
effect O
on O
bone O
loss O
between O
phenytoin B-drug
and O
Accutane B-brand
. O

Analysis O
of O
the O
concentration O
of O
budesonide B-drug
following O
ultracentrifugation O
indicated O
that O
there O
is O
rapid O
equilibration O
of O
budesonide B-drug
between O
the O
Survanta B-brand
and O
aqueous O
phase O
. O

The O
immediate O
release O
, O
but O
not O
the O
coat-core O
formulation O
of O
nisoldipine B-drug
increased O
plasma O
quinidine B-drug
concentrations O
by O
about O
20 O
% O
. O

Because O
busulfan B-drug
is O
eliminated O
from O
the O
body O
via O
conjugation O
with O
glutathione O
, O
use O
of O
acetaminophen B-drug
prior O
to O
( O
72 O
hours O
) O
or O
concurrent O
with O
BUSULFEX B-brand
may O
result O
in O
reduced O
busulfan B-drug
clearance O
based O
upon O
the O
known O
property O
of O
acetaminophen B-drug
to O
decrease O
glutathione O
levels O
in O
the O
blood O
and O
tissues O
. O

Response O
to O
Treatment O
for O
Anaphylactic O
Reaction O
: O
While O
taking O
beta-blockers B-group
, O
patients O
with O
a O
history O
of O
severe O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
be O
more O
reactive O
to O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
, O
or O
therapeutic O
. O

Amphetamines B-group
may O
interfere O
with O
urinary O
steroid O
determinations O
. O

If O
combination O
therapy O
is O
initiated O
or O
withdrawn O
in O
conjunction O
with O
propranolol B-drug
, O
an O
adjustment O
in O
the O
propranolol B-drug
dose O
may O
be O
warranted O
. O

Other O
than O
with O
probenecid B-drug
, O
no O
specific O
clinical O
drug O
interaction O
studies O
have O
been O
conducted O

Alternate O
or O
additional O
contraceptive O
measures O
should O
be O
used O
during O
therapy O
with O
VIRACEPT B-brand

Also O
, O
although O
minimal O
alterations O
of O
fluvastatin B-drug
clearance O
in O
patients O
with O
renal O
insufficiency O
are O
anticipated O
due O
to O
limited O
renal O
excretion O
( O
5 O
% O
) O
, O
a O
study O
in O
this O
patient O
group O
is O
currently O
underway O
to O
examine O
this O
further O
. O

However O
, O
neuromuscular O
paralysis O
may O
be O
potentiated O
by O
co-administration O
or O
overlapping O
administration O
of O
different O
botulinum B-group
toxin I-group
serotypes O
. O

The O
effects O
of O
ruthenium B-drug_n
red I-drug_n
( O
RR B-drug_n
) O
on O
inositol B-drug_n
1,4,5-trisphosphate I-drug_n
( O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
) I-drug_n
-induced O
responses O
were O
studied O
in O
rat O
bone O
marrow O
megakaryocytes O
with O
the O
patch-clamp O
whole-cell O
recording O
technique O
in O
combination O
with O
fura-2 O
microfluorometry O
. O

Extended O
Release O
Tablets O
: O
Administration O
of O
nifedipine B-drug
with O
digoxin B-drug
increased O
digoxin B-drug
levels O
in O
9 O
of O
12 O
normal O
volunteers O
. O

Other O
antihypertensive B-group
drugs I-group
: O
additive O
effect O
or O
potentiation O
. O

Unfortunately O
, O
folic B-drug
acid I-drug
will O
not O
correct O
changes O
in O
the O
nervous O
system O
that O
result O
from O
vitamin O
B12 O
deficiency O
. O

These O
effects O
not O
only O
improve O
insulin O
sensitivity O
and O
glycemic O
control O
with O
reduced O
insulin O
requirements O
, O
but O
also O
have O
potentially O
favorable O
effects O
on O
other O
components O
of O
the O
cardiovascular O
dysmetabolic O
syndrome O
. O

= O
increase O
; O

No O
rashes O
were O
reported O
in O
these O
patients O
. O

The O
data O
presented O
here O
demonstrate O
that O
with O
serial O
pharmacokinetic O
dosing O
of O
gentamicin B-drug
, O
the O
iatrogenic O
alteration O
caused O
by O
gentamicin B-drug
therapy O
can O
be O
avoided O
. O

Ritonavir B-drug
and O
indinavir B-drug
: O
Upon O
concomitant O
administration O
of O
5 O
mg O
of O
Vardenafil B-drug
with O
600 O
mg O
BID O
ritonavir B-drug
, O
the O
Cmax O
and O
AUC O
of O
ritonavir B-drug
were O
reduced O
by O
approximately O
20 O
% O
. O

These O
data O
raise O
the O
question O
of O
whether O
sertraline B-drug
is O
the O
best O
choice O
for O
prolonged O
use O
for O
diabetic O
individuals O
, O
because O
of O
its O
antihyperglycemic O
effects O
. O

Due O
to O
the O
considerable O
variability O
of O
these O
interactions O
, O
the O
dosage O
of O
digoxin B-drug
should O
be O
individualized O
when O
patients O
receive O
these O
medications O
concurrently O
. O

increased O
prothrombin O
and O
factors O
VII O
, O
VIII O
, O
IX O
, O
and O
X O
; O

Tablet O
If O
a O
patient O
receiving O
clonidine B-drug
hydrochloride I-drug
is O
also O
taking O
tricyclic B-group
antidepressants I-group
, O
the O
effect O
of O
clonidine B-drug
may O
be O
reduced O
, O
thus O
necessitating O
an O
increase O
in O
dosage O
. O

As O
a O
consequence O
, O
when O
INDOCIN B-brand
and O
lithium B-drug
are O
given O
concomitantly O
, O
the O
patient O
should O
be O
carefully O
observed O
for O
signs O
of O
lithium B-drug
toxicity O
. O

Blood O
Sugar O
: O
Some O
patients O
receiving O
retinoids B-group
have O
experienced O
problems O
with O
blood O
sugar O
control O
. O

Antifungals B-group

avoid O
use O
if O
possible O
or O
closely O
monitor O
cardiovascular O
status O
at O
the O
end O
of O
drug O
interactions O

Caffeine B-drug
Theobromine I-drug
Grepafloxacin I-drug
, O
like O
other O
quinolones B-group
, O
may O
inhibit O
the O
metabolism O
of O
caffeine B-drug
and O
theobromine B-drug
. O

Clinical O
studies O
of O
PEGASYS B-brand
alone O
or O
in O
combination O
with O
COPEGUS B-brand
did O
not O
include O
sufficient O
numbers O
of O
subjects O
aged O
65 O
or O
over O
to O
determine O
whether O
they O
respond O
differently O
from O
younger O
subjects O
. O

d-amphetamine B-drug
with O
desipramine B-drug
or O
protriptyline B-drug
and O
possibly O
other O
tricyclics B-group
cause O
striking O
and O
sustained O
increases O
in O
the O
concentration O
of O
d-amphetamine B-drug
in O
the O
brain O
; O

RESULTS O
: O
Insulin B-drug
increased O
renal O
plasma O
flow O
and O
fundus O
pulsation O
amplitude O
but O
not O
the O
glomerular O
filtration O
rate O
. O

During O
concomitant O
therapy O
with O
NSAIDs B-group
, O
the O
patient O
should O
be O
observed O
closely O
for O
signs O
of O
renal O
failure O
, O
as O
well O
as O
to O
assure O
diuretic O
efficacy O
. O

Mixtures O
should O
not O
be O
administered O
intravenously O
. O

Magnesium B-drug
: O
Magnesium-containing B-drug
preparations O
( O
eg O
, O
antacids B-group
) O
may O
cause O
hypermagnesemia O
and O
should O
therefore O
not O
be O
taken O
during O
therapy O
with O
vitamin B-group
D I-group
by O
patients O
on O
chronic O
renal O
dialysis O
. O

The O
safety O
of O
using O
STADOL B-brand
NS I-brand
and O
IMITREX B-brand
( O
sumatriptan B-drug
) O
Nasal O
Spray O
during O
the O
same O
episode O
of O
migraine O
has O
not O
been O
established O
. O

Cevimeline B-drug
should O
be O
administered O
with O
caution O
to O
patients O
taking O
beta B-group
adrenergic I-group
antagonists I-group
, O
because O
of O
the O
possibility O
of O
conduction O
disturbances O
. O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCAmay B-group
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Depending O
on O
the O
fraction O
of O
drug O
metabolized O
by O
P450 O
2D6 O
, O
the O
increase O
in O
plasma O
concentration O
may O
be O
small O
, O
or O
quite O
large O
( O
8 O
fold O
increase O
in O
plasma O
AUC O
of O
the O
TCA B-group
) O
. O

No O
interaction O
with O
the O
tricyclic B-group
antidepressant I-group
imipramine B-drug
was O
shown O
in O
a O
single-dose O
study O
with O
entacapone B-drug
without O
coadministered O
levodopa/dopa-decarboxylase B-drug
inhibitor B-group
. O

Drug/Laboratory O
Test O
Interactions O
Effect O
on O
Blood O
Coagulation O
: O
Diclofenac B-drug
increases O
platelet O
aggregation O
time O
but O
does O
not O
affect O
bleeding O
time O
, O
plasma O
thrombin O
clotting O
time O
, O
plasma O
fibrinogen O
, O
or O
factors O
V O
and O
VII O
to O
XII O
. O

Such O
patients O
may O
be O
unresponsive O
to O
the O
usual O
doses O
of O
epinephrine B-drug
used O
to O
treat O
the O
allergic O
reaction O
. O

This O
diminution O
is O
not O
sufficient O
to O
preclude O
effectiveness O
of O
the O
pressor O
agent O
for O
therapeutic O
use O
. O
) O

Morphine B-drug
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
the O
clearance O
of O
morphine B-drug
. O

This O
may O
potentiate O
and O
prolong O
hypnotic O
and O
sedative O
effects O
. O

Ketoconazole B-drug
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P450 O
3A4 O
enzyme O
system O
. O

Each O
healthy O
subject O
( O
N O
= O
10 O
) O
received O
rofecoxib B-drug
( O
75 O
mg O
once O
daily O
) O
or O
placebo O
for O
11 O
days O
in O
a O
double-blind O
, O
randomized O
, O
balanced O
, O
two-period O
crossover O
study O
. O

Since O
colestipol B-drug
hydrochloride I-drug
is O
an O
anion B-group
exchange I-group
resin I-group
, O
it O
may O
have O
a O
strong O
affinity O
for O
anions O
other O
than O
the O
bile O
acids O
. O

In O
such O
cases O
of O
combined O
treatment O
, O
the O
dose O
of O
one O
or O
both O
agents O
should O
be O
reduced O
. O

Intracellular O
resistance O
to O
thyroid B-group
hormone I-group
is O
quite O
rare O
. O

Drugs O
that O
suppress O
the O
immune O
system O
are O
widely O
used O
. O

Saquinavir B-drug
steady-state O
Cmax O
, O
A.C. O
and O
Cmin O
were O
increased O
21 O
% O
, O
decreased O
19 O
% O
, O
and O
decreased O
48 O
% O
, O
respectively O
, O
by O
concomitant O
amprenavir B-drug
. O

Anticholinergics B-group
antagonize O
the O
effects O
of O
antiglaucoma B-group
agents I-group
. O

The O
intake O
of O
furosemide B-drug
and O
sucralfate B-drug
should O
be O
separated O
by O
at O
least O
two O
hours O
. O

Patients O
taking O
digoxin B-drug
should O
be O
monitored O
appropriately O
. O

For O
this O
reason O
the O
dose O
of O
adrenaline B-drug
should O
be O
restricted O
and O
an O
antiarrhythmic B-group
agent I-group
administered O
as O
appropriate O
. O

On O
the O
other O
hand O
, O
the O
density O
of O
D2 O
binding O
sites O
in O
the O
SST O
and O
the O
RBC O
mice O
in O
the O
STR O
was O
significantly O
increased O
in O
cocaine-treated B-drug
groups O
without O
change O
in O
Kd O
. O

This O
study O
investigated O
the O
role O
of O
neuronal O
uptake O
of O
norepinephrine B-drug
( O
uptake-1 O
) O
in O
human O
heart O
failure O
as O
a O
local O
factor O
for O
altering O
concentrations O
of O
norepinephrine O
at O
the O
cardiac O
myocyte O
membranes O
. O

In O
clinical O
trials O
, O
mean O
decreases O
of O
1 O
to O
2 O
mg/dL O
were O
observed O
in O
arthritic O
patients O
receiving O
etodolac B-drug
( O
600 O
mg O
to O
1000 O
mg/day O
) O
after O
4 O
weeks O
of O
therapy O
. O

Breakthrough O
bleeding O
has O
been O
reported O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

A O
variety O
of O
toxic O
neurological O
effects O
and O
malignant O
hyperpyrexia O
can O
occur O
, O
sometimes O
with O
fatal O
results O
. O

Postoperative O
respiratory O
depression O
may O
be O
enhanced O
or O
prolonged O
by O
these O
agents O
. O

Both O
groups O
of O
agents O
increase O
blood O
levels O
and O
therefore O
potentiate O
the O
actions O
of O
amphetamines B-group
. O

Therefore O
, O
monitoring O
of O
blood O
glucose O
is O
recommended O
when O
these O
agents O
are O
co-administered O
. O

Hypersensitivity O
reactions O
have O
been O
reported O
in O
patients O
receiving O
combination O
regimens O
containing O
sequential O
high O
dose O
PROLEUKIN B-brand
and O
antineoplastic B-group
agents I-group
, O
specifically O
, O
dacarbazine B-drug
, O
cis-platinum B-drug
, O
tamoxifen B-drug
and O
interferon-alfa B-drug
. O

Concurrent O
administration O
of O
oxyphenbutazone B-drug
and O
androgens B-group
may O
result O
in O
elevated O
serum O
levels O
of O
oxyphenbutazone B-drug
. O

Increased O
ectopic O
pacemaker O
activity O
can O
occur O
when O
pseudoephedrine B-drug
is O
used O
concomitantly O
with O
digitalis B-group
. O

When O
concomitant O
treatment O
with O
agents B-group
with I-group
b-blocking I-group
properties I-group
and O
clonidine B-drug
is O
to O
be O
terminated O
, O
the O
b-blocking B-group
agent I-group
should O
be O
discontinued O
first O
. O

Blunting O
of O
the O
antihypertensive O
effect O
of O
beta-adrenoceptor B-group
blocking I-group
agents I-group
by O
non-steroidal B-group
antiinflammatory I-group
drugs I-group
including O
INDOCIN B-brand
has O
been O
reported O
. O

Serious O
cardiac O
dysrhythmias O
, O
some O
resulting O
in O
death O
, O
have O
occurred O
in O
patients O
receiving O
terfenadine B-drug
concomitantly O
with O
other O
macrolide B-group
antibiotics I-group
. O

The O
growth O
of O
Pseudomonas O
aeruginosa O
, O
particularly O
serotype O
O11 O
, O
in O
pentazocine B-drug
and O
tripelennamine B-drug

There O
is O
strong O
evidence O
that O
insulin O
resistance O
is O
involved O
in O
the O
development O
of O
not O
only O
hyperglycemia O
, O
but O
also O
dyslipidemia O
, O
hypertension O
, O
hypercoagulation O
, O
vasculopathy O
, O
and O
ultimately O
atherosclerotic O
cardiovascular O
disease O
. O

Central B-group
Nervous I-group
System I-group
Depressants I-group
: O
The O
concomitant O
use O
of O
DURAGESIC B-brand
( O
fentanyl B-drug
transdermal O
system O
) O
with O
other O
central B-group
nervous I-group
system I-group
depressants I-group
, O
including O
but O
not O
limited O
to O
other O
opioids B-group
, O
sedatives B-group
, O
hypnotics B-group
, O
tranquilizers B-group
( O
e.g. O
, O
benzodiazepines B-group
) O
, O
general O
anesthetics B-group
, O
phenothiazines B-group
, O
skeletal B-group
muscle I-group
relaxants I-group
, O
and O
alcohol B-drug
, O
may O
cause O
respiratory O
depression O
, O
hypotension O
, O
and O
profound O
sedation O
, O
or O
potentially O
result O
in O
coma O
or O
death O
. O

OBJECTIVE O
: O
Our O
objective O
was O
to O
examine O
the O
interaction O
between O
fluvoxamine B-drug
and O
tolbutamide B-drug
to O
confirm O
that O
fluvoxamine B-drug
inhibits O
CYP2C9 O
. O

Abciximab B-drug
has O
been O
administered O
to O
patients O
with O
ischemic O
heart O
disease O
treated O
concomitantly O
with O
a O
broad O
range O
of O
medications O
used O
in O
the O
treatment O
of O
angina O
myocardial O
infarction O
and O
hypertension O
. O

Patients O
receiving O
insulin B-drug
or O
oral O
hypoglycemics B-group
should O
be O
closely O
watched O
during O
initiation O
of O
thyroid O
replacement O
therapy O
. O

No O
data O
for O
saquinavir B-drug
. O

N=48 O
) O
decreases O
hydrocodone B-drug
( O
10 O
mg O
; O

Appropriate O
laboratory O
testing O
should O
be O
considered O
prior O
to O
initiating O
combination O
therapy O
with O
Amprenavir B-drug
and O
ritonavir B-drug
and O
at O
periodic O
intervals O
or O
if O
any O
clinical O
signs O
or O
symptoms O
of O
hyperlipidemia O
or O
elevated O
liver O
function O
tests O
occur O
during O
therapy O
. O

Griseofulvin B-drug
: O
Griseofulvin B-drug
may O
induce O
the O
metabolism O
of O
combination B-group
hormonal I-group
contraceptives I-group
causing O
menstrual O
changes O
; O

It O
is O
not O
known O
whether O
other O
progestational B-group
contraceptives I-group
, O
such O
as O
implants O
and O
injectables O
, O
are O
adequate O
methods O
of O
contraception O
during O
acitretin B-drug
therapy O
. O

Because O
heparin B-drug
, O
aspirin B-brand
, O
or O
Activase B-brand
may O
cause O
bleeding O
complications O
, O
careful O
monitoring O
for O
bleeding O
is O
advised O
, O
especially O
at O
arterial O
puncture O
sites O
. O

There O
is O
no O
pharmacokinetic O
interaction O
between O
ethanol B-drug
and O
flumazenil B-drug
. O

This O
is O
demonstrated O
for O
cigarette O
smokers O
and O
industrial O
workers O
involved O
in O
chemical O
waste O
incineration O
. O

Differences O
in O
clearance O
between O
patients O
on O
these O
medications O
( O
at O
any O
occasion O
in O
the O
study O
) O
and O
those O
off O
medications O
varied O
between O
-16 O
% O
and O
+3 O
% O
. O

The O
adverse O
effects O
of O
CAMPTOSAR B-brand
, O
such O
as O
myelosuppression O
and O
diarrhea O
, O
would O
be O
expected O
to O
be O
exacerbated O
by O
other O
antineoplastic B-group
agents I-group
having O
similar O
adverse O
effects O
. O

It O
is O
, O
however O
, O
possible O
that O
concomitant O
use O
of O
other O
known O
photosensitizing B-group
agents I-group
such O
as O
griseofulvin B-drug
, O
thiazide B-group
diuretics I-group
, O
sulfonylureas B-group
, O
phenothiazines B-group
, O
sulfonamides B-group
and O
tetracyclines B-group
might O
increase O
the O
photosensitivity O
reaction O
of O
actinic O
keratoses O
treated O
with O
the O
LEVULAN B-brand
KERASTICK I-brand
for O
Topical O
Solution O
. O

No O
evaluation O
of O
EXTRANEALs B-brand
effects O
on O
the O
cytochrome O
P450 O
system O
was O
conducted O
. O

These O
increases O
should O
be O
considered O
when O
selecting O
an O
oral O
contraceptive B-group
for O
a O
woman O
taking O
atorvastatin B-drug
. O

Cimetidine B-drug
: O
Cimetidine B-drug
has O
been O
reported O
to O
produce O
clinically O
significant O
fluctuations O
in O
steady-state O
serum O
concentrations O
of O
various O
tricyclic B-group
antidepressants I-group
. O

In O
patients O
on O
chronic O
warfarin B-drug
therapy O
, O
the O
prothrombin O
time O
( O
INR O
) O
should O
be O
closely O
monitored O
in O
the O
2-week O
period O
, O
particularly O
at O
7 O
to O
10 O
days O
, O
following O
initiation O
of O
the O
3-day O
regimen O
of O
Aprepitant B-drug
with O
each O
chemotherapy O
cycle O
. O

Therefore O
, O
a O
potent O
effect O
of O
etofibrate B-drug
on O
both O
chylomicron O
lipolysis O
and O
remnant O
removal O
was O
achieved O
, O
indicating O
that O
this O
drug O
can O
be O
used O
to O
improve O
this O
metabolism O
in O
future O
prospective O
studies O
. O

Antimycobacterial B-group
: O
rifampin B-drug

Patients O
already O
stabilized O
on O
valdecoxib B-drug
should O
be O
closely O
monitored O
for O
loss O
of O
symptom O
control O
with O
phenytoin B-drug
coadministration O
. O

There O
were O
26 O
PI O
with O
drugs O
of O
low O
intrinsic O
value O
( O
7.6 O
% O
; O
95 O
% O
CI O
, O
+/- O
2.8 O
) O
. O

Seizures O
have O
been O
reported O
in O
patients O
taking O
another O
quinolone B-group
class I-group
antimicrobial I-group
and O
the O
nonsteroidal B-group
anti-inflammatory I-group
drug I-group
fenbufen B-drug
concurrently O
. O

Monitoring O
of O
disopyramide B-drug
plasma O
levels O
is O
recommended O
in O
such O
concurrent O
use O
to O
avoid O
ineffective O
therapy O
. O

Available O
data O
are O
not O
sufficient O
, O
however O
, O
to O
predict O
the O
effects O
of O
concomitant O
medication O
on O
patients O
with O
impaired O
ventricular O
function O
or O
cardiac O
conduction O
abnormalities O
. O

Withdrawal O
of O
rifampin B-drug
decreased O
the O
warfarin B-drug
requirement O
by O
50 O
% O
. O

In O
patients O
who O
have O
received O
general O
anesthesia O
utilizing O
a O
volatile O
agent O
known O
to O
sensitize O
the O
myocardium O
to O
catecholamines O
, O
administration O
of O
doxapram B-drug
should O
be O
delayed O
until O
the O
volatile O
agent O
has O
been O
excreted O
in O
order O
to O
lessen O
the O
potential O
for O
arrhythmias O
, O
including O
ventricular O
tachycardia O
and O
ventricular O
fibrillation O
. O

This O
defect O
in O
the O
failing O
heart O
can O
be O
mimicked O
by O
the O
effects O
of O
uptake O
blocking O
agents O
, O
such O
as O
cocaine B-drug
and O
desipramine B-drug
, O
in O
the O
nonfailing O
heart O
only O
. O

Patients O
treated O
with O
Nalfon B-brand
may O
be O
resistant O
to O
the O
effects O
of O
loop B-group
diuretics I-group
. O

In O
Europe O
, O
Nimotop B-brand
was O
observed O
to O
occasionally O
intensify O
the O
effect O
of O
antihypertensive B-group
compounds I-group
taken O
concomitantly O
by O
patients O
suffering O
from O
hypertension O
; O

Inhibits O
CYP2D6 O
( O
weak O
) O
. O

Cholestyramine B-drug
, O
an O
anionic-binding O
resin O
, O
has O
a O
considerable O
effect O
in O
lowering O
the O
rate O
and O
extent O
of O
fluvastatin B-drug
bioavailability O
. O

Drugs O
that O
have O
been O
reported O
to O
diminish O
oral O
anticoagulant B-group
response O
, O
ie O
, O
decreased O
prothrom-bin O
time O
response O
, O
in O
man O
significantly O
include O
: O
adrenocortical B-group
steroids I-group
; O

Certain O
concomitant O
medications O
( O
such O
as O
rifampin B-drug
, O
anticonvulsants B-group
, O
St O
. O

The O
authors O
investigated O
the O
possibility O
of O
a O
similar O
interaction O
between O
oxycodone B-drug
and O
levofloxacin B-drug
. O

The O
successive O
application O
of O
glycine B-drug
( O
5 O
or O
10 O
mg/kg O
egg O
weight O
( O
e.w O
. O
) O

Combinations O
of O
clindamycin B-drug
and O
gentamicin B-drug
were O
indifferent O
for O
16 O
and O
synergistic O
for O
11 O
of O
the O
resistant O
strains O
. O

Concurrent O
use O
of O
erythromycin B-drug
and O
ergotamine B-drug
or O
dihydroergotamine B-drug
has O
been O
associated O
in O
some O
patients O
with O
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O

Triazolam B-drug
- O
Combined O
administration O
of O
racemic O
citalopram B-drug
( O
titrated O
to O
40 O
mg/day O
for O
28 O
days O
) O
and O
the O
CYP3A4 O
substrate O
triazolam B-drug
( O
single O
dose O
of O
0.25 O
mg O
) O
did O
not O
significantly O
affect O
the O
pharmacokinetics O
of O
either O
citalopram B-drug
or O
triazolam B-drug
. O

Aprepitant B-drug
is O
a O
substrate O
, O
a O
moderate O
inhibitor O
, O
and O
an O
inducer O
of O
CYP3A4 O
. O

Due O
to O
highintersubject O
variability O
, O
however O
, O
somepatients O
may O
experience O
large O
increases O
inrifabutin B-drug
exposure O
and O
may O
be O
at O
higher O
riskfor O
rifabutin O
toxicity O
. O

In O
eight O
experiments O
the O
perfusion O
medium O
contained O
oxytocin B-drug
. O

The O
anticoagulant O
effect O
of O
heparin B-drug
is O
enhanced O
by O
concurrent O
treatment O
with O
antithrombin B-drug
III I-drug
( O
human O
) O
in O
patients O
with O
hereditary O
antithrombin O
III O
deficiency O
. O

After O
multiple O
dosing O
, O
interferon B-drug
beta-1a I-drug
( O
AVONEX B-brand
30 O
mcg O
IM O
once O
weekly O
) O
reduced O
TYSABRI B-brand
clearance O
by O
approximately O
30 O
% O
. O

Drug O
interactions O
between O
NEUPOGEN B-brand
and O
other O
drugs O
have O
not O
been O
fully O
evaluated O
. O

Fluconazole B-drug
, O
an O
inhibitor O
of O
P450 O
2C9 O
, O
decreased O
active O
metabolite O
concentration O
and O
increased O
losartan B-drug
concentration O
. O

A O
proposed O
mechanism O
for O
the O
potentiation O
of O
cAMP-mediated O
acid O
secretion O
by O
carbachol B-drug
. O

Renal O
Impairment O
There O
are O
currently O
no O
clinical O
studies O
with O
SPRYCEL B-brand
in O
patients O
with O
impaired O
renal O
function O
( O
clinical O
studies O
have O
excluded O
patients O
with O
serum O
creatinine O
concentration O
1.5 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
. O

Limited O
clinical O
data O
in O
angina O
patients O
receiving O
concomitant O
bepridil B-drug
hydrochloride I-drug
and O
digoxin B-drug
therapy O
indicate O
no O
discernible O
changes O
in O
serum O
digoxin O
levels O
. O

FLEXERIL B-brand
may O
enhance O
the O
effects O
of O
alcohol B-drug
, O
barbiturates B-group
, O
and O
other O
CNS B-group
depressants I-group
. O

Interactions O
of O
cobalt B-drug
and O
iron B-drug
in O
absorption O
and O
retention O
. O

Adenosine B-drug
: O
Dipyridamole B-drug
has O
been O
reported O
to O
increase O
the O
plasma O
levels O
and O
cardiovascular O
effects O
of O
adenosine B-drug
. O

Cholestyramine B-drug
and O
colestipol B-drug
resins B-group
: O
Absorption O
of O
hydrochlorothiazide B-drug
is O
impaired O
in O
the O
presence O
of O
anionic B-group
exchange I-group
resins I-group
. O

Beta-adrenergic B-group
Blocking I-group
Agents I-group
: O
The O
effect O
of O
flurbiprofen B-drug
on O
blood O
pressure O
response O
to O
propranolol B-drug
and O
atenolol B-drug
was O
evaluated O
in O
men O
with O
mild O
uncomplicated O
hypertension O
( O
n O
= O
10 O
) O
. O

methyldopa B-drug
; O

Because O
the O
nitrosourea B-group
CCNU B-drug
is O
given O
exclusively O
by O
the O
oral O
route O
in O
man O
, O
we O
have O
carried O
out O
studies O
in O
mice O
on O
the O
antitumour O
activity O
, O
acute O
toxicity O
and O
pharmacokinetics O
of O
oral O
CCNU B-drug
, O
either O
alone O
or O
in O
combination O
with O
the O
chemosensitizer O
misonidazole B-drug_n
. O

Given O
the O
primary O
CNS O
effects O
of O
Anafranil B-brand
, O
caution O
is O
advised O
in O
using O
it O
concomitantly O
with O
other O
CNS-active O
drugs O
. O

This O
may O
occur O
because O
diflunisal B-drug
competitively O
displaces O
coumarins B-group
from O
protein O
binding O
sites O
. O

In O
vivo O
studies O
: O
Cytochrome O
P450 O
Inhibitors O

These O
potential O
drug O
interactions O
are O
listed O
in O
Table O
4 O
. O

It O
is O
recommended O
not O
to O
exceed O
a O
single O
2.5 O
mg O
Vardenafil B-drug
dose O
in O
a O
24-hour O
period O
when O
used O
in O
combination O
with O
indinavir B-drug
. O

Because O
severe O
hypoglycemia O
has O
been O
reported O
in O
patients O
concomitantly O
receiving O
oral O
miconazole B-drug
( O
an O
imidazole B-group
) O
and O
oral O
hypoglycemic B-group
agents I-group
, O
such O
a O
potential O
interaction O
involving O
the O
latter O
agents O
when O
used O
concomitantly O
with O
ketoconazole B-drug
tablets O
( O
an O
imidazole B-group
) O
can O
not O
be O
ruled O
out O
. O

The O
oral O
dexamethasone B-drug
doses O
should O
be O
reduced O
by O
approximately O
50 O
% O
when O
coadministered O
with O
Aprepitant B-drug
, O
to O
achieve O
exposures O
of O
dexamethasone B-drug
similar O
to O
those O
obtained O
when O
it O
is O
given O
without O
Aprepitant B-drug
. O

Beta-Blocking O
Agents O
A O
pharmacokinetic O
study O
of O
felodipine B-drug
in O
conjunction O
with O
metoprolol B-drug
demonstrated O
no O
significant O
effects O
on O
the O
pharmacokinetics O
of O
felodipine B-drug
. O

ROMAZICON B-brand
blocks O
the O
central O
effects O
of O
benzodiazepines B-group
by O
competitive O
interaction O
at O
the O
receptor O
level O
. O

Serum O
Amylase O
An O
apparent O
decrease O
in O
serum O
amylase O
activity O
has O
been O
observed O
in O
patients O
administered O
EXTRANEAL B-brand
. O

Therefore O
, O
if O
concomitant O
use O
of O
such O
agents O
is O
indicated O
, O
they O
should O
be O
given O
with O
caution O
, O
and O
the O
patient O
's O
serum O
potassium O
should O
be O
monitored O
frequently O
. O

In O
addition O
, O
certain O
drugs O
that O
are O
metabolized O
by O
this O
isozyme O
, O
including O
many O
antidepressants B-group
( O
clozapine B-drug
, O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
, O
and O
others O
) O
, O
may O
inhibit O
the O
activity O
of O
this O
isozyme O
, O
and O
thus O
may O
make O
normal O
metabolizers O
resemble O
poor O
metabolizers O
with O
regard O
to O
concomitant O
therapy O
with O
other O
drugs O
metabolized O
by O
this O
enzyme O
system O
, O
leading O
to O
drug O
interaction O
. O

increased O
alkaline O

Ethanol B-drug
or O
Triazolam B-drug
: O
No O
significant O
differences O
were O
observed O
in O
the O
pharmacokinetics O
of O
triazolam B-drug
( O
0.125 O
mg O
) O
and O
tiagabine B-drug
( O
10 O
mg O
) O
when O
given O
together O
as O
a O
single O
dose O
. O

Studies O
have O
demonstrated O
that O
pretreatment O
with O
isoniazid B-drug
potentiates O
a O
cetaminophen O
hepatoxicity O
in O
rats O
. O

Ibogaine B-drug_n
attenuates O
, O
but O
18-MC B-drug_n
potentiates O
, O
the O
acute O
locomotor O
effects O
of O
morphine B-drug
; O

The O
carbamazepine B-drug
steady-state O
Cmin O
decreased O
31 O
% O
to O
5 O
1 O
micrograms/mL O
when O
felbamate B-drug
( O
3000 O
mg/day O
, O
divided O
into O
three O
doses O
) O
was O
coadministered O
. O

Sodium B-drug
cephalothin I-drug
may O
enhance O
the O
nephrotoxicity O
of O
Coly-Mycin B-brand
M I-brand
Parenteral O
. O

magnesium B-drug
salts O
; O

The O
gradual O
withdrawal O
of O
guafacine B-drug
or O
a O
cardioselective B-group
beta-blocker I-group
could O
be O
substituted O
. O

Refer O
to O
the O
package O
insert O
for O
lithium B-drug
preparations O
before O
use O
of O
such O
preparations O
with O
Hydrochlorothiazide B-drug
. O

Therefore O
, O
if O
theophylline B-drug
is O
co-administered O
with O
fluvoxamine B-drug
maleate I-drug
, O
its O
dose O
should O
be O
reduced O
to O
one O
third O
of O
the O
usual O
daily O
maintenance O
dose O
and O
plasma O
concentrations O
of O
theophylline B-drug
should O
to O
monitored O
. O

Caution O
in O
using O
concomitant O
drugs O
such O
as O
beta-blockers B-group
( O
ophthalmic O
and O
systemic O
) O
, O
anti-hypertensives B-group
and/or O
cardiac B-group
glycosides I-group
is O
advised O
. O

Beta-adrenergic B-group
blocking I-group
agents I-group
may O
also O
interact O
with O
sympathomimetics B-group
. O

EDECRIN B-brand
may O
increase O
the O
ototoxic O
potential O
of O
other O
drugs O
such O
as O
aminoglycoside B-group
and O
some O
cephalosporin B-group
antibiotics I-group
. O

A O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper O
reduction O
tests O
( O
Benedicts O
or O
Fehlings O
solution O
or O
with O
CLINITEST O
tablets O
) O
, O
but O
not O
with O
enzyme-based O
tests O
for O
glycosuria O
( O
e.g. O
, O
CLINISTIX O
, O
TES-TAPE O
) O
. O

Immunosuppressants B-group
: O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
sirolimus B-drug

Pentamidine B-drug
may O
cause O
hypoglycemia O
, O
which O
may O
sometimes O
be O
followed O
by O
hyperglycemia O
. O

quinine B-drug
; O

This O
effect O
may O
be O
mediated O
by O
the O
known O
inhibition O
of O
hepatic O
cytochrome O
P- O
450 O
by O
cimetidine B-drug
, O
which O
could O
decrease O
first O
pass O
metabolism O
of O
nimodipine B-drug
. O

It O
is O
not O
known O
whether O
this O
potentiation O
of O
ampicillin B-drug
rashes O
is O
due O
to O
allopurinol B-drug
or O
the O
hyperuricemia O
present O
in O
these O
patients O
. O

Theophylline B-drug
: O
Following O
co-administration O
of O
two O
250-mg O
dirithromycin B-drug
tablets O
administered O
once O
daily O
with O
200-mg O
theophylline B-drug
tablets O
administered O
twice O
daily O
for O
10 O
days O
to O
14 O
healthy O
subjects O
, O
the O
steady-state O
plasma O
concentration O
of O
theophylline B-drug
was O
not O
significantly O
altered O
. O

These O
reactions O
have O
also O
been O
reported O
in O
patients O
who O
have O
discontinued O
that O
drug O
and O
have O
been O
started O
on O
a O
MAOI B-group
. O

Zidovudine B-drug
: O
There O
is O
no O
significant O
pharmacokinetic O
interaction O
between O
ZDV B-drug
and O
zalcitabine B-drug
which O
has O
been O
confirmed O
clinically O
. O

The O
concomitant O
use O
of O
transdermal O
fentanyl B-drug
with O
ritonavir B-drug
or O
other O
potent O
3A4 O
inhibitors O
such O
as O
ketoconazole B-drug
, O
itraconazole B-drug
, O
troleandomycin B-drug
, O
clarithromycin B-drug
, O
nelfinavir B-drug
, O
and O
nefazadone O
may O
result O
in O
an O
increase O
in O
fentanyl B-drug
plasma O
concentrations O
. O

Most O
( O
98 O
% O
) O
of O
plasma O
doxazosin B-drug
is O
protein O
bound O
. O

Tetracycline B-drug
, O
a O
bacteriostatic B-group
antibiotic I-group
, O
may O
antagonize O
the O
bactercidal O
effect O
of O
penicillin B-drug
and O
concurrent O
use O
of O
these O
drugs O
should O
be O
avoided O
. O

Specific O
interaction O
studies O
have O
demonstrated O
the O
following O
: O
Cyclosporine B-drug
A I-drug
: O
During O
the O
first O
day O
of O
concomitant O
administration O
, O
trough O
concentrations O
of O
bosentan B-drug
were O
increased O
by O
about O
30-fold O
. O

This O
has O
been O
demonstrated O
in O
view O
, O
however O
, O
the O
clinical O
significance O
of O
this O
interaction O
is O
not O
well O
documented O
. O

Ketoconazole B-drug
( O
400 O
mg O
once O
daily O
) O

Conflicting O
results O
have O
been O
reported O
regarding O
the O
effects O
of O
EPA B-drug
supplements O
on O
glycemic O
control O
in O
non-diabetics O
with O
glucose O
intolerance O
, O
and O
those O
with O
type O
2 O
diabetes O
. O

Hematology O
: O
TAXOL B-brand
therapy O
should O
not O
be O
administered O
to O
patients O
with O
baseline O
neutrophil O
counts O
of O
less O
than O
1,500 O
cells/mm3 O
. O

However O
, O
another O
HMG-CoA B-group
reductase I-group
inhibitor I-group
has O
been O
found O
to O
produce O
a O
less O
than O
two-second O
increase O
in O
prothrombin O
time O
in O
healthy O
volunteers O
receiving O
low O
doses O
of O
warfarin B-drug
. O

Warfarin B-drug
: O
Co-administration O
of O
bosentan B-drug
500 O
mg O
b.i.d O
. O
for O
6 O
days O
decreased O
the O
plasma O
concentrations O
of O
both O
S-warfarin B-drug
( O
a O
CYP2C9 O
substrate O
) O
and O
R-warfarin B-drug
( O
a O
CYP3A4 O
substrate O
) O
by O
29 O
and O
38 O
% O
, O
respectively O
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

The O
administration O
of O
local O
anesthetic B-group
solutions I-group
containing O
epinephrine B-drug
or O
norepinephrine B-drug
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
or O
phenothiazines B-group
may O
produce O
severe O
, O
prolonged O
hypotension O
or O
hypertension O
. O

Acid O
secretion O
in O
isolated O
rabbit O
gastric O
glands O
was O
monitored O
by O
the O
accumulation O
of O
[ O
( O
14 O
) O
C O
] O
aminopyrine B-drug
. O

Antiarrhythmics B-group
: O
bepridil B-drug
, O
lidocaine B-drug
( O
systemic O
) O
and O
quinidine B-drug

Therefore O
, O
when O
INDOCIN B-brand
and O
INDOCIN B-brand
. O

decreased O
levels O
of O
anti-factor O
Xa O
and O
antithrombin B-drug
III I-drug
, O
decreased O
antithrombin B-drug
III I-drug
activity O
; O

Anticoagulant B-brand
therapy O
should O
be O
monitored O
, O
particularly O
during O
the O
first O
few O
weeks O
, O
after O
initiating O
therapy O
with O
BEXTRA B-brand
in O
patients O
receiving O
warfarin B-drug
or O
similar O
agents O
. O

Based O
on O
in O
vitro O
data O
, O
no O
interaction O
would O
be O
expected O
with O
drugs O
whose O
metabolism O
is O
dependent O
upon O
cytochrome O
P450 O
isozymes O
1A1 O
, O
1A2,2A6,2B6,2D6,2E1 O
, O
or O
3A4 O
. O

Ketoconazole B-drug
: O
Coadministration O
of O
ketoconazole B-drug
with O
VIRACEPT B-brand
resulted O
in O
a O
35 O
% O
increase O
in O
nelfinavir B-drug
plasma O
A.C O
. O

Moreover O
, O
additional O
interaction O
studies O
with O
niacin B-drug
and O
propranolol B-drug
have O
not O
demonstrated O
any O
effect O
on O
fluvastatin B-drug
plasma O
levels O
, O
and O
administration O
to O
a O
patient O
population O
chronically O
receiving O
digoxin B-drug
resulted O
in O
no O
difference O
in O
the O
extent O
of O
bioavailability O
of O
digoxin B-drug
relative O
to O
control O
data O
. O

The O
initiation O
of O
alcohol B-drug
or O
nicotine B-drug
use O
may O
be O
precipitated O
by O
similar O
personality O
characteristics O
in O
the O
user O
, O
such O
as O
impulsivity O
and O
sensation O
seeking O
. O

ZINECARD B-brand
does O
not O
influence O
the O
pharmacokinetics O
of O
doxorubicin B-drug
. O

FORADIL B-brand
should O
not O
be O
used O
as O
a O
substitute O
for O
oral O
or O
inhaled O
corticosteroids B-group
. O

dmPGE2 B-drug_n
( O
0.1-1.0 O
mg/kg O
, O
p.o O
. O
) O

A O
subset O
( O
3 O
% O
-10 O
% O
) O
of O
the O
population O
has O
reduced O
activity O
of O
certain O
drug O
metabolizing O
enzymes O
such O
as O
the O
cytochrome O
P450 O
isozyme O
P450 O
2D6 O
. O

It O
may O
also O
produce O
artifactually O
low O
results O
in O
dexamethasone O
or O
metyrapone O
tests O
. O

- O
Reduced O
response O
to O
metyrapone O
test O

Potential O
drug O
interactions O
for O
doxylamine B-drug
include O
, O
increased O
sedation O
if O
doxylamine B-drug
is O
combined O
with O
other O
CNS B-group
depressant I-group
drugs I-group
. O

Amprenavir B-drug
plus O
rifabutin B-drug
was O
poorly O
tolerated O
, O
and O
5 O
of O
11 O
subjects O
discontinued O
therapy O
. O

Concurrent O
administration O
of O
HEXALEN B-brand
and O
antidepressants B-group
of I-group
the I-group
MAO I-group
inhibitor I-group
class I-group
may O
cause O
severe O
orthostatic O
hypotension.Cimetidine B-drug
, O
an O
inhibitor O
of O
microsomal O
drug O
metabolism O
, O
increased O
altretamines B-drug
half-life O
and O
toxicity O
in O
a O
rat O
model O
. O

Anticholinesterases B-group
: O
Concomitant O
use O
of O
anticholinesterase B-group
agents I-group
and O
corticosteroids B-group
may O
produce O
severe O
weakness O
in O
patients O
with O
myasthenia O
gravis O
. O

Such O
information O
assists O
in O
development O
of O
safe O
dosing O
regimens O
, O
prediction O
of O
abnormal O
handling O
of O
drugs O
in O
states O
of O
disease O
and O
disorder O
and O
anticipation O
of O
drug O
interactions O
. O

The O
effect O
of O
administering O
different O
botulinum B-group
neurotoxin I-group
serotypes O
at O
the O
same O
time O
or O
within O
several O
months O
of O
each O
other O
is O
unknown O
. O

In O
some O
patients O
, O
the O
administration O
of O
a O
non- B-group
steroidal I-group
antiinflammatory I-group
agent I-group
can O
reduce O
the O
diuretic B-group
, I-group
natriuretic O
, O
and O
antihypertensive O
effects O
of O
loop O
, O
potassium- O
sparing O
and O
thiazide B-group
diuretics I-group
. O

Given O
the O
primary O
CNS O
effects O
of O
Clozapine B-drug
, O
caution O
is O
advised O
in O
using O
it O
concomitantly O
with O
other O
CNS-active O
drugs O
or O
alcohol B-drug
. O

This O
suggests O
that O
an O
interaction O
of O
aripiprazole B-drug
with O
inhibitors O
or O
inducers O
of O
these O
enzymes O
, O
or O
other O
factors O
, O
like O
smoking O
, O
is O
unlikely O
. O

Animal O
reproduction O
studies O
, O
however O
, O
are O
not O
always O
predictive O
of O
human O
response O
and O
there O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant O
women O
. O

Increased O
plasma O
HDL O
and O
HDL2 O
cholesterol O
subfraction O
concentrations O
, O
reduced O
LDL O
cholesterol O
concentration O
, O
increased O
triglyceride O
levels O
. O

The O
urinary O
excretion O
of O
meclofenamate B-drug
sodium I-drug
is O
unaffected O
by O
aspirin B-brand
, O
indicating O
no O
change O
in O
meclofenamate B-drug
sodium I-drug
absorption O
. O

Renal O
function O
should O
be O
monitored O
carefully O
if O
high O
doses O
of O
aminoglycosides B-group
are O
to O
be O
administered O
with O
MAXIPIME B-brand
because O
of O
the O
increased O
potential O
of O
nephrotoxicity O
and O
ototoxicity O
of O
aminoglycoside B-group
antibiotics I-group
. O

Netilmicin B-drug
should O
not O
be O
administered O
concomitantly O
with O
potent O
loop B-group
diuretics I-group
such O
as O
furosemide B-drug
and O
ethacrynic B-drug
acid I-drug
as O
the O
potential O
for O
ototoxicity O
is O
enhanced O
by O
the O
combination O
. O

When O
warfarin B-drug
is O
co-administered O
with O
nevirapine B-drug
, O
anticoagulation O
levels O
should O
be O
monitored O
frequently O
. O

Sucralfate B-drug
administered O
2 O
hours O
before O
lomefloxacin B-drug
resulted O
in O
a O
slower O
absorption O
( O
mean O
C O
max O
decreased O
by O
30 O
% O
and O
mean O
T O
max O
increased O
by O
1 O
hour O
) O
and O
a O
lesser O
extent O
of O
absorption O
( O
mean O
AUC O
decreased O
by O
approximately O
25 O
% O
) O
. O

Medication O
is O
rarely O
needed O
. O

Liver O
Function O
Tests O
: O
Since O
elevations O
of O
liver O
enzymes O
have O
been O
observed O
during O
clinical O
trials O
, O
and O
hepatitis O
has O
been O
reported O
, O
pretreatment O
and O
follow-up O
liver O
function O
tests O
should O
be O
performed O
at O
weekly O
or O
biweekly O
intervals O
until O
the O
response O
to O
Accutane B-brand
has O
been O
established O

Renal O
function O
should O
be O
carefully O
monitored O
, O
especially O
if O
higher O
dosages O
of O
the O
aminoglycosides B-group
are O
to O
be O
administered O
or O
if O
therapy O
is O
prolonged O
, O
because O
of O
the O
potential O
nephrotoxicity O
and O
ototoxicity O
of O
aminoglycosidic B-group
antibiotics I-group
. O

A O
case O
report O
of O
one O
patient O
taking O
amiodarone B-drug
200 O
mg O
and O
indinavir B-drug
800 O
mg O
three O
times O
a O
day O
resulted O
in O
increases O
in O
amiodarone B-drug
concentrations O
from O
0.9 O
mg/L O
to O
1.3 O
mg/L O
. O

The O
addition O
of O
tiagabine B-drug
in O
a O
limited O
number O
of O
patients O
in O
three O
well-controlled O
studies O
caused O
no O
systematic O
changes O
in O
phenobarbital B-drug
or O
primidone B-drug
concentrations O
when O
compared O
to O
placebo O
. O

Therefore O
, O
injection O
of O
these O
agents O
into O
patients O
receiving O
thyroid B-group
preparations I-group
increases O
the O
risk O
of O
precipitating O
coronary O
insufficiency O
especially O
in O
patients O
with O
coronary O
artery O
disease O
. O

Here O
, O
we O
have O
examined O
whether O
METH B-drug
administration O
affects O
expression O
of O
an O
effector O
IEG O
arc O
( O
activity-regulated O
, O
cytoskeleton-associated O
) O
that O
encodes O
a O
protein O
with O
homology O
to O
spectrin O
. O

Lotensin B-brand
has O
been O
used O
concomitantly O
with O
beta-adrenergic-blocking B-group
agents I-group
, O
calcium-channel-blocking B-group
agents I-group
, O
diuretics B-group
, O
digoxin B-drug
, O
and O
hydralazine B-drug
, O
without O
evidence O
of O
clinically O
important O
adverse O
interactions O
. O

These O
pharmacokinetic O
effects O
seen O
during O
diltiazem B-drug
coadministration O
can O
result O
in O
increased O
clinical O
effects O
( O
e.g. O
, O
prolonged O
sodation O
) O
of O
both O
midazolam B-drug
and O
triazolam B-drug
. O

Combinations O
of O
clozapine B-drug
and O
phencyclidine B-drug_n
: O
effects O
on O
drug O
discrimination O
and O
behavioral O
inhibition O
in O
rats O
. O

No O
drug O
interaction O
studies O
were O
performed O
. O

RESULTS O
: O
Everolimus B-drug
steady O
state O
was O
reached O
on O
or O
before O
day O
7 O
, O
with O
a O
median O
3-fold O
accumulation O
of O
drug O
exposure O
compared O
with O
that O
after O
the O
first O
postoperative O
dose O
. O

The O
binding O
of O
thyroxine O
by O
thyroxine-binding O
prealbumin O
( O
TBPA O
) O
is O
inhibited O
by O
salicylates B-group

Warfarin B-drug
: O
Eszopiclone B-drug
3 O
mg O
administered O
daily O
for O
5 O
days O
did O
not O
affect O
the O
pharmacokinetics O
of O
( O
R O
) B-drug
- I-drug
or I-drug
( I-drug
S I-drug
) I-drug
-warfarin I-drug
, O
nor O
were O
there O
any O
changes O
in O
the O
pharmacodynamic O
profile O
( O
prothrombin O
time O
) O
following O
a O
single O
25 O
mg O
oral O
dose O
of O
warfarin B-drug

The O
patient O
continued O
to O
receive O
intermittent O
hemodialysis O
until O
his O
death O
from O
infectious O
complications O
that O
occurred O
three O
months O
after O
admission O
. O

Pharmacoeconomic O
analyses O
indicate O
that O
olanzapine B-drug
does O
not O
significantly O
increase O
, O
and O
may O
even O
decrease O
, O
the O
overall O
direct O
treatment O
costs O
of O
schizophrenia O
, O
compared O
with O
haloperidol B-drug
. O

In O
spite O
of O
the O
absence O
of O
kidney O
function O
, O
the O
value O
of O
the O
elimination O
rate O
constant O
was O
significantly O
decreased O
in O
the O
presence O
of O
probenecid B-drug
( O
from O
0.326 O
to O
0.263/h O
) O
. O

Information O
on O
precautions O
and O
contraindications O
, O
indications O
, O
use O
instructions O
, O
and O
instructions O
for O
appropriate O
actions O
after O
missing O
a O
pill O
is O
appended O
. O

Alcohol B-drug
: O
Has O
a O
synergistic O
effect O
with O
aspirin B-brand
in O
causing O
gastrointestinal O
bleeding O
. O

Immunosuppressive B-group
drugs I-group
and O
their O
complications O
. O

Current O
immunosuppressive O
therapies O
are O
effective O
but O
can O
be O
associated O
with O
significant O
adverse O
reactions O
. O

In O
addition O
, O
there O
was O
no O
pharmacodynamic O
interaction O
as O
a O
result O
of O
coadministration O
of O
zaleplon B-drug
and O
venlafaxine B-drug
ER O
. O

Increases O
in O
plasma O
levels O
of O
tricyclic B-drug
antidepressants I-drug
, O
and O
in O
the O
frequency O
and O
severity O
of O
side O
effects O
, O
particularly O
anticholinergic B-drug
, O
have O
been O
reported O
when O
cimetidine B-drug
was O
added O
to O
the O
drug B-drug
regimen O
. O

The O
mechanism O
of O
resveratrol-induced B-drug_n
vasorelaxation O
differs O
in O
the O
mesenteric O
resistance O
arteries O
of O
lean O
and O
obese O
rats O
. O

clinical O
implications O
are O
unclear O
. O

When O
the O
muscle O
was O
exposed O
to O
the O
potassium-depleted O
solution O
, O
the O
first O
contractile O
response O
to O
PTX B-drug_n
was O
rather O
potentiated O
. O

Addition O
or O
deletion O
of O
any O
drug O
from O
the O
therapeutic O
regimen O
of O
patients O
receiving O
oral O
anticoagulants B-group
may O
affect O
patient O
response O
to O
the O
anticoagulant B-group
. O

Concomitant O
use O
of O
agents O
in O
the O
tricyclic B-group
antidepressant I-group
class I-group
( O
which O
includes O
Anafranil B-brand
) O
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
agent I-group
or O
the O
other O
drug O
. O

Patients O
receiving O
other O
narcotic B-group
analgesics O
, O
general O
anesthetics B-group
, O
phenothiazines B-group
, O
tranquilizers B-group
, O
sedative-hypnotics B-group
, O
tricyclic B-group
antidepressants I-group
or O
other O
CNS B-group
depressants I-group
( O
including O
alcohol B-drug
) O
concomitantly O
with O
DILAUDID B-brand
may O
exhibit O
an O
additive O
CNS O
depression O
. O

In O
vitro O
studies O
of O
human O
CYP O
enzymes O
showed O
that O
entacapone B-drug
inhibited O
the O
CYP O
enzymes O
1A2 O
, O
2A6 O
, O
2C9 O
, O
2C19 O
, O
2D6 O
, O
2E1 O
and O
3A O
only O
at O
very O
high O
concentrations O
( O
IC50 O
from O
200 O
to O
over O
1000 O
uM O
; O

900 O

NSAIDs B-group
: O
In O
in O
vitro O
studies O
, O
M1 O
was O
shown O
to O
cause O
increases O
ranging O
from O
13 O
- O
50 O
% O
in O
the O
free O
fraction O
of O
diclofenac B-drug
and O
ibuprofen B-drug
at O
concentrations O
in O
the O
clinical O
range O
. O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

Hydrochlorothiazide B-drug
: O
In O
normal O
volunteers O
, O
concomitant O
administration O
of O
diflunisal B-drug
and O
hydrochlorothiazide B-drug
resulted O
in O
significantly O
increased O
plasma O
levels O
of O
hydrochlorothiazide B-drug
. O

Enhanced O
theophylline B-drug
clearance O
secondary O
to O
phenytoin B-drug
therapy O
. O

Glyburide B-drug
: O
An O
increased O
risk O
of O
elevated O
liver O
aminotransferases O
was O
observed O
in O
patients O
receiving O
concomitant O
therapy O
with O
glyburide B-drug
. O

Concomitant O
administration O
of O
an O
aluminum-containing B-drug
antacid B-group
had O
no O
significant O
effect O
in O
the O
bioavailability O
of O
6MNA B-drug_n
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
MICRONASE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Although O
the O
interaction O
between O
almotriptan B-drug
and O
other O
potent O
CYP3A4 O
inhibitors O
( O
e.g. O
, O
itraconazole B-drug
, O
ritonavir B-drug
, O
and O
erythromycin B-drug
) O
has O
not O
been O
studied O
, O
increased O
exposures O
to O
almotriptan B-drug
may O
be O
expected O
when O
almotriptan B-drug
is O
used O
concomitantly O
with O
these O
medications O
. O

Pretreatment O
and O
follow-up O
measurements O
should O
be O
obtained O
under O
fasting O
conditions O
. O

Ergotamine B-drug
or O
dihydroergotamine B-drug
acute O
ergot O
toxicity O
characterized O
by O
severe O
peripheral O
vasospasm O
and O
dysesthesia O
. O

Interactions O
with O
Other O
CNS O
Agents O
: O
Concurrent O
use O
of O
Levo-Dromoran B-brand
with O
all O
central B-group
nervous I-group
system I-group
depressants I-group
( O
eg O
, O
alcohol B-drug
, O
sedatives B-group
, O
hypnotics B-group
, O
other O
opioids B-group
, O
general O
anesthetics B-group
, O
barbiturates B-group
, O
tricyclic B-group
antidepressants I-group
, O
phenothiazines B-group
, O
tranquilizers B-group
, O
skeletal B-group
muscle I-group
relaxants I-group
and O
antihistamines B-group
) O
may O
result O
in O
additive O
central O
nervous O
system O
depressant O
effects O
. O

Propantheline B-drug
and O
diphenoxylate B-drug
, O
by O
decreasing O
gut O
motility O
, O
may O
increase O
digoxin B-drug
absorption O
. O

If O
taken O
1 O
hour O
before O
indinavir B-drug
( O
IDV B-drug
) O
, O
didanosine B-drug
does O
not O
affect O
IDV B-drug
exposure O
, O
despite O
persistent O
buffering O
effects O
. O

5 O
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type B-group
1C I-group
antiarrhythmics I-group
propafenone B-drug
and O
flecainide B-drug
) O
. O

The O
effect O
of O
concomitant O
administration O
of O
fluconazole B-drug
and O
glipizide B-drug
has O
been O
demonstrated O
in O
a O
placebo-controlled O
crossover O
study O
in O
normal O
volunteers O
. O

However O
, O
in O
the O
second O
study O
, O
administration O
of O
12 O
g O
cholestyramine B-drug
1 O
hour O
before O
the O
evening O
meal O
and O
0.3 O
mg O
cerivastatin B-drug
sodium I-drug
approximately O
4 O
hours O
after O
the O
same O
evening O
meal O
resulted O
in O
a O
decrease O
in O
the O
cerivastatin B-drug
AUC O
of O
less O
than O
8 O
% O
, O
and O
a O
decrease O
in O
Cmax O
of O
about O
30 O
% O
when O
compared O
to O
dosing O
cerivastatin B-drug
sodium I-drug
alone O
. O

These O
results O
suggest O
that O
the O
hepatoxicity O
of O
ethanol B-drug
in O
alcoholic O
beverages O
is O
enhanced O
by O
interaction O
with O
its O
congeners O
and O
acetaldehyde B-drug_n
; O

It O
is O
now O
clear O
that O
topoisomerase O
activity O
level O
is O
an O
important O
determinant O
of O
sensitivity O
to O
topo O
drugs O
. O

( O
See O
CLINICAL O
PHARMACOLOGY O
) O
Coadministration O
of O
Femara B-brand
and O
tamoxifen B-drug
20 O
mg O
daily O
resulted O
in O
a O
reduction O
of O
letrozole B-drug
plasma O
levels O
by O
38 O
% O
on O
average O
. O

however O
, O
the O
total O
amount O
of O
6MNA B-drug_n
in O
the O
plasma O
is O
unchanged O
. O

Therefore O
, O
amiodarone B-drug
has O
the O
potential O
for O
interactions O
with O
drugs O
or O
substances O
that O
may O
be O
substrates O
, O
inhibitors O
or O
inducers O
of O
CYP3A4 O
. O

Neither O
racemic O
warfarin B-drug
nor O
isradipine B-drug
binding O
to O
plasma O
proteins O
in O
vitro O
was O
altered O
by O
the O
addition O
of O
the O
other O
drug O
. O

These O
agents O
, O
including O
norfloxacin B-drug
, O
ciprofloxacin B-drug
, O
ofloxacin B-drug
, O
enoxacin B-drug
, O
and O
lomefloxacin B-drug
, O
have O
been O
extensively O
studied O
and O
have O
demonstrated O
efficacy O
and O
safety O
profiles O
comparable O
to O
those O
of O
other O
traditional O
agents O
for O
the O
treatment O
of O
complicated O
or O
uncomplicated O
urinary O
tract O
infections O
and O
prostatitis O
. O

Furosemide B-drug
: O
When O
aliskiren B-drug
was O
co-administered O
with O
furosemide B-drug
, O
the O
AUC O
and O
Cmax O
of O
furosemide B-drug
were O
reduced O
by O
about O
30 O
% O
and O
50 O
% O
, O
respectively O
. O

Treatment O
with O
antidepressant B-group
drugs I-group
can O
directly O
interfere O
with O
blood O
glucose O
levels O
or O
may O
interact O
with O
hypoglycemic B-group
agents I-group
. O

Ethinyl B-drug
Estradiol I-drug
and O
Norethindrone B-drug
: O
Coadministration O
of O
VIRACEPT B-brand
with O
OVCON-35 B-brand
resulted O
in O
a O
47 O
% O
decrease O
in O
ethinyl B-drug
estradiol I-drug
and O
an O
18 O
% O
decrease O
in O
norethindrone B-drug
plasma O
concentrations O
. O

- O
Sulfoxone B-drug
( O
e.g. O
, O
Diasone B-brand
) O
or O

The O
8.5 O
% O
incidence O
of O
akathisia O
, O
however O
, O
is O
within O
the O
range O
reported O
for O
use O
of O
prochlorperazine B-drug
when O
given O
as O
a O
premedication O
for O
other O
chemotherapies O
. O

- O
a O
nonsteroidal B-group
anti-inflammatory I-group
drug I-group
( O
NSAID B-group
) O
such O
as O
ibuprofen B-drug
( O
Motrin B-brand
, O
Advil B-brand
, O
Nuprin B-brand
, O
others O
) O
, O
ketoprofen B-drug
( O
Orudis B-brand
, O
Orudis B-brand
KT I-brand
, O
Oruvail B-brand
) O
, O
diclofenac B-drug
( O
Voltaren B-brand
, O
Cataflam B-brand
) O
, O
etodolac B-drug
( O
Lodine B-brand
) O
, O
indomethacin B-drug
( O
Indocin B-brand
) O
, O
nabumetone B-drug
( O
Relafen B-brand
) O
, O
oxaprozin B-drug
( O
Daypro B-brand
) O
, O
and O
naproxen B-drug
( O
Anaprox B-brand
, O
Naprosyn B-brand
, O
Aleve B-brand
) O
; O

However O
, O
when O
any O
additional O
drug O
, O
including O
INDOCIN B-brand
, O
is O
added O
to O
the O
treatment O
of O
patients O
on O
anticoagulant B-group
therapy O
, O
the O
patients O
should O
be O
observed O
for O
alterations O
of O
the O
prothrombin O
time O
. O

Lorazepam B-drug
: O
Coadministration O
of O
single O
doses O
of O
eszopiclone B-drug
3 O
mg O
and O
lorazepam B-drug
2 O
mg O
did O
not O
have O
clinically O
relevant O
effects O
on O
the O
pharmacodynamics O
or O
pharmacokinetics O
of O
either O
drug O
. O

Drug O
Interaction O
During O
Pregnancy O
: O
Cromolyn B-drug
sodium I-drug
and O
isoproterenol B-drug
were O
studied O
following O
subcutaneous O
injections O
in O
pregnant O
mice O
. O

Symptoms O
resolved O
within O
a O
few O
hours O
. O

The O
threohydrobupropion B-drug_n
metabolite O
of O
bupropion B-drug
does O
not O
appear O
to O
be O
produced O
by O
the O
cytochrome O
P450 O
isoenzymes O
. O

When O
such O
drugs O
are O
withdrawn O
from O
a O
patient O
receiving O
DIABINESE B-brand
, O
the O
patient O
should O
be O
observed O
closely O
for O
hypoglycemia O
. O

Concurrent O
use O
of O
these O
agents O
should O
generally O
be O
avoided O
. O

In O
the O
case O
that O
you O
are O
taking O
digoxin B-drug
while O
taking O
aminosalicylic B-drug
acid I-drug
, O
higher O
doses O
of O
digoxin B-drug
may O
be O
needed O
. O

no O
evidence O
of O
mutagenicity O
was O
observed O
. O

Further O
, O
in O
rabbits O
dosed O
at O
0.25 O
mg/kg/day O
( O
about O
one-half O
the O
human O
dose O
on O
BSA O
) O
, O
increases O
in O
placental O
weight O
and O
post-implantation O
loss O
were O
observed O
but O
, O
there O
were O
no O
observed O
effects O
on O
fetal O
development O
. O

The O
following O
are O
examples O
of O
substances O
that O
may O
reduce O
the O
blood-glucose-lowering O
effect O
of O
insulin B-drug
: O
corticosteroids B-group
, O
danazol B-drug
, O
diuretics B-group
, O
sympathomimetic B-group
agents I-group
( O
e.g. O
, O
epinephrine B-drug
, O
albuterol B-drug
, O
terbutaline B-drug
) O
, O
isoniazid B-drug
, O
phenothiazine B-group
derivatives I-group
, O
somatropin B-drug
, O
thyroid B-group
hormones I-group
, O
estrogens B-group
, O
progestogens B-group
( O
e.g. O
, O
in O
oral O
contraceptives B-group
) O
. O

In O
order O
to O
monitor O
the O
occurrence O
of O
myelotoxicity O
, O
it O
is O
recommended O
that O
frequent O
peripheral O
blood O
cell O
counts O
be O
performed O
on O
all O
patients O
receiving O
TAXOL B-brand
. O

Acid-base O
and O
electrolyte O
alterations O
were O
not O
reported O
in O
the O
clinical O
trials O
with O
brinzolamide B-drug
. O

. O

Albendazole B-drug
sulfoxide I-drug
plasma O
concentrations O
were O
unchanged O
4 O
hours O
after O
dosing O
. O

HIV B-group
Antiviral I-group
Agents I-group

Drugs O
that O
inhibit O
or O
Induce O
CYP O
2D6 O
and O
CYP O
3A4 O
may O
affect O
the O
concentration O
on O
Aricept B-brand
. O

The O
optimal O
dosing O
interval O
for O
coadministration O
with O
VIDEX B-brand
should O
be O
determined O
by O
consulting O
the O
appropriate O
quinolone B-group
package O
insert O
. O

Itraconazole B-drug
decreases O
busulfan B-drug
clearance O
by O
up O
to O
25 O
% O
, O
and O
may O
produce O
AUCs O
1500 O
M O
min O
in O
some O
patients O
. O

Antacids B-group
: O
Concomitant O
administration O
of O
antacids B-group
containing O
magnesium B-drug
or O
aluminum B-drug
with O
VIDEX B-brand
Chewable/Dispersible O
Buffered O
Tablets O
or O
Pediatric O
Powder O
for O
Oral O
Solution O
may O
potentiate O
adverse O
events O
associated O
with O
the O
antacid B-group
components O
. O

This O
article O
will O
describe O
the O
escalating O
use O
of O
herbal O
therapy O
and O
the O
hazards O
of O
herbal O
remedy O
use O
among O
patients O
. O

Nelfinavir B-drug

Interferon O
induction O
: O
tool O
for O
establishing O
interactions O
among O
homopolyribonucleotides O
. O

- O
Pressor O
amines O
( O
e.g. O
, O
norepinephrine B-drug
) O
: O
Possible O
decreased O
response O
to O
pressor O
amines O
but O
not O
sufficient O
to O
preclude O
their O
use O

This O
study O
demonstrated O
that O
the O
potent O
cytochrome O
P450 O
enzyme-inducer O
phenytoin B-drug
did O
indeed O
have O
a O
marked O
effect O
on O
the O
metabolism O
of O
quetiapine B-drug
, O
resulting O
in O
a O
5-fold O
increase O
in O
clearance O
when O
administered O
concomitantly O
to O
patients O
with O
DSM-IV-diagnosed O
schizophrenia O
, O
schizoaffective O
disorder O
, O
or O
bipolar O
disorder O
. O

Accordingly O
, O
when O
diflunisal B-drug
is O
administered O
with O
oral O
anticoagulants B-group
, O
the O
prothrombin O
time O
should O
be O
closely O
monitored O
during O
and O
for O
several O
days O
after O
concomitant O
drug O
administration O
. O

Imidazoles B-group
( O
e. O
g. O
, O
ketoconazole B-drug
, O
miconazole B-drug
, O
clotrimazole B-drug
, O
fluconazole B-drug
, O
etc O
. O
) O
: O
in O
vitro O
and O
animal O
studies O
with O
the O
combination O
of O
amphotericin B-drug
B I-drug
and O
imidazoles B-group
suggest O
that O
imidazoles B-group
may O
induce O
fungal O
resistance O
to O
amphotericin B-drug
B I-drug
. O

Phenobarbital B-drug
: O
Amphetamines B-group
may O
delay O
intestinal O
absorption O
of O
phenobarbital B-drug
; O

Benzodiazepines B-group

A O
study O
in O
rats O
to O
assess O
the O
carcinogenic O
potential O
of O
ribavirin B-drug
is O
ongoing O
. O

Although O
bupropion B-drug
is O
not O
metabolized O
by O
this O
isoenzyme O
, O
bupropion B-drug
and O
hydroxybupropion B-drug_n
are O
inhibitors O
of O
the O
CYP2D6 O
isoenzyme O
in O
vitro O
. O

Although O
there O
have O
been O
no O
formal O
interaction O
studies O
other O
than O
with O
antipyrine B-drug
, O
based O
on O
these O
in O
vivo O
and O
in O
vitro O
studies O
, O
it O
is O
unlikely O
that O
co-administration O
of O
a O
1 O
mg O
dose O
of O
ARIMIDEX B-brand
with O
other O
drugs O
will O
result O
in O
clinically O
significant O
drug O
inhibition O
of O
cytochrome O
P450-mediated O
metabolism O
of O
the O
other O
drugs O
. O

Probenecid B-drug
: O
Probenecid B-drug
, O
a O
renal O
tubular O
secretion O
blocking O
agent O
, O
administered O
at O
a O
dose O
of O
500 O
mg O
four O
times O
a O
day O
, O
did O
not O
change O
the O
pharmacokinetics O
of O
levetiracetam B-drug
1000 O
mg O
twice O
daily O
. O

18-MC B-drug_n
does O
not O
produce O
these O
effects O
. O

Plasma O
levels O
of O
flecainide B-drug
have O
been O
reported O
to O
increase O
in O
the O
presence O
of O
oral O
amiodarone B-drug
; O

No O
increase O
in O
mortality O
was O
observed O
in O
patients O
taking O
digoxin B-drug
as O
concomitant O
medication O
. O

However O
, O
if O
the O
patients O
thyroid O
gland O
has O
sufficient O
function O
, O
the O
decreased O
free O
thyroxine B-drug
will O
result O
in O
a O
compensatory O
increase O
in O
thyroxine O
output O
by O
the O
thyroid O
. O

The O
drug O
interaction O
data O
described O
in O
this O
section O
were O
obtained O
from O
studies O
involving O
healthy O
adults O
and O
adult O
patients O
with O
epilepsy O
. O

Administration O
of O
repeat O
doses O
of O
FACTIVE B-brand
had O
no O
effect O
on O
the O
repeat O
dose O
pharmacokinetics O
of O
theophylline B-drug
, O
digoxin B-drug
or O
an O
ethinylestradiol/levonorgestrol B-drug
oral O
contraceptive B-group
product I-group
in O
healthy O
subjects O
. O

There O
was O
no O
change O
after O
a O
single O
dose O
of O
PGF2alpha B-drug
. O

Studies O
in O
vitro O
show O
that O
caspofungin B-drug
acetate I-drug
is O
not O
an O
inhibitor O
of O
any O
enzyme O
in O
the O
cytochrome O
P450 O
( O
CYP O
) O
system O
. O

Salicylates-Salicylates B-group
in O
large O
doses O
may O
inhibit O
vitamin O
K O
epoxide O
reductase O
resulting O
in O
vitamin O
K O
deficiency O
. O

During O
co-administration O
, O
systemic O
levels O
of O
TMP B-drug
and O
SMX B-drug
were O
essentially O
unchanged O
. O

After O
incubation O
at O
0 O
degrees O
C O
for O
4 O
h O
this O
number O
fell O
to O
2.3 O
plus O
or O
minus O
0.1 O
S.E.M O
. O

- O
Valproic B-drug
acid I-drug
( O
e.g. O
, O
Depakene B-brand
) O
Use O
of O
sulfapyridine B-drug
with O
these O
medicines O
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
liver O

Ketoconazole B-drug
tablets O
may O
alter O
the O
metabolism O
of O
cyclosporine B-drug
, O
tacrolimus B-drug
, O
and O
methylprednisolone B-drug
, O
resulting O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
drugs O
. O

- O
The O
action O
of O
sulphonylureas B-group
and O
insulin B-drug
may O
be O
enhanced O
by O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
. O

However O
, O
these O
studies O
did O
not O
show O
whether O
ginsenosides-induced B-drug_n
inhibition O
of O
Ca O
( O
2+ O
) O
currents O
discriminates O
among O
the O
various O
Ca O
( O
2+ O
) O
channel O
subtypes O
, O
although O
it O
is O
known O
that O
there O
are O
at O
least O
five O
different O
Ca O
( O
2+ O
) O
channel O
subtypes O
in O
neuronal O
cells O
. O

Concomitant O
administration O
of O
erythromycin B-drug
and O
digoxin B-drug
has O
been O
reported O
to O
result O
in O
elevated O
digoxin B-drug
serum O
levels O
. O

Differential O
actions O
of O
intrathecal O
naloxone B-drug
on O
blocking O
the O
tail-flick O
inhibition O
induced O
by O
intraventricular O
beta-endorphin B-drug_n
and O
morphine B-drug
in O
rats O
. O

While O
taking O
beta B-group
blockers I-group
, O
patients O
with O
a O
history O
of O
anaphylactic O
reaction O
to O
a O
variety O
of O
allergens O
may O
have O
a O
more O
severe O
reaction O
on O
repeated O
challenge O
, O
either O
accidental O
, O
diagnostic O
or O
therapeutic O
. O

Q4H O
, O
and O
levofloxacin B-drug
, O
500 O
mg O
p.o O
. O

Nonetheless O
, O
their O
relevance O
continues O
to O
be O
demonstrated O
by O
the O
dependence O
of O
each O
agent O
on O
intact O
liver O
blood O
flow O
and O
function O
for O
normal O
rates O
of O
elimination O
; O

However O
, O
in O
vitro O
studies O
have O
shown O
that O
at O
high O
concentrations O
( O
7.4 O
mMol/L O
or O
0.97 O
mg/mL O
and O
greater O
) O
EACA B-drug
inhibits O
ADP O
and O
collagen-induced O
platelet O
aggregation O
, O
the O
release O
of O
ATP O
and O
serotonin O
, O
and O
the O
binding O
of O
fibrinogen O
to O
the O
platelets O
in O
a O
concentration-response O
manner O
. O

Use O
with O
Allopurinol B-drug
: O
The O
principal O
pathway O
for O
detoxification O
of O
azathioprine B-drug
is O
inhibited O
by O
allopurinol B-drug
. O

Familial O
hyper- O
or O
hypo-thyroxine-binding-globulinemias O
have O
been O
described O
. O

Talk O
to O
your O
doctor O
if O
you O
are O
taking O
certain O
antibiotics B-group
such O
as O
erythromycin B-drug
, O
clarithromycin B-drug
or O
azithromycin B-drug
. O

This O
response O
has O
been O
attributed O
to O
inhibition O
of O
renal O
prostaglandin O
synthesis O
. O

Guardians O
of O
children O
who O
have O
been O
prescribed O
FORADIL B-brand
should O
be O
alerted O
to O
the O
general O
concern O
regarding O
asthma O
therapy O
compliance O
, O
especially O
neglect O
of O
anti-inflammatory O
therapy O
and O
overuse O
of O
short-acting B-group
beta2-agonists I-group
. O

Injection O
: O
Lorazepam B-drug
injection O
, O
like O
other O
injectable O
benzodiazepines B-group
, O
produces O
depression O
of O
the O
central O
nervous O
system O
when O
administered O
with O
ethyl B-drug
alcohol I-drug
, O
phenothiazines B-group
, O
barbiturates B-group
, O
MAO B-group
inhibitors I-group
, O
and O
other O
antidepressants.When B-group
scopolamine B-drug
is O
used O
concomitantly O
with O
injectable O
lorazepam B-drug
, O
an O
increased O
incidence O
of O
sedation O
, O
hallucinations O
, O
and O
irrational O
behavior O
has O
been O
observed O
. O

Acidifying B-group
agents I-group
: O
Gastrointestinal B-group
acidifying I-group
agents I-group
( O
guanethidine B-drug
, O
reserpine B-drug
, O
glutamic B-drug
acid I-drug
HCl I-drug
, O
ascorbic B-drug
acid I-drug
, O
fruit O
juices O
, O
etc O
. O
) O
lower O
absorption O
of O
amphetamines B-group
. O

Positive O
direct O
and O
indirect O
antiglobulin O
( O
Coombs O
) O
tests O
have O
occurred O
; O

Drugs O
highly O
bound O
to O
albumin O
could O
increase O
the O
unbound O
fraction O
of O
fosphenytoin B-drug
. O

The O
concomitant O
use O
of O
beta-adrenergic B-group
blocking I-group
agents I-group
with O
digitalis B-group
and O
calcium B-group
antagonists O
may O
have O
additive O
effects O
on O
prolonging O
atrioventricular O
conduction O
time O
. O

RESULTS O
: O
The O
two O
treatment O
groups O
were O
well O
matched O
with O
regard O
to O
patient O
demographics O
, O
NHL O
characteristics O
, O
HIV O
status O
, O
and O
treatment O
, O
i.e. O
, O
the O
number O
of O
cycles O
and O
chemotherapy O
dose O
. O

Avoid O
the O
concomitant O
use O
of O
chlorprothixene B-drug
and O
tramadol B-drug
( O
Ultram B-brand
) O
. O

Coadministration O
of O
NIZORAL B-brand
Tablets O
with O
midazolam B-drug
or O
triazolam B-drug
has O
resulted O
in O
elevated O
plasma O
concentrations O
of O
the O
latter O
two O
drugs O
. O

This O
treatment O
arm O
was O
discontinued O
from O
the O
trial O
. O

No O
dose O
adjustment O
is O
necessary O
. O

An O
in O
vitro O
effect O
occurs O
when O
the O
medication O
interferes O
with O
the O
assay O
, O
and O
the O
result O
is O
erroneous O
and O
can O
not O
be O
interpreted O
. O

Ironically O
, O
benzodiazepines B-group
are O
often O
used O
in O
the O
treatment O
of O
heroin B-drug
addiction O
while O
they O
cause O
much O
more O
severe O
withdrawal O
symptoms O
. O

However O
, O
a O
crossover O
study O
in O
healthy O
subjects O
receiving O
either O
Tagamet B-brand
300 O
mg O
q.i.d O
. O
or O
800 O
mg O
h.s O
. O
concomitantly O
with O
a O
300 O
mg O
b.i.d O
. O
dosage O
of O
theophylline B-drug
( O
Theo-Dur B-brand
, O
Key O
Pharmaceuticals O
, O
Inc. O
) O
demonstrated O
less O
alteration O
in O
steady-state O
theophylline B-drug
peak O
serum O
levels O
with O
the O
800 O
mg O
h.s O
. O
regimen O
, O
particularly O
in O
subjects O
aged O
54 O
years O
and O
older O
. O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
NSAIDs B-group
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

cardiac B-group
glycosides I-group
; O

Specific O
studies O
have O
confirmed O
these O
effects O
with O
sevoflurane B-drug
, O
isoflurane B-drug
, O
propofol B-drug
, O
alfentanil B-drug
, O
and O
midazolam B-drug
. O

Anti-arrhythmics B-group
and O
tricyclic B-group
anti-depressants I-group
could O
exaggerate O
the O
prolongation O
of O
the O
QT O
interval O
observed O
with O
bepridil B-drug
hydrochloride I-drug
. O

It O
is O
assumed O
that O
increased O
interaction O
between O
3H-spiroperidol B-drug_n
and O
high O
affinity O
binding O
sites O
for O
apomorphine B-drug
on O
dopamine2- O
and O
serotonin2-receptors O
underlies O
the O
antipsychotic O
action O
of O
neuroleptics B-group
after O
their O
prolonged O
administration O
. O

The O
most O
commonly O
occurring O
drug O
interactions O
are O
listed O
below O
: O
- O
Drugs O
that O
may O
increase O
plasma O
phenytoin B-drug
concentrations O
include O
: O
acute O
alcohol B-drug
intake O
, O
amiodarone B-drug
, O
chboramphenicol O
, O
chlordiazepoxide B-drug
, O
cimetidine B-drug
, O
diazepam B-drug
, O
dicumarol B-drug
, O
disulfiram B-drug
, O
estrogens B-group
, O
ethosuximide B-drug
, O
fluoxetine B-drug
, O
H2-antagonists B-group
, O
halothane B-drug
, O
isoniazid B-drug
, O
methylphenidate B-drug
, O
phenothiazines B-group
, O
phenylbutazone B-drug
, O
salicylates B-group
, O
succinimides B-group
, O
sulfonamides B-group
, O
tolbutamide B-drug
, O
trazodone B-drug

If O
they O
do O
occur O
, O
the O
EPA B-drug
dose O
should O
be O
lowered O
or O
discontinued O
. O

For O
digoxin B-drug
AUC O
( O
0-infinity O
) O
, O
AUC O
( O
0-24 O
) O
, O
and O
Cmax O
, O
the O
geometric O
mean O
ratios O
( O
90 O
% O
confidence O
interval O
) O
for O
( O
rofecoxib B-drug
+ O
digoxin/placebo B-drug
+ O
digoxin B-drug
) O
were O
1.04 O
( O
0.94 O
, O
1.14 O
) O
, O
1.02 O
( O
0.94 O
, O
1.09 O
) O
, O
and O
1.00 O
( O
0.91 O
, O
1.10 O
) O
, O
respectively O
. O

washout O
( O
days O
7-13 O
) O
; O

In O
a O
study O
in O
which O
patients O
with O
active O
RA O
were O
treated O
for O
up O
to O
24 O
weeks O
with O
concurrent O
Kineret B-brand
and O
etanercept B-drug
therapy O
, O
a O
7 O
% O
rate O
of O
serious O
infections O
was O
observed O
, O
which O
was O
higher O
than O
that O
observed O
with O
etanercept B-drug
alone O
( O
0 O
% O
) O
. O

Because O
Nalfon B-brand
has O
not O
been O
shown O
to O
produce O
any O
additional O
effect O
beyond O
that O
obtained O
with O
aspirin B-brand
alone O
and O
because O
aspirin B-brand
increases O
the O
rate O
of O
excretion O
of O
Nalfon B-brand
, O
the O
concomitant O
use O
of O
Nalfon B-brand
and O
salicylates B-group
is O
not O
recommended O
. O

In O
that O
same O
study O
, O
aspirin B-brand
alone O
produced O
a O
marked O
inhibition O
in O
platelet O
aggregation O
ex O
vivo O
. O

When O
used O
concomitantly O
, O
anesthetics B-group
and O
calcium B-group
channel I-group
blockers I-group
should O
be O
titrated O
carefully O
. O

When O
estrogen B-group
therapy O
is O
initiated O
, O
a O
reduction O
in O
corticosteroid B-group
dosage O
may O
be O
required O
, O
and O
increased O
amounts O
may O
be O
required O
when O
estrogen B-group
is O
terminated O
. O

In O
neither O
case O
were O
the O
pharmacokinetics O
of O
sumatriptan B-drug
affected O
by O
coadministration O
with O
STADOL B-brand
NS I-brand
. O

Some O
cases O
presented O
with O
features O
resembling O
neuroleptic O
malignant O
syndrome O
. O

Therefore O
, O
intake O
of O
supplemental O
folic B-drug
acid I-drug
should O
not O
exceed O
1000 O
micrograms O
( O
g O
, O
sometimes O
mcg O
) O
per O
day O
to O
prevent O
folic B-drug
acid I-drug
from O
masking O
symptoms O
of O
vitamin O
B12 O
deficiency O
. O

Xigris B-brand
present O
in O
plasma O
samples O
does O
not O
interfere O
with O
one-stage O
factor O
assays O
based O
on O
the O
PT O
( O
such O
as O
factor O
II O
, O
V O
, O
VII O
, O
and O
X O
assays O
) O
. O

These O
compounds O
interfere O
with O
chemical O
color O
development O
essential O
to O
the O
analytical O
procedures O
. O

GI O
motility O
agents O
: O
cisapride B-drug

Amprenavir B-drug
is O
metabolized O
in O
the O
liver O
by O
the O
cytochrome O
P450 O
enzyme O
system O
. O

At O
least O
14 O
days O
should O
elapse O
between O
discontinuation O
of O
a O
MAO B-group
inhibitor I-group
and O
initiation O
of O
treatment O
with O
dexfenfluramine B-drug
. O

Phenytoin B-drug
is O
extensively O
bound O
to O
serum O
plasma O
proteins O
and O
is O
prone O
to O
competitive O
displacement O
. O

the O
third O
group O
( O
SH/EA O
) O
was O
treated O
with O
a O
hydroalcoholic O
solution O
of O
ethanol B-drug
; O

Administration O
of O
rifampin B-drug
concomitantly O
with O
oral O
amiodarone B-drug
has O
been O
shown O
to O
result O
in O
decreases O
in O
serum O
concentrations O
of O
amiodarone B-drug
and O
desethylamiodarone B-drug
. O

The O
fluoroquinolones B-group
are O
also O
extensively O
used O
in O
urologic O
surgery O
. O

Each O
serum O
without O
the O
other O
added O
drug O
as O
well O
as O
the O
serum O
supplemented O
with O
the O
other O
drug O
at O
the O
three O
concentrations O
was O
dialyzed O
against O
phosphate O
buffer O
. O

endocrine O
dysfunction O
; O

Quinolones B-group
have O
been O
shown O
to O
interfere O
with O
the O
metabolism O
of O
caffeine B-drug
. O

Therefore O
, O
concurrent O
use O
of O
Trileptal B-brand
with O
hormonal B-group
contraceptives I-group
may O
render O
these O
contraceptives B-group
less O
effective O
. O

In O
controlled O
clinical O
trials O
of O
AUGMENTIN B-brand
XR I-brand
, O
22 O
patients O
received O
concomitant O
allopurinol B-drug
and O
AUGMENTIN B-brand
XR I-brand
. O

Examples O
of O
Drugs O
in O
Which O
Plasma O
Concentrations O
May O
Be O
Decreased O
By O
Co-administration O
With O
Nevirapine B-drug

Using O
calcium B-drug
acetate I-drug
with O
digitalis B-group
glycosides I-group
( O
heart O
medicine O
) O
may O
cause O
hypercalcemia O
( O
too O
much O
calcium B-drug
in O
the O
blood O
) O
, O
which O
could O
increase O
the O
chance O
of O
developing O
an O
irregular O
heartbeat O
. O

Fentanyl B-drug
Anesthesia O
: O
Severe O
hypotension O
has O
been O
reported O
during O
fentanyl B-drug
anesthesia O
with O
concomitant O
use O
of O
a O
beta B-group
blocker I-group
and O
a O
calcium B-group
channel I-group
blocker I-group
. O

Laboratory O
Tests O
If O
significant O
abnormal O
laboratory O
results O
are O
obtained O
, O
either O
dosage O
reduction O
with O
careful O
monitoring O
or O
treatment O
discontinuation O
is O
recommended O
, O
depending O
on O
clinical O
judgement O
. O

reliable O
estimates O
of O
the O
prevalence O
of O
reduced O
P450 O
2D6 O
isozyme O
activity O
among O
Asian O
, O
African O
and O
other O
populations O
are O
not O
yet O
available O
. O

Although O
ROMAZICON B-brand
exerts O
a O
slight O
intrinsic O
anticonvulsant O
effect O
, O
its O
abrupt O
suppression O
of O
the O
protective O
effect O
of O
a O
benzodiazepine B-group
agonist O
can O
give O
rise O
to O
convulsions O
in O
epileptic O
patients O
. O

In O
healthy O
volunteers O
, O
the O
pharmacokinetics O
of O
a O
1-mg O
dose O
of O
butorphanol B-drug
administered O
as O
STADOL B-brand
NS I-brand
were O
not O
affected O
by O
the O
coadministration O
of O
a O
single O
6-mg O
subcutaneous O
dose O
of O
sumatriptan B-drug
. O

In O
post-marketing O
experience O
, O
bleeding O
has O
been O
reported O
in O
patients O
on O
concomitant O
treatment O
with O
anticoagulants B-group
and O
INDOCIN B-brand
. O

Concurrent O
administration O
of O
low-dose O
dopamine B-drug
HCl I-drug
and O
diuretic B-group
agents I-group
may O
produce O
an O
additive O
or O
potentiating O
effect O
on O
urine O
flow O
. O

Maximal O
hypotension O
was O
found O
120 O
minutes O
post O
ethanol B-drug
, O
and O
returned O
to O
normal O
300 O
minutes O
after O
ethanol B-drug
. O

Since O
bacteriostatic O
drugs O
, O
such O
as O
the O
tetracycline B-group
class I-group
of O
antibiotics B-group
, O
may O
interfere O
with O
the O
bactericidal O
action O
of O
penicillins B-group
, O
it O
is O
not O
advisable O
to O
administer O
these O
drugs O
concomitantly O
. O

In O
healthy O
volunteers O
, O
Exjade B-brand
had O
no O
effect O
on O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

Dexfenfluramine B-drug
should O
not O
be O
administered O
with O
other O
serotoninergic B-group
agents I-group
. O

Nevirapine I-drug

To O
prevent O
stomach O
irritation O
, O
subjects O
received O
rantidine B-drug
hydrochloride I-drug
before O
each O
experimental O
session O
. O

Amiodarone B-drug
is O
known O
to O
raise O
serum O
digoxin B-drug
levels O
. O

No O
formal O
drug O
interaction O
studies O
of O
Aranesp B-brand
have O
been O
performed O
. O

Deaths O
from O
severe O
enterocolitis O
, O
diarrhea O
, O
and O
dehydration O
have O
been O
reported O
in O
elderly O
patients O
receiving O
weekly O
leucovorin B-drug
and O
fluorouracil B-drug
. O

The O
response O
rates O
were O
similar O
between O
the O
two O
groups O
. O

Antacids B-group
and O
kaolin B-drug
: O
Antacids B-group
and O
kaolin B-drug
can O
reduce O
absorption O
of O
chloroquine B-drug
; O

However O
, O
the O
effects O
of O
stress O
and O
glucocorticoids B-group
on O
the O
subjective O
and O
behavioral O
effects O
of O
psychostimulants B-group
have O
not O
been O
well O
studied O
in O
humans O
. O

filipin B-drug_n
was O
more O
potent O
in O
lysing O
human O
red O
blood O
cells O
, O
whereas O
amphotericin B-drug
B I-drug
was O
more O
potent O
in O
inhibiting O
yeast O
cell O
growth O
; O

Oral O
contraceptives B-group
may O
be O
less O
effective O
while O
you O
are O
taking O
lymecycline B-drug
. O

AIMS/HYPOTHESIS O
: O
There O
is O
evidence O
that O
insulin B-drug
and O
glucose B-drug
cause O
renal O
and O
ocular O
vasodilation O
. O

Latent O
LCV O
infection O
is O
generally O
asymptomatic O
, O
but O
can O
lead O
to O
B-cell O
lymphomas O
when O
animals O
are O
immune O
suppressed O
. O

PEGASYS B-brand
should O
be O
assumed O
to O
have O
abortifacient O
potential O
. O

Adrenergic B-group
Agents I-group
: O
Some O
individuals O
receiving O
ZYVOX B-brand
may O
experience O
a O
reversible O
enhancement O
of O
the O
pressor O
response O
to O
indirect-acting O
sympathomimetic B-group
agents I-group
, O
vasopressor B-group
or O
dopaminergic B-group
agents I-group
. O

Effect O
of O
Other O
Drugs O
on O
the O
Pharmacokinetics O
of O
Clonazepam B-drug
: O
Literature O
reports O
suggest O
that O
ranitidine B-drug
, O
an O
agent O
that O
decreases O
stomach O
acidity O
, O
does O
not O
greatly O
alter O
clonazepam B-drug
pharmacokinetics O
. O

Substances O
that O
inhibit O
the O
cytochrome O
P450 O
isoenzyme O
( O
CYP3A4 O
) O
activity O
may O
decrease O
metabolism O
and O
increase O
imatinib B-drug
concentrations O
. O

However O
, O
in O
a O
well-controlled O
study O
of O
patients O
with O
lymphoma O
on O
combination O
therapy O
, O
allopurinol B-drug
did O
not O
increase O
the O
marrow O
toxicity O
of O
patients O
treated O
with O
cyclophosphamide B-drug
, O
doxorubicin B-drug
, O
bleomycin B-drug
, O
procarbazine B-drug
and/or O
mechlorethamine B-drug
. O

Diabetic O
patients O
have O
a O
20 O
% O
higher O
risk O
of O
depression O
than O
the O
general O
population O
. O

Drug/Laboratory O
Test O
Interactions O
A O
false-positive O
reaction O
for O
ketones O
in O
the O
urine O
may O
occur O
with O
tests O
using O
nitroprusside B-drug
, O
but O
not O
with O
those O
using O
nitroferricyanide B-drug
. O

General O
No O
clinical O
drug O
interaction O
studies O
were O
performed O
. O

The O
interaction O
between O
lomefloxacin B-drug
and O
cimetidine B-drug
has O
not O
been O
studied O
. O

When O
these O
products O
are O
administered O
concomitantly O
, O
prothrombin O
time O
or O
other O
suitable O
coagulation O
tests O
should O
be O
closely O
monitored O
. O

Beta B-group
blockers I-group
may O
exacerbate O
the O
hypertensive O
response O
seen O
with O
clonidine B-drug
withdrawl O
. O

Potential O
for O
reduction O
in O
anticonvulsant B-group
and/or O
efavirenz B-drug
plasma O
levels O
; O

Beta-blockers B-group
( O
metoprolol B-drug
, O
propranolol B-drug
) O
serum O
concentrations O
and O
pharmacologic O
effects O
may O
be O
increased O
. O

Aprepitant B-drug
is O
unlikely O
to O
interact O
with O
drugs O
that O
are O
substrates O
for O
the O
P-glycoprotein O
transporter O
, O
as O
demonstrated O
by O
the O
lack O
of O
interaction O
of O
Aprepitant B-drug
with O
digoxin B-drug
in O
a O
clinical O
drug O
interaction O
study O
. O

Hypotension O
: O
Patients O
on O
Diuretic O
Therapy O
: O
Patients O
on O
diuretics B-drug
and O
especially O
those O
in O
whom O
diuretic O
therapy O
was O
recently O
instituted O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
enalapril B-drug
or O
enalaprilat B-drug
. O

Warfarin B-drug
: O
No O
significant O
differences O
were O
observed O
in O
the O
steady-state O
pharmacokinetics O
of O
R-warfarin B-drug
or O
S-warfarin B-drug
with O
the O
addition O
of O
tiagabine B-drug
given O
as O
a O
single O
dose O
. O

In O
patients O
receiving O
FORADIL B-brand
, O
other O
inhaled O
medications O
should O
be O
used O
only O
as O
directed O
by O
the O
physician O
. O

With O
the O
exception O
of O
albuterol B-drug
, O
there O
are O
no O
formal O
studies O
fully O
evaluating O
the O
interaction O
effects O
of O
ATROVENT B-brand
Inhalation O
Aerosol O
and O
these O
drugs O
with O
respect O
to O
effectiveness O
. O

We O
demonstrate O
that O
the O
conversion O
of O
1,3-difluoro-2-propanol B-drug_n
to O
1,3-difluoroacetone B-drug_n
by O
an O
NAD+-dependent O
oxidation O
is O
the O
rate-limiting O
step O
in O
the O
synthesis O
of O
the O
toxic O
product O
, O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
from O
1,3-difluoro-2-propanol B-drug_n
. O

These O
results O
suggest O
that O
exposure O
to O
environmental O
lead B-drug_n
may O
alter O
the O
biological O
and O
behavioral O
responsiveness O
of O
an O
animal O
to O
alcohol B-drug
. O

No O
drug O
interactions O
were O
detected O
except O
for O
an O
increase O
in O
symptomatic O
hypotension O
in O
patients O
receiving O
oral O
ACE B-group
inhibitors I-group
. O

Excessive O
neuromuscular O
weakness O
may O
be O
exacerbated O
by O
administration O
of O
another O
botulinum B-group
toxin I-group
prior O
to O
the O
resolution O
of O
the O
effects O
of O
a O
previously O
administered O
botulinum B-group
toxin I-group
. O

SINCE O
THE O
CONCOMITANT O
ADMINISTRATION O
OF O
THESE O
TWO O
DRUGS O
CAN O
LEAD O
TO O
PHENYTOIN B-drug
INTOXICATION O
, O
PRIOR O
TO O
ADMINISTERING O
DISULFIRAM B-drug
TO O
A O
PATIENT O
ON O
PHENYTOIN B-drug
THERAPY O
, O
A O
BASELINE O
PHENYTOIN B-drug
SERUM O
LEVEL O
SHOULD O
BE O
OBTAINED O
. O

Other O
CNS B-group
depressant I-group
drugs I-group
should O
be O
used O
with O
caution O
in O
patients O
taking O
fenfluramine B-drug
, O
since O
the O
effects O
may O
be O
additive O
. O

When O
taken O
concurrently O
with O
ethanol B-drug
, O
a O
pharmacological O
interaction O
may O
occur O
, O
potentiating O
the O
central O
nervous O
system O
depression O
produced O
by O
either O
drug O
. O

Cytochrome O
P-450 O
is O
not O
known O
to O
be O
involved O
in O
the O
metabolism O
of O
Plenaxis B-brand
. O

Diuretics B-group
: O
Patients O
on O
diuretics B-group
, O
especially O
those O
with O
intravascular O
volume O
depletion O
, O
may O
occasionally O
experience O
an O
excessive O
reduction O
of O
blood O
pressure O
after O
initiation O
of O
therapy O
with O
fosinopril B-drug
sodium I-drug
. O

Drug/Laboratory O
Test O
Interactions O
Acetaminophen B-drug
may O
produce O
false-positive O
test O
results O
for O
urinary O
5-hydroxyindoleacetic O
acid O
. O

Some O
quinolone B-group
antibiotics I-group
would O
be O
expected O
to O
have O
similar O
effects O
and O
these O
combinations O
should O
be O
avoided O
. O

Colestipol-Concomitant B-drug
intake O
of O
colestipol B-drug
and O
vitamin B-group
K I-group
may O
reduce O
the O
absorption O
of O
vitamin B-group
K I-group
. O

Since O
fondaparinux B-drug
does O
not O
markedly O
inhibit O
CYP450s O
( O
CYP1A2 O
, O
CYP2A6 O
, O
CYP2C9 O
, O
CYP2C19 O
, O
CYP2D6 O
, O
CYP2E1 O
, O
or O
CYP3A4 O
) O
in O
vitro O
, O
fondaparinux B-drug
sodium I-drug
is O
not O
expected O
to O
significantly O
interact O
with O
other O
drugs O
in O
vivo O
by O
inhibition O
of O
metabolism O
mediated O
by O
these O
isozymes O
. O

Several O
studies O
indicate O
that O
olanzapine B-drug
has O
benefits O
against O
symptoms O
of O
aggression O
and O
agitation O
, O
while O
other O
studies O
strongly O
support O
the O
effectiveness O
of O
olanzapine B-drug
in O
the O
treatment O
of O
depressive O
symptomatology O
. O

In O
view O
of O
the O
potential O
risk O
of O
dehydration O
secondary O
to O
vomiting O
and/or O
diarrhea O
induced O
by O
CAMPTOSAR B-brand
, O
the O
physician O
may O
wish O
to O
withhold O
diuretics B-group
during O
dosing O
with O
CAMPTOSAR B-brand
and O
, O
certainly O
, O
during O
periods O
of O
active O
vomiting O
or O
diarrhea O
. O

Co-administration O
of O
bosentan B-drug
decreased O
the O
plasma O
concentrations O
of O
glyburide B-drug
by O
approximately O
40 O
% O
. O

Diltiazem B-drug
: O
In O
patients O
with O
mild O
to O
moderate O
hypertension O
, O
administration O
of O
aprepitant B-drug
once O
daily O
, O
as O
a O
tablet O
formulation O
comparable O
to O
230 O
mg O
of O
the O
capsule O
formulation O
, O
with O
diltiazem B-drug
120 O
mg O
3 O
times O
daily O
for O
5 O
days O
, O
resulted O
in O
a O
2-fold O
increase O
of O
aprepitant B-drug
AUC O
and O
a O
simultaneous O
1.7-fold O
increase O
of O
diltiazem B-drug
AUC O
. O

This O
increase O
is O
greatest O
in O
the O
evening O
. O

Drugs O
That O
Should O
Not O
Be O
Coadministered O
With O
INVIRASE/Ritonavir B-brand

Concomitant O
administration O
of O
drugs O
known O
to O
induce O
cytochrome O
P450 O
enzymes O
may O
decrease O
the O
plasma O
levels O
of O
clozapine B-drug
. O

Digoxin B-drug
is O
eliminated O
renally O
. O

However O
, O
LDL-C O
reduction O
was O
not O
altered O
. O

There O
was O
no O
apparent O
pharmacokinetic O
interaction O
between O
zaleplon B-drug
and O
ibuprofen B-drug
following O
single O
dose O
administration O
( O
10 O
mg O
and O
600 O
mg O
, O
respectively O
) O
of O
each O
drug O
. O

In O
controlled O
clinical O
trials O
, O
however O
, O
beta B-drug
blockers I-drug
including O
metoprolol B-drug
were O
concurrently O
administered O
with O
felodipine B-drug
and O
were O
well O
tolerated O
. O

When O
amiodarone B-drug
is O
added O
to O
flecainide B-drug
therapy O
, O
plasma O
flecainide B-drug
levels O
may O
increase O
two-fold O
or O
more O
in O
some O
patients O
, O
if O
flecainide B-drug
dosage O
is O
not O
reduced O
. O

Digoxin B-drug
: O
Enoxacin B-drug
may O
raise O
serum O
digoxin B-drug
levels O
in O
some O
individuals O
. O

Cardiovascular O
collapse O
in O
patients O
treated O
simultaneously O
with O
varapamil O
and O
dantrolene B-drug
sodium I-drug
is O
rare O
. O

tolbutamide B-drug
; O

In O
such O
a O
case O
, O
the O
peripheral O
vascular O
resistance O
may O
increase O
. O

9 O
. O

The O
effects O
of O
diethyl B-drug_n
pyrocarbonate I-drug_n
could O
be O
reversed O
by O
hydroxylamine B-drug_n
treatment O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

both O
compounds O
attenuate O
morphine-induced B-drug
locomotion O
in O
morphine-experienced B-drug
rats O
. O

ACE B-group
Inhibitors I-group
and O
Angiotensin B-group
II I-group
Receptor I-group
Antagonists I-group
( O
Hypertension O
) O
- O
In O
clinical O
studies O
of O
patients O
with O
hypertension O
, O
the O
addition O
of O
INSPRA B-brand
50 O
to O
100 O
mg O
to O
ACE B-group
inhibitors I-group
and O
angiotensin B-group
II I-group
receptor I-group
antagonists I-group
increased O
mean O
serum O
potassium O
slightly O
( O
about O
0.09-0.13 O
mEq/L O
) O
. O

Although O
results O
have O
varied O
from O
study O
to O
study O
, O
effects O
have O
been O
shown O
on O
furosemide-stimulated B-drug
diuresis O
, O
natriuresis O
, O
and O
kaliuresis O
. O

The O
possibility O
of O
reduced O
statin B-group
efficacy O
should O
be O
considered O
. O

These O
data O
indicate O
that O
levetiracetam B-drug
does O
not O
influence O
the O
plasma O
concentration O
of O
other O
AEDs B-group
and O
that O
these O
AEDs B-group
do O
not O
influence O
the O
pharmacokinetics O
of O
levetiracetam B-drug
. O

Multiple-dose O
administration O
of O
the O
potent O
CYP3A4 O
inducer O
rifampin B-drug
( O
600 O
mg O
every O
24 O
hours O
, O
q24h O
, O
for O
14 O
days O
) O
, O
however O
, O
reduced O
zaleplon B-drug
Cmax O
and O
AUC O
by O
approximately O
80 O
% O
. O

. O

In O
vitro O
studies O
have O
indicated O
that O
colestipol B-drug
hydrochloride I-drug
binds O
a O
number O
of O
drugs O
. O

Combination O
hormonal B-group
contraceptives I-group
may O
also O
increase O
risk O
of O
thromboembolic O
disorders O
. O

( O
1968 O
, O
1970 O
) O
, O
the O
higher O
serum O
concentrations O
of O
penicillins B-group
and O
cephaloridine B-drug
reached O
after O
administration O
of O
probenecid B-drug
are O
due O
not O
only O
to O
slower O
renal O
elimination O
but O
also O
to O
an O
altered O
distribution O
in O
the O
body O
. O

Caution O
should O
also O
be O
applied O
for O
other O
sympathomimetics B-group
, O
and O
for O
aminophylline B-drug
and O
theophylline B-drug
and O
tricyclic B-group
antidepressants I-group
, O
which O
may O
also O
precipitate O
arrhythmias O
. O

CNS O
Drugs O
- O
Given O
the O
primary O
CNS O
effects O
of O
escitalopram B-drug
, O
caution O
should O
be O
used O
when O
it O
is O
taken O
in O
combination O
with O
other O
centrally O
acting O
drugs O
. O

nc1 O
40 O
% O
decrease O
[ O
CI O
: O
17 O
% O
decrease O
, O
57 O
% O
decrease O
] O

approximately O
one-hundredth O
of O
the O
human O
recommended O
dose O
based O
on O
body O
surface O
area O
[ O
BSA O
] O
) O
, O
fulvestrant B-drug
caused O
a O
reversible O
reduction O
in O
female O
fertility O
, O
as O
well O
as O
effects O
on O
embryo/fetal O
development O
consistent O
with O
its O
anti-estrogenic O
activity O
. O

The O
appropriate O
doses O
for O
this O
combination O
, O
with O
respect O
to O
efficacy O
and O
safety O
, O
have O
not O
been O
established O
. O

Morphine B-drug
analgesia O
and O
pupil O
constriction O
were O
unaffected O
by O
ADL B-drug
8-2698 I-drug
and O
differed O
from O
placebo O
( O
P O
< O
.002 O
) O
. O

Survanta B-brand
increased O
the O
extent O
of O
dissolution O
of O
budesonide B-drug
in O
proportion O
to O
the O
added O
concentration O
, O
which O
was O
also O
verified O
by O
equilibrium O
solubilization O
studies O
. O

Each O
volunteer O
was O
administered O
one O
400-mg O
ceftibuten B-drug
capsule O
. O

Other O
drugs O
have O
not O
been O
studied O
. O

Dimenhydrinate B-drug
may O
decrease O
emetic B-group
response O
to O
apomorphine B-drug
. O

Electrocardiograms O
were O
done O
at O
baseline O
and O
on O
the O
last O
day O
of O
the O
washout O
period O
and O
phase O
2 O
. O

Because O
of O
the O
variability O
of O
individual O
patient O
response O
, O
multiple O
interacting O
mechanisms O
with O
some O
drugs O
, O
the O
dependency O
of O
the O
extent O
of O
the O
interaction O
on O
the O
dosage O
and O
duration O
of O
therapy O
, O
and O
the O
possible O
administration O
of O
several O
interacting O
drugs O
simultaneously O
, O
it O
is O
difficult O
to O
predict O
the O
direction O
and O
degree O
of O
the O
ultimate O
effect O
of O
concomitant O
medications O
on O
anticoagulant B-group
response O
. O

However O
, O
caution O
should O
be O
exercised O
because O
there O
have O
been O
a O
few O
spontaneous O
reports O
of O
prolonged O
prothrombin O
times O
, O
with O
or O
without O
bleeding O
, O
in O
etodolac-treated B-drug
patients O
receiving O
concomitant O
warfarin B-drug
therapy O
. O

Doxepin B-drug
is O
primarily O
metabolized O
by O
CYP2D6 O
( O
with O
CYP1A2 O
and O
CYP3A4 O
as O
minor O
pathways O
) O
. O

Release O
of O
arachidonic O
acid O
from O
membrane O
phospholipids O
as O
well O
as O
subsequent O
synthesis O
and O
release O
of O
vasoconstrictor O
thromboxane O
A2 O
are O
also O
regulated O
by O
movement O
of O
calcium O
ions O
. O

DESIGN O
: O
Cross-sectional O
descriptive O
study O
. O

Finasteride B-drug
does O
not O
appear O
to O
affect O
the O
cytochrome O
P450-linked O
drug-metabolizing O
enzyme O
system O
. O

We O
have O
shown O
that O
MCF-7 O
cells O
treated O
with O
100 O
nM O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
exhibit O
characteristic O
apoptotic O
morphology O
( O
pyknotic O
nuclei O
, O
chromatin O
and O
cytoplasmic O
condensation O
, O
nuclear O
matrix O
protein O
reorganization O
) O
within O
48 O
h O
. O

Therefore O
, O
the O
potential O
exists O
for O
a O
drug O
interaction O
between O
WELLBUTRIN B-brand
and O
drugs O
that O
affect O
the O
CYP2B6 O
isoenzyme O
( O
e.g. O
, O
orphenadrine B-drug
and O
cyclophosphamide B-drug
) O
. O

Dose O
adjustment O
of O
Sensipar B-brand
may O
be O
required O
and O
PTH O
and O
serum O
calcium O
concentrations O
should O
be O
closely O
monitored O
if O
a O
patient O
initiates O
or O
discontinues O
therapy O
with O
a O
strong O
CYP3A4 O
inhibitor O
( O
e.g. O
, O
ketoconazole B-drug
, O
erythromycin B-drug
, O
itraconazole B-drug
; O

There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
, O
achieving O
a O
maximum O
relaxation O
of O
> O
95 O
% O
at O
a O
concentration O
of O
35 O
micromol/l O
. O

It O
was O
concluded O
that O
, O
although O
gentamycin B-drug
did O
augment O
the O
neuromuscular O
blockade O
of O
atracurium B-drug
, O
the O
effect O
was O
minimal O
. O

Whether O
this O
interaction O
also O
occurs O
with O
the O
intravenous O
, O
topical O
or O
vaginal O
preparations O
of O
miconazole B-drug
is O
not O
known O
. O

The O
mode O
of O
toxic O
action O
of O
the O
pesticide O
gliftor B-drug_n
: O
the O
metabolism O
of O
1,3-difluoroacetone B-drug_n
to O
( B-drug_n
- I-drug_n
) I-drug_n
-erythro-fluorocitrate I-drug_n
. O

. O

Rare O
cases O
of O
elevated O
plasma O
concentrations O
of O
digoxin B-drug
have O
been O
reported O
. O

At O
75 O
% O
recovery O
of O
fade O
, O
hoof O
twitch O
was O
87 O
+/- O
3 O
% O
for O
atracurium B-drug
alone O
and O
82 O
+/- O
4 O
% O
for O
atracurium B-drug
plus O
gentamycin B-drug
. O

CYP3A4 B-drug
Inhibitors O
Felodipine O
is O
metabolized O
by O
CYP3A4 B-drug
. O

therefore O
, O
if O
glucocorticoid B-group
replacement O
is O
needed O
, O
hydrocortisone B-drug
should O
be O
prescribed O
. O

Hepatic O
Impairment O
There O
are O
currently O
no O
clinical O
studies O
with O
SPRYCEL B-brand
in O
patients O
with O
impaired O
liver O
function O
( O
clinical O
studies O
have O
excluded O
patients O
with O
ALT O
and/or O
AST O
2.5 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
and/or O
total O
bilirubin O
2 O
times O
the O
upper O
limit O
of O
the O
normal O
range O
) O
. O

Digoxin B-drug
: O
Studies O
of O
concomitant O
administration O
of O
flurbiprofen B-drug
and O
digoxin B-drug
to O
healthy O
men O
( O
n= O
14 O
) O
did O
not O
show O
a O
change O
in O
the O
steady O
state O
serum O
levels O
of O
either O
drug O
. O

Thus O
, O
when O
ibuprofen B-drug
and O
lithium B-drug
are O
administered O
concurrently O
, O
subjects O
should O
be O
observed O
carefully O
for O
signs O
of O
lithium B-drug
toxicity O
. O

Acarbose B-drug
may O
affect O
digoxin B-drug
bioavailabillty O
and O
may O
require O
dose O
adjustment O
of O
digoxin B-drug
by O
16 O
% O
( O
90 O
% O
confidence O
interval O
: O
8-23 O
% O
) O
, O
decrease O
mean O
C O
max O
digoxin B-drug
by O
26 O
% O
( O
90 O
% O
confidence O
interval O
: O
16-34 O
% O
) O
and O
decrease O
mean O
trough O
concentrations O
of O
digoxin B-drug
by O
9 O
% O
( O
90 O
% O
confidence O
limit O
: O
19 O
% O
decrease O
to O
2 O
% O
increase O
) O
. O

According O
to O
Gibaldi O
et O
al O
. O

Concurrent O
use O
of O
hydroxyurea B-drug
and O
other O
myelosuppressive O
agents O
or O
radiation O
therapy O
may O
increase O
the O
likelihood O
of O
bone O
marrow O
depression O
or O
other O
adverse O
events O
. O

Ketoconazole B-drug
: O
Ketoconazole B-drug
may O
inhibit O
both O
synthetic O
and O
catabolic O
enzymes O
of O
vitamin B-group
D I-group
. O

Due O
to O
the O
frequent O
occurrence O
of O
severe O
and O
prolonged O
thrombocytopenia O
, O
the O
potential O
benefits O
of O
medications O
which O
interfere O
with O
platelet O
function O
and/or O
anticoagulation O
should O
be O
weighed O
against O
the O
potential O
increased O
risks O
of O
bleeding O
and O
hemorrhage O
. O

Carbamazepine B-drug_n
epoxide I-drug_n
steady-state O
Cmin O
concentrations O
increased O
57 O
% O
from O
1.0 O
0.3 O
to O
1.6 O
0.4 O
micrograms/mL O
with O
the O
addition O
of O
felbamate B-drug
. O

LABORATORY O
TEST O
FINDINGS O
Asymptomatic O
, O
transitory O
changes O
in O
serum O
iron O
have O
been O
observed O
. O

In O
separate O
single O
or O
multiple O
dose O
pharmacokinetic O
interaction O
studies O
with O
chlorthalidone B-drug
, O
nifedipine B-drug
, O
propanolol B-drug
, O
hydrochlorothiazide B-drug
, O
cimetidine B-drug
, O
metoclopramide B-drug
, O
propantheline B-drug
, O
digoxin B-drug
, O
and O
warfarin B-drug
, O
the O
bioavailability O
of O
fosinoprilat B-drug_n
was O
not O
altered O
by O
coadministration O
of O
fosinopril B-drug
with O
any O
one O
of O
these O
drugs O
. O

Caution O
, O
however O
, O
is O
advised O
in O
patients O
taking O
tricyclic B-group
antidepressants I-group
which O
can O
affect O
the O
metabolism O
and O
uptake O
of O
circulating O
amines O
. O

Caution O
should O
be O
exercised O
if O
tacrolimus B-drug
and O
bosentan B-drug
are O
used O
together O
. O

Patients O
taking O
isoniazid B-drug
when O
disulfiram B-drug
is O
given O
should O
be O
observed O
for O
the O
appearance O
of O
unsteady O
gait O
or O
marked O
changes O
in O
mental O
status O
; O

ADL-8-2698 B-drug
is O
a O
novel O
peripherally B-group
restricted I-group
opioid I-group
antagonist I-group
that O
may O
selectively O
prevent O
opioid-induced B-group
gastrointestinal O
effects O
without O
reversing O
analgesia O
. O

This O
was O
due O
to O
reductions O
in O
both O
renal O
clearance O
( O
from O
105 O
+/- O
39 O
to O
84 O
+/- O
15 O
ml/min O
) O
( O
p O
less O
than O
0.05 O
) O
and O
nonrenal O
clearance O
( O
from O
130 O
+/- O
38 O
to O
88 O
+/- O
20 O
ml/min O
) O
( O
p O
less O
than O
0.01 O
) O
. O

Use O
with O
caution O
. O

Diabetics O
should O
discuss O
the O
use O
of O
these O
supplements O
with O
their O
physicians O
and O
note O
if O
the O
supplements O
affect O
their O
glycemic O
control O
. O

Infusion O
of O
arginine B-drug
alone O
markedly O
decreased O
the O
amount O
of O
extractable O
pancreatic O
insulin O
and O
glucagon O
. O

Aspirin B-brand
: O
Vardenafil B-drug
( O
10 O
mg O
and O
20 O
mg O
) O
did O
not O
potentiate O
the O
increase O
in O
bleeding O
time O
caused O
by O
aspirin B-brand
( O
two O
81 O
mg O
tablets O
) O
. O

In O
a O
12-week O
endoscopy O
study O
conducted O
in O
OA O
patients O
there O
was O
no O
difference O
in O
the O
cumulative O
incidence O
of O
endoscopic O
gastroduodenal O
ulcers O
in O
patients O
taking O
low-dose O
( O
81 O
mg O
) O
enteric O
coated O
aspirin B-brand
plus O
VIOXX B-brand
25 O
mg O
daily O
, O
as O
compared O
to O
those O
taking O
ibuprofen B-drug
2400 O
mg O
daily O
alone O
. O

Patients O
receiving O
both O
drugs O
should O
be O
under O
careful O
observation O
. O

Cmax O
and O
AUC O
values O
are O
3 O
% O
to O
4 O
% O
lower O
, O
respectively O
, O
after O
administration O
of O
125 O
mg O
Neurontin B-brand
and O
21 O
% O
to O
22 O
% O
lower O
, O
respectively O
, O
after O
administration O
of O
500 O
mg O
Neurontin B-brand
. O

The O
concomitant O
use O
of O
INDOCIN B-brand
with O
other O
NSAIDs B-group
is O
not O
recommended O
due O
to O
the O
increased O
possibility O
of O
gastrointestinal O
toxicity O
, O
with O
little O
or O
no O
increase O
in O
efficacy O
. O

Concomitant O
treatment O
with O
coumarin B-group
derivatives I-group
( O
vitamin B-group
K I-group
antagonists I-group
) O
and O
drugs O
that O
affect O
platelet O
function O
may O
also O
increase O
the O
risk O
of O
bleeding O
. O

1,25-Dihydroxycholecalciferol B-drug
D3 I-drug
( O
1,25 B-drug
( I-drug
OH I-drug
) I-drug
2D3 I-drug
) O
, O
the O
active O
metabolite O
of O
vitamin B-group
D I-group
, O
is O
a O
potent O
inhibitor O
of O
breast O
cancer O
cell O
growth O
both O
in O
vivo O
and O
in O
vitro O
. O

cmaxSS O
( O
Peak O
plasma O
concentration O
) O

Dexbrompheniramine B-drug
can O
interact O
with O
alcohol B-drug
or O
other O
CNS B-group
depressants I-group
( O
may O
potentiate O
the O
CNS O
depressant O
effects O
of O
either O
these O
medications O
or O
antihistamines B-group
) O
, O
anticholinergics B-group
or O
other O
medications O
with O
anticholinergic O
activity O
( O
anticholinergic O
effects O
may O
be O
potentiated O
when O
these O
medications O
are O
used O
concurrently O
with O
antihistamines B-group
) O
, O
and O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
( O
concurrent O
use O
with O
antihistamines B-group
may O
prolong O
and O
intensify O
the O
anticholinergic O
and O
CNS O
depressant O
effects O
of O
antihistamines B-group
) O
. O

These O
reactions O
include O
fever O
, O
chills O
, O
nausea O
, O
vomiting O
, O
pruritus O
, O
rash O
, O
diarrhea O
, O
hypotension O
, O
edema O
, O
and O
oliguria O
. O

Increases O
of O
22 O
% O
with O
MHD B-drug_n
and O
47 O
% O
with O
oxcarbazepine B-drug
were O
observed O
. O

Interaction O
of O
the O
constituents O
of O
alcoholic O
beverages O
in O
the O
promotion O
of O
liver O
damage O
. O

Resistance O
was O
measured O
near O
the O
placental O
margin O
after O
spontaneous O
term O
delivery O
. O

Elevated O
serum O
levels O
of O
cyclosporine B-drug
have O
been O
reported O
with O
concomitant O
use O
of O
cyclosporine B-drug
with O
norfloxacin B-drug
. O

Warfarin B-drug

Geriatric O
Use O
Younger O
patients O
have O
higher O
virologic O
response O
rates O
than O
older O
patients O
. O

Rifampin B-drug

The O
magnitude O
and O
relative O
importance O
of O
the O
effects O
noted O
below O
are O
likely O
to O
be O
patient O
specific O
and O
may O
vary O
by O
such O
factors O
as O
age O
, O
gender O
, O
race O
, O
intercurrent O
illnesses O
, O
dose O
of O
either O
agent O
, O
additional O
concomitant O
medications O
, O
and O
timing O
of O
drug O
administration O
. O

Phenothiazine-related B-group
compounds I-group
and O
beta-adrenergic B-group
blocking I-group
agents I-group
may O
have O
additive O
hypotensite O
effects O
due O
to O
the O
inhibition O
of O
each O
other O
s O
metabolism O
. O

Lethargy O
and O
somnolence O
have O
been O
reported O
following O
doses O
of O
REVIA B-brand
and O
thioridazine B-drug
. O

Coadministration O
of O
amprenavir B-drug
and O
methadone B-drug
as O
compared O
to O
a O
non-matched O
historicalcontrol O
group O
resulted O
in O
a O
30 O
% O
, O
27 O
% O
, O
and O
25 O
% O
decrease O
in O
serum O
amprenavir B-drug
AUC O
, O
Cmax O
, O
andCmin O
, O
respectively O
. O

MAO B-group
inhibitors I-group
prolong O
and O
intensify O
the O
anticholinergic O
( O
drying O
) O
effects O
of O
antihistamines B-group
. O

In O
vitro O
metabolism O
studies O
have O
suggested O
that O
decitabine B-drug
is O
not O
a O
substrate O
for O
the O
human O
liver O
cytochrome O
P450 O
enzymes O
. O

For O
the O
identification O
of O
" O
limit O
values O
" O
, O
it O
has O
generally O
been O
suggested O
in O
the O
literature O
that O
the O
possible O
effects O
deriving O
from O
multiple O
exposure O
be O
considered O
as O
additive O
. O

Cancer O
in O
the O
elderly O
: O
basic O
science O
and O
clinical O
aspects O
. O

Rare O
cases O
of O
serious O
cardiovascular O
adverse O
events O
, O
including O
electrocardiographic O
QT/QTc O
interval O
prolongation O
, O
cardiac O
arrest O
, O
torsades O
de O
pointes O
, O
and O
other O
ventricular O
arrhythmias O
have O
been O
observed O
. O

Other O
Agents O
: O
PRINIVIL B-brand
has O
been O
used O
concomitantly O
with O
nitrates B-group
and/or O
digoxin B-drug
without O
evidence O
of O
clinically O
significant O
adverse O
interactions O
. O

Animal O
studies O
also O
suggest O
an O
increased O
potential O
for O
seizures O
when O
these O
2 O
drugs O
are O
given O
concomitantly O
. O

It O
is O
important O
that O
patients O
understand O
how O
to O
use O
FORADIL B-brand
( O
formoterol B-drug
fumarate I-drug
) O
capsules O
with O
the O
supplied O
AerolizerTM O
inhalation O
device O
and O
how O
it O
should O
be O
used O
in O
relation O
to O
other O
asthma O
or O
COPD O
medications O
they O
are O
taking O
. O

Coadministration O
of O
alosetron B-drug
and O
strong O
CYP3A4 O
inhibitors O
, O
such O
as O
clarithromycin B-drug
, O
telithromycin B-drug
, O
protease B-group
inhibitors I-group
, O
voriconazole B-drug
, O
and O
itraconazole B-drug
has O
not O
been O
evaluated O
but O
should O
be O
undertaken O
with O
caution O
because O
of O
similar O
potential O
drug O
interactions O
. O

In O
vitro O
studies O
suggest O
that O
coadministration O
of O
cytochrome O
P450 O
inhibitors O
to O
PMs O
will O
not O
increase O
the O
plasma O
concentrations O
of O
atomoxetine B-drug
. O

Effect O
of O
dofetillide B-drug
on O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

. O

miconazole B-drug
; O

An O
individual O
who O
is O
stable O
on O
a O
given O
dose O
of O
TCA B-group
may O
become O
abruptly O
toxic O
when O
given O
one O
of O
these O
inhibiting O
drugs O
as O
concomitant O
therapy O
. O

Caution O
should O
be O
exercised O
when O
anticoagulants B-group
are O
given O
in O
conjunction O
with O
Atromid-S B-brand
. O

Because O
tetracyclines B-group
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-group
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-group
dosage O
. O

Caspofungin B-drug
is O
not O
a O
substrate O
for O
P-glycoprotein O
and O
is O
a O
poor O
substrate O
for O
cytochrome O
P450 O
enzymes O
. O

When O
such O
drugs O
are O
administered O
to O
a O
patient O
receiving O
Acarbose B-drug
, O
the O
patient O
should O
be O
closely O
observed O
for O
loss O
of O
blood O
glucose O
control O
. O

Antacids B-group
containing O
aluminum B-drug
hydroxide I-drug
and O
magnesium B-drug
hydroxide I-drug
reduce O
the O
oral O
absorption O
of O
enoxacin B-drug
by O
75 O
% O
. O

Green B-drug
tea I-drug
polyphenols I-drug
as O
potent O
enhancers B-drug
of O
glucocorticoid-induced O
mouse O
mammary O
tumor O
virus O
gene O
expression O
. O

1- O
nc O
denotes O
a O
mean O
change O
of O
less O
than O
10 O
% O
2- O
Pediatrics O
3- O
Mean O
increase O
in O
adults O
at O
high O
Trileptal B-brand
doses O
In O
vivo O
, O
the O
plasma O
levels O
of O
phenytoin B-drug
increased O
by O
up O
to O
40 O
% O
, O
when O
Trileptal B-brand
was O
given O
at O
doses O
above O
1200 O
mg/day O
. O

- O
Androgens B-group
( O
male O
hormones O
) O
or O

Cimetidine B-drug
( O
400 O
mg O
b.i.d O
. O
) O
had O
no O
effect O
on O
vardenafil B-drug
bioavailability O
( O
AUC O
) O
and O
maximum O
concentration O
( O
Cmax O
) O
of O
vardenafil B-drug
when O
co-administered O
with O
20 O
mg O
Vardenafil B-drug
in O
healthy O
volunteers O
. O

Furosemide B-drug
: O
In O
normal O
volunteers O
, O
the O
concomitant O
administration O
of O
diflunisal B-drug
and O
furosemide B-drug
had O
no O
effect O
on O
the O
diuretic O
activity O
of O
furosemide B-drug
. O

While O
the O
effects O
of O
chronic O
phenytoin B-drug
or O
carbamazepine B-drug
therapy O
on O
the O
action O
of O
NIMBEX B-brand
are O
unknown O
, O
slightly O
shorter O
durations O
of O
neuromuscular O
block O
may O
be O
anticipated O
and O
infusion O
rate O
requirements O
may O
be O
higher O
. O

Animal O
toxicology O
studies O
showed O
increased O
DEET B-drug
toxicity O
when O
DEET B-drug
was O
included O
as O
proof O
of O
the O
formulation O
. O

Itraconazole B-drug
Ketoconazole I-drug
Erythromycin I-drug
Clarithromycin I-drug
Telithromycin I-drug
HIV B-group
protease I-group
inhibitors I-group
Nefazodone B-drug
Cyclosporine I-drug
Large O
quantities O
of O
grapefruit O
juice O
( O
1 O
quart O
daily O
) O

The O
fluoroquinolones B-group
for O
urinary O
tract O
infections O
: O
a O
review O
. O

A O
clinical O
study O
in O
healthy O
male O
volunteers O
( O
n=24 O
) O
demonstrated O
that O
mixing O
NovoLog B-brand
with O
NPH B-drug
human I-drug
insulin I-drug
immediately O
before O
injection O
produced O
some O
attenuation O
in O
the O
peak O
concentration O
of O
NovoLog B-brand
, O
but O
that O
the O
time O
to O
peak O
and O
the O
total O
bioavailability O
of O
NovoLog B-brand
were O
not O
significantly O
affected O
. O

Therefore O
, O
when O
INDOCIN B-brand
and O
digoxin B-drug
are O
used O
concomitantly O
, O
serum O
digoxin B-drug
levels O
should O
be O
closely O
monitored O
. O

Hyperglycaemia O
increased O
all O
the O
renal O
and O
ocular O
parameters O
studied O
. O

Increase O
daily O
dose O
of O
rifabutin B-drug
by O
50 O
% O
. O

After O
30 O
min O
, O
fasting O
glycemia O
was O
measured O
. O

Co-administration O
of O
celecoxib B-drug
with O
drugs O
that O
are O
known O
to O
inhibit O
2C9 O
should O
be O
done O
with O
caution O
. O

Potassium B-drug
Supplements O
and O
Potassium-Sparing B-group
Diuretics I-group
Lotensin O
can O
attenuate O
potassium O
loss O
caused O
by O
thiazide B-group
diuretics I-group
. O

In O
case O
of O
theophylline B-drug
toxicity O
and/or O
elevated O
serum O
theophylline B-drug
levels O
, O
the O
dose O
of O
theophylline B-drug
should O
be O
reduced O
while O
the O
patient O
is O
receiving O
concomitant O
erythromycin B-drug
therapy O
. O

Phenytoin B-drug
: O
In O
post-marketing O
experience O
, O
there O
have O
been O
reports O
of O
both O
increases O
and O
decreases O
in O
phenytoin B-drug
levels O
with O
dexamethasone B-drug
co-administration O
, O
leading O
to O
alterations O
in O
seizure O
control O
. O

In O
vitro O
binding O
studies O
with O
human O
serum O
proteins O
indicate O
that O
glipizide B-drug
binds O
differently O
than O
tolbutamide B-drug
and O
does O
not O
interact O
with O
salicylate B-group
or O
dicumarol B-drug
. O

It O
is O
not O
known O
if O
hormonal B-group
contraceptives I-group
differ O
in O
their O
effectiveness O
when O
used O
with O
Accutane B-brand
. O

Administration O
of O
dantrolene B-drug
may O
potentiate O
vecuronium-induced B-drug
neuromuscular O
block O
. O

This O
decrease O
in O
bioavailability O
was O
about O
5 O
% O
when O
gabapentin B-drug
was O
administered O
2 O
hours O
after O
Maalox B-brand
. O

Folic B-drug
acid I-drug
supplements O
can O
correct O
the O
anemia O
associated O
with O
vitamin O
B12 O
deficiency O
. O

Taking O
amyl B-drug
nitrite I-drug
after O
drinking O
alcohol B-drug
may O
worsen O
side O
effects O
and O
may O
cause O
severe O
hypotension O
and O
cardiovascular O
collapse O
. O

Indomethacin B-drug
was O
also O
ineffective O
in O
altering O
resveratrol B-drug_n
activity O
in O
arteries O
from O
both O
lean O
and O
dietary-obese O
rats O
. O

INDOCIN B-brand
given O
concomitantly O
with O
digoxin B-drug
has O
been O
reported O
to O
increase O
the O
serum O
concentration O
and O
prolong O
the O
half-life O
of O
digoxin B-drug
. O

Considerable O
caution O
should O
be O
exercised O
if O
PEGANONE B-brand
is O
administered O
concurrently O
with O
Phenurone B-brand
( O
phenacemide B-drug
) O
since O
paranoid O
symptoms O
have O
been O
reported O
during O
therapy O
with O
this O
combination O
. O

Paroxetine B-drug
produced O
only O
minor O
changes O
in O
the O
levels O
of O
clozapine B-drug
and O
its O
metabolites O
. O

Formulation O
of O
fluorescence O
labelled O
bacitracin B-drug
and O
insulin B-drug
in O
unconjugated O
NaCMC B-drug_n
( O
1 O
% O
m/v O
) O
did O
not O
significantly O
improve O
the O
permeation O
, O
however O
in O
the O
presence O
of O
1 O
% O
( O
m/v O
) O
CMC-Cys7.3 B-drug_n
a O
significantly O
improved O
permeation O
was O
observed O
( O
R= O
1.3 O
) O
. O

Interaction O
of O
ketamine B-drug
and O
halothane B-drug
in O
rats O
. O

Thus O
, O
if O
a O
patient O
has O
been O
titrated O
to O
a O
stable O
dosage O
on O
one O
of O
the O
agents O
in O
this O
category O
, O
and O
then O
begins O
a O
course O
of O
treatment O
with O
EQUETROTM B-brand
, O
it O
is O
reasonable O
to O
expect O
that O
a O
dose O
increase O
for O
the O
concomitant O
agent O
may O
be O
necessary O
. O

PEGASYS B-brand
should O
be O
used O
with O
caution O
in O
patients O
with O
creatinine O
clearance O
50 O
mL/min O
and O
COPEGUS B-brand
should O
not O
be O
administered O
to O
patients O
with O
creatinine O
clearance O
50 O
mL/min O

Other O
binding O
proteins O
may O
be O
elevated O
in O
serum O
, O
( O
i.e. O
, O
corticosteroid O
binding O
globulin O
( O
CBG O
) O
, O
sex O
hormone O
binding O
globulin O
( O
SHBG O
) O
) O
leading O
to O
increased O
total O
circulating O
corticosteroids B-group
and O
sex B-group
steroids I-group
, O
respectively O
. O

Decreases O
in O
TBg O
concentrations O
are O
observed O
in O
nephrosis O
, O
acromegaly O
and O
after O
androgen B-group
or O
corticosteroid B-group
therapy O
. O

Concomitant O
administration O
of O
clarithromycin B-drug
with O
pimozide B-drug
is O
contraindicated O
. O

In O
comparison O
with O
haloperidol B-drug
, O
the O
adverse O
events O
reported O
significantly O
more O
frequently O
with O
olanzapine B-drug
in O
> O
or O
= O
3.5 O
% O
of O
patients O
were O
dry O
mouth O
, O
bodyweight O
gain O
and O
increased O
appetite O
and O
compared O
with O
risperidone B-drug
, O
only O
bodyweight O
gain O
occurred O
significantly O
more O
frequently O
with O
olanzapine B-drug
. O

These O
medications O
have O
included O
heparin B-drug
, O
warfarin B-drug
, O
beta-adrenergic B-group
receptor I-group
blockers I-group
, O
calcium B-group
channel I-group
antagonists I-group
, O
angiotensin B-group
converting I-group
enzyme I-group
inhibitors I-group
, O
intravenous O
and O
oral O
nitrates B-group
, O
ticlopidine B-drug
, O
and O
aspirin B-brand
. O

Pretreatment O
of O
rats O
with O
allopurinol B-drug
( O
100 O
mg/kg O
, O
ip O
) O
or O
Vitamin B-drug
E I-drug
( O
100 O
mg/kg O
per O
day O
, O
ig O
, O
for O
3 O
days O
and O
a O
dose O
of O
40 O
mg/kg O
on O
the O
4th O
day O
) O
provided O
significant O
protection O
against O
the O
elevation O
of O
TBARS O
levels O
in O
cerebral O
and O
hepatic O
tissues O
, O
induced O
by O
single O
high O
dose O
of O
oral O
cypermethrin B-drug
administration O
within O
4 O
h O
. O

These O
would O
include O
a O
variety O
of O
preparations O
which O
contain O
androgens B-group
, O
estrogens B-group
, O
progestins B-group
, O
or O
glucocorticoids B-group
. O

Theophylline B-drug
: O
Theophylline B-drug
clearance O
may O
decrease O
in O
hypothyroid O
patients O
and O
return O
toward O
normal O
when O
a O
euthyroid O
state O
is O
achieved O
. O

These O
data O
suggest O
that O
rofecoxib B-drug
may O
produce O
a O
modest O
inhibition O
of O
cytochrome O
P450 O
( O
CYP O
) O
1A2 O
. O

Because O
many O
drugs O
are O
excreted O
in O
human O
milk O
, O
and O
because O
of O
the O
potential O
for O
serious O
adverse O
reactions O
from O
FASLODEX B-brand
in O
nursing O
infants O
, O
a O
decision O
should O
be O
made O
whether O
to O
discontinue O
nursing O
or O
to O
discontinue O
the O
drug O
taking O
into O
account O
the O
importance O
of O
the O
drug O
to O
the O
mother O
. O

A O
return O
to O
normal O
menstrual O
rhythm O
followed O
cessation O
of O
treatment O
. O

The O
higher O
verografine B-drug
and O
iodamide B-drug
excretion O
was O
due O
to O
their O
increased O
renal O
tubular O
secretion O
. O

Opioids B-group
are O
strong O
central B-group
nervous I-group
system I-group
depressants I-group
, O
but O
regular O
users O
develop O
physiological O
tolerance O
allowing O
gradually O
increased O
dosages O
. O

Calcium B-group
Channel I-group
Blockers I-group
, O
Dihydropyridine B-group
: O
e.g. O
, O
felodipine B-drug
, O
nifedipine B-drug
, O
nicardipine B-drug

Additionally O
, O
paroxetine B-drug
did O
not O
alter O
the O
pharmacokinetics O
of O
Sonata B-brand
, O
reflecting O
the O
absence O
of O
a O
role O
of O
CYP2D6 O
in O
zaleplon B-drug
s O
metabolism O
. O

Therefore O
, O
monitoring O
of O
plasma O
digoxin B-drug
levels O
may O
be O
indicated O
in O
patients O
receiving O
similar O
combination O
chemotherapy O
regimens O
. O

Concomitant O
use O
of O
tricyclic B-group
antidepressants I-group
with O
drugs O
that O
can O
inhibit O
cytochrome O
P450 O
2D6 O
may O
require O
lower O
doses O
than O
usually O
prescribed O
for O
either O
the O
tricyclic B-group
antidepressant I-group
or O
the O
other O
drug O
. O

Dolasetron B-drug
has O
been O
safely O
coadministered O
with O
drugs O
used O
in O
chemotherapy O
and O
surgery O
. O

Phenobarbital B-drug
: O
Coadministration O
of O
felbamate B-drug
with O
phenobarbital B-drug
causes O
an O
increase O
in O
phenobarbital B-drug
plasma O
concentrations O
, O
In O
12 O
otherwise O
healthy O
male O
volunteers O
ingesting O
phenobarbital B-drug
, O
the O
steady-state O
trough O
( O
Cmin O
) O
phenobarbital B-drug
concentration O
was O
14.2 O
micrograms/mL O
. O

Antihypertensives B-group
: O
Amphetamines B-group
may O
antagonize O
the O
hypotensive O
effects O
of O
antihypertensives B-drug
. O

In O
these O
subjects O
, O
celecoxib B-drug
did O
not O
alter O
the O
anticoagulant O
effect O
of O
warfarin B-drug
as O
determined O
by O
prothrombin O
time O
. O

Repeating O
the O
study O
with O
6 O
healthy O
male O
volunteers O
in O
the O
absence O
of O
glibenclamide B-drug
did O
not O
detect O
an O
effect O
of O
acitretin B-drug
on O
glucose O
tolerance O
. O

Two O
weeks O
after O
bilateral O
ovariectomy O
, O
female O
rats O
received O
a O
s.c O
. O

( O
Effectiveness O
may O
be O
decreased O
when O
used O
concurrently O
with O
thiazide B-group
diuretics I-group
because O
of O
alkalinization O
of O
the O
urine O
. O
) O

Although O
not O
studied O
with O
alosetron B-drug
, O
inhibition O
of O
N-acetyltransferase O
may O
have O
clinically O
relevant O
consequences O
for O
drugs O
such O
as O
isoniazid B-drug
, O
procainamide B-drug
, O
and O
hydralazine B-drug
. O

However O
, O
if O
Argatroban B-drug
is O
to O
be O
initiated O
after O
cessation O
of O
heparin B-drug
therapy O
, O
allow O
sufficient O
time O
for O
heparins O
effect O
on O
the O
aPTT O
to O
decrease O
prior O
to O
initiation O
of O
Argatroban B-drug
therapy O
. O

- O
Antidiabetics B-group
, O
oral O
( O
diabetes O
medicine O
you O
take O
by O
mouth O
) O
Use O
of O
oral O
antidiabetics B-group
with O
sulfapyridine B-drug
may O
increase O
the O
chance O
of O
side O
effects O
affecting O
the O
blood O
and/or O
the O
side O
effects O
or O
oral O
antidiabetics B-group

Data O
suggest O
that O
coadministration O
of O
oral O
ketoconazole B-drug
and O
cisapride B-drug
can O
result O
in O
prolongation O
of O
the O
QT O
interval O
on O
the O
ECG O
. O

If O
you O
are O
taking O
a O
tricyclic B-group
antidepressant I-group
, O
talk O
to O
your O
doctor O
before O
taking O
this O
medicine O
. O

Carbamazepine B-drug
: O
Isoniazid B-drug
is O
known O
to O
slow O
the O
metabolism O
of O
carbamazepine B-drug
and O
increase O
its O
serum O
levels O
Carbamazepine B-drug
levels O
should O
be O
determined O
prior O
to O
concurrent O
administration O
with O
isoniazid B-drug
, O
signs O
and O
symptoms O
of O
carbamazepine B-drug
toxicity O
should O
be O
monitored O
closely O
, O
and O
appropriate O
dosage O
adjustment O
of O
the O
anticonvulsant B-group
should O
be O
made O
. O

Furosemide B-drug
: O
Clinical O
studies O
, O
as O
well O
as O
post O
marketing O
observations O
, O
have O
shown O
that O
NSAIDs B-group
can O
reduce O
the O
natriuretic O
effect O
of O
furosemide B-drug
and O
thiazides B-group
in O
some O
patients O
. O

Butyrophenones B-group
( O
such O
as O
haloperidol B-drug
) O
and O
phenothiazines B-group
can O
suppress O
the O
dopaminergic B-drug
renal O
and O
mesenteric O
vasodilation O
induced O
with O
low O
dose O
dopamine O
infusion O
. O

Erythromycin I-drug
( O
500 O
mg O
q8h O
) O
+ O
40 O
% O
+46 O
% O

Also O
, O
due O
to O
the O
potential O
for O
additive O
effects O
such O
as O
bradycardia O
and O
AV O
block O
, O
caution O
is O
warranted O
in O
patients O
receiving O
clonidine B-drug
with O
agents O
known O
to O
affect O
sinus O
node O
function O
or O
AV O
nodal O
conduction O
( O
e.g. O
, O
digitalis B-group
, O
calcium B-group
channel I-group
blockers I-group
, O
and O
beta-blockers B-group
. O
) O

The O
size O
of O
wheal O
and O
flare O
were O
significantly O
larger O
when O
fexofenadine B-drug
hydrochloride I-drug
was O
administered O
with O
either O
grapefruit O
or O
orange O
juices O
compared O
to O
water O
. O

Effects O
of O
Lapatinib B-drug
on O
Drug O
Metabolizing O
Enzymes O
and O
Drug O
Transport O
Systems O
Lapatinib B-drug
inhibits O
CYP3A4 O
and O
CYP2C8 O
in O
vitro O
at O
clinically O
relevant O
concentrations O
. O

Certain O
drugs O
tend O
to O
produce O
hyperglycemia O
and O
may O
lead O
to O
loss O
of O
control O
. O

Administration O
of O
epinephrine B-drug
to O
patients O
receiving O
cyclopropane B-drug
or O
halogenated B-group
hydrocarbon I-group
general I-group
anesthetics I-group
such O
as O
halothane B-drug
which O
sensitize O
the O
myocardium O
, O
may O
induce O
cardiac O
arrhythmia.. O

AZOPT B-brand
( O
brinzolamide B-drug
ophthalmic O
suspension O
) O
1 O
% O
contains O
a O
carbonic B-group
anhydrase I-group
inhibitor I-group
. O

All O
20 O
strains O
of O
enterococcus O
, O
three O
strains O
of O
Clostridium O
, O
three O
strains O
of O
Escherichia O
coli O
, O
and O
one O
strain O
of O
Proteus O
rettgeri O
were O
resistant O
to O
both O
clindamycin B-drug
( O
minimal O
inhibitory O
concentration O
greater O
than O
3.1 O
mug/ml O
) O
and O
gentamicin B-drug
( O
minimal O
inhibitory O
concentration O
greater O
than O
6.2 O
mug/ml O
) O
. O

In O
combination O
with O
other O
central B-group
nervous I-group
system I-group
depressants I-group
, O
heroin B-drug_n
may O
still O
kill O
even O
experienced O
users O
, O
particularly O
if O
their O
tolerance O
to O
the O
drug O
has O
reduced O
or O
the O
strength O
of O
their O
usual O
dose O
has O
increased O
. O

Caution O
is O
advised O
when O
TRISENOX B-brand
is O
coadministered O
with O
other O
medications O
that O
can O
prolong O
the O
QT O
interval O
( O
e.g O
. O
certain O
antiarrhythmics B-group
or O
thioridazine B-drug
) O
or O
lead O
to O
electrolyte O
abnormalities O
( O
such O
as O
diuretics B-group
or O
amphotericin B-drug
B I-drug
) O
. O

Available O
data O
indicate O
that O
platelet O
function O
and O
arachidonic O
acid O
metabolism O
are O
important O
factors O
in O
hemostasis O
and O
regulation O
of O
vascular O
tone O
. O

All O
patients O
in O
whom O
this O
effect O
was O
observed O
remained O
asymptomatic O
. O

Combination O
of O
amiodarone B-drug
with O
other O
antiarrhythmic B-drug
therapy O
should O
be O
reserved O
for O
patients O
with O
life-threatening O
ventricular O
arrhythmias O
who O
are O
incompletely O
responsive O
to O
a O
single O
agent O
or O
incompletely O
responsive O
to O
amiodarone B-drug
. O

RESULTS O
: O
During O
treatment O
with O
fluvoxamine B-drug
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
the O
median O
of O
the O
total O
clearance O
of O
tolbutamide B-drug
, O
from O
845 O
mL/h O
to O
688 O
mL/h O
, O
among O
the O
volunteers O
who O
received O
75 O
mg/d O
. O

Disopyramide B-drug
increases O
QT O
prolongation O
which O
could O
cause O
arrhythmia O
. O

When O
combined O
with O
ofloxacin B-drug
, O
KRM-1648 B-drug_n
exhibited O
strong O
synergistic O
activity O
while O
only O
additive O
effects O
were O
observed O
with O
the O
combination O
of O
rifampicin B-drug
( O
or O
rifabutin B-drug
) O
and O
ofloxacin B-drug
. O

Clarithromycin B-drug
exposure O
was O
significantly O
decreased O
by O
nevirapine B-drug
; O

Pregnancies O
have O
been O
reported O
by O
users O
of O
combined B-group
hormonal I-group
contraceptives I-group
who O
also O
used O
some O
form O
of O
St. O
Johns O
Wort O
. O

Patients O
currently O
receiving O
diltiazem B-drug
therapy O
should O
be O
carefully O
monitored O
for O
a O
change O
in O
pharmacological O
effect O
when O
initiating O
and O
discontinuing O
therapy O
with O
cimetidine B-drug
. O

Anticoagulants B-group
, O
oral O
: O
Co-administration O
of O
corticosteroids B-group
and O
warfarin B-drug
usually O
results O
in O
inhibition O
of O
response O
to O
warfarin B-drug
, O
although O
there O
have O
been O
some O
conflicting O
reports O
. O

- O
a O
phenothiazine B-group
such O
as O
chlorpromazine B-drug
( O
Thorazine B-brand
) O
, O
fluphenazine B-drug
( O
Prolixin B-brand
, O
Permitil B-brand
) O
, O
prochlorperazine B-drug
( O
Compazine B-brand
) O
, O
promethazine B-drug
( O
Phenergan B-brand
) O
, O
and O
others O
; O

Rifampin B-drug
: O
Following O
concomitant O
administration O
of O
a O
single O
dose O
of O
ARAVA B-brand
to O
subjects O
receiving O
multiple O
doses O
of O
rifampin B-drug
, O
M1 O
peak O
levels O
were O
increased O
( O
~40 O
% O
) O
over O
those O
seen O
when O
ARAVA B-brand
was O
given O
alone O
. O

sulfonamides B-group
, O
long O
acting O
; O

In O
both O
plasma O
and O
KHT O
tumour O
the O
peak O
concentration O
and O
" O
early O
" O

The O
monoamine O
oxidase O
inhibitory O
effects O
of O
Isocarboxazid B-drug
may O
persist O
for O
a O
substantial O
period O
after O
discontinuation O
of O
the O
drug O
, O
and O
this O
should O
be O
borne O
in O
mind O
when O
another O
drug O
is O
prescribed O
following O
Isocarboxazid B-drug
. O

When O
cholestyramine B-drug
resin B-group
is O
given O
for O
long O
periods O
of O
time O
, O
concomitant O
supplementation O
with O
water-miscible O
( O
or O
parenteral O
) O
forms O
of O
fat-soluble B-group
vitamins I-group
should O
be O
considered O
. O

Drugs O
That O
Induce O
CYP3A4 O
( O
Rifampicin B-drug
) O
Racemic O
zopiclone B-drug
exposure O
was O
decreased O
80 O
% O
by O
concomitant O
useof O
rifampicin B-drug
, O
a O
potent O
inducer O
of O
CYP3A4 O
. O

Prothrombin O
time O
was O
not O
affected O
. O

400-2000 O

The O
concomitant O
administration O
of O
rifampin B-drug
and O
warfarin B-drug
resulted O
in O
the O
need O
for O
an O
unusually O
high O
maintenance O
dose O
of O
warfarin B-drug
( O
20 O
mg O
per O
day O
) O
in O
order O
to O
produce O
a O
therapeutic O
effect O
. O

Cyclosporin B-drug
: O
After O
introduction O
of O
chloroquine B-drug
( O
oral O
form O
) O
, O
a O
sudden O
increase O
in O
serum O
cyclosporin B-drug
level O
has O
been O
reported O
. O

Although O
a O
dose O
adjustment O
of O
azithromycin B-drug
is O
not O
recommended O
when O
administered O
in O
combination O
with O
nelfinavir B-drug
, O
close O
monitoring O
for O
known O
side O
effects O
of O
azithromycin B-drug
, O
such O
as O
liver O
enzyme O
abnormalities O
and O
hearing O
impairment O
, O
is O
warranted O
. O

Special O
consideration O
should O
be O
given O
to O
the O
administration O
of O
ETHYOL B-brand
in O
patients O
receiving O
antihypertensive B-group
medications I-group
or O
other O
drugs O
that O
could O
cause O
or O
potentiate O
hypotension O
. O

Synergism O
between O
xanthine B-group
bronchodilators I-group
( O
e.g. O
, O
theophylline B-drug
) O
, O
ephedrine B-drug
, O
and O
other O
sympathomimetic B-group
bronchodilators I-group
has O
been O
reported O
. O

Promethazine B-drug
: O
Coadministration O
of O
a O
single O
dose O
of O
zaleplon B-drug
and O
promethazine B-drug
( O
10 O
and O
25 O
mg O
, O
respectively O
) O
resulted O
in O
a O
15 O
% O
decrease O
in O
maximal O
plasma O
concentrations O
of O
zaleplon B-drug
, O
but O
no O
change O
in O
the O
area O
under O
the O
plasma O
concentration-time O
curve O
. O

Although O
no O
specific O
drug O
interactions O
with O
topical O
glaucoma O
drugs O
or O
systemic O
medications O
were O
identified O
in O
clinical O
studies O
of O
IOPIDINE B-brand
0.5 O
% O
Ophthalmic O
Solution O
, O
the O
possibility O
of O
an O
additive O
or O
potentiating O
effect O
with O
CNS B-group
depressants I-group
( O
alcohol B-drug
, O
barbiturates B-group
, O
opiates B-group
, O
sedatives B-group
, O
anesthetics B-group
) O
should O
be O
considered O
. O

CONCLUSIONS O
: O
It O
is O
important O
to O
identify O
the O
medications O
most O
commonly O
involved O
in O
the O
PICR O
so O
as O
to O
establish O
corrective O
measures O
to O
minimise O
the O
risks O
arising O
from O
multiple O
medication O
. O

Lithium B-drug
: O
Lithium B-drug
toxicity O
has O
been O
reported O
in O
patients O
receiving O
lithium B-drug
concomitantly O
with O
drugs O
which O
cause O
elimination O
of O
sodium O
, O
including O
ACE B-group
inhibitors I-group
. O

Effect O
on O
Concentration O
of O
Nevirapine B-drug
or O
Concomitant O
Drug O

Additionally O
, O
higher O
than O
expected O
tricyclic B-group
antidepressant I-group
levels O
have O
been O
observed O
when O
they O
are O
begun O
in O
patients O
already O
taking O
cimetidine B-drug
. O

Interactions O
may O
occur O
between O
EPA B-drug
supplements O
and O
aspirin B-brand
and O
other O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
and O
herbs O
such O
as O
garlic O
( O
Allium O
sativum O
) O
and O
ginkgo B-drug
( O
Ginkgo B-drug
biloba I-drug
) O
. O

Theoretically O
, O
it O
may O
decrease O
hepatic O
toxicity O
in O
the O
case O
of O
other O
potential O
hepatotoxic O
drugs O
, O
as O
well O
. O

On O
the O
basis O
of O
the O
principles O
observed O
the O
concentrations O
fo O
these O
hormones O
were O
investigated O
in O
the O
plasma O
of O
dogs O
deprived O
of O
water O
for O
3 O
days O
and O
then O
allowed O
to O
drink O
. O

Ocupress B-brand
should O
be O
used O
with O
caution O
in O
patients O
who O
are O
receiving O
a O
beta-adrenergic B-group
blocking I-group
agent I-group
orally O
because O
of O
the O
potential O
for O
additive O
effects O
on O
systemic O
beta-blockade O
. O

In O
diabetics O
, O
blood-sugar O
levels O
should O
be O
monitored O
very O
carefully O
. O

Ketoconazole B-drug
: O
Co-administration O
of O
bosentan B-drug
125 O
mg O
b.i.d O
. O
and O
ketoconazole B-drug
, O
a O
potent O
CYP3A4 O
inhibitor O
, O
increased O
the O
plasma O
concentrations O
of O
bosentan B-drug
by O
approximately O
2-fold O
. O

clarithromycin I-drug
concentration O
indinavir B-drug
concentration O

Further O
, O
no O
effects O
on O
either O
warfarin B-drug
levels O
or O
prothrombin O
times O
were O
observed O
in O
a O
study O
involving O
concomitant O
administration O
of O
warfarin B-drug
and O
fluvastatin B-drug
. O

The O
amplitude O
data O
from O
this O
study O
suggest O
that O
ethanol B-drug
's O
augmentation O
of O
component O
P2 O
may O
result O
, O
at O
least O
in O
part O
, O
from O
alterations O
in O
cholinergic O
functions O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
with O
DOXIL B-brand
. O

The O
effect O
may O
be O
mediated O
by O
cimetidines B-drug
known O
inhibition O
of O
hepatic O
cytochrome O
P-450 O
, O
the O
enzyme O
system O
responsible O
for O
the O
first-pass O
metabolism O
of O
diltiazem B-drug
. O

Therefore O
, O
a O
lower O
total O
daily O
dosage O
of O
INDOCIN B-brand
may O
produce O
a O
satisfactory O
therapeutic O
effect O
. O

Drug O
interaction O
studies O
with O
decitabine B-drug
have O
not O
been O
conducted O
. O

It O
is O
recommended O
not O
to O
exceed O
a O
single O
5 O
mg O
dose O
of O
Vardenafil B-drug
in O
a O
24-hour O
period O
when O
used O
in O
combination O
with O
erythromycin B-drug
. O

The O
concomitant O
administration O
of O
griseofulvin B-drug
has O
been O
reported O
to O
reduce O
the O
efficacy O
of O
oral O
contraceptives B-group
and O
to O
increase O
the O
incidence O
of O
breakthrough O
bleeding O
. O

Fluvoxamine B-drug
is O
a O
known O
strong O
inhibitor O
of O
CYP1A2 O
and O
also O
inhibits O
CYP3A4 O
, O
CYP2C9 O
, O
and O
CYP2C19 O
. O

No O
information O
is O
available O
. O

Greater O
fecal O
blood O
loss O
results O
from O
concomitant O
administration O
of O
both O
drugs O
than O
from O
either O
drug O
alone O
. O

Concomitant O
use O
with O
other O
oxytocic B-group
agents I-group
is O
not O
recommended O

Data O
from O
in O
vitro O
studies O
of O
alprazolam B-drug
suggest O
a O
possible O
drug O
interaction O
with O
alprazolam B-drug
for O
the O
following O
: O
sertraline B-drug
and O
paroxetine B-drug
. O

Concurrent O
use O
of O
rifampin B-drug
increases O
the O
metabolic O
clearance O
of O
ZEBETA B-brand
, O
resulting O
in O
a O
shortened O
elimination O
half-life O
of O
ZEBETA B-brand
. O

Urinary O
Alkalinizers O
: O
Decrease O
aspirin B-brand
effectiveness O
by O
increasing O
the O
rate O
of O
salicylate B-group
renal O
excretion O
. O

When O
concomitant O
administration O
of O
ketoconazole B-drug
with O
aripiprazole B-drug
occurs O
, O
aripiprazole B-drug
dose O
should O
be O
reduced O
to O
one-half O
of O
its O
normal O
dose O
. O

Therefore O
, O
the O
dose O
of O
corticosteroid B-group
should O
be O
titrated O
to O
avoid O
steroid O
toxicity O
. O

In O
patients O
taking O
an O
anticonvulsant B-group
( O
eg O
, O
valproic B-drug
acid I-drug
, O
carbamazepine B-drug
, O
phenobarbital B-drug
or O
phenytoin B-drug
) O
, O
the O
concomitant O
use O
of O
Mefloquine B-drug
may O
reduce O
seizure O
control O
by O
lowering O
the O
plasma O
levels O
of O
the O
anticonvulsant B-group
. O

Moreover O
, O
the O
mechanisms O
underlying O
the O
development O
of O
dependence O
may O
be O
similar O
for O
alcohol B-drug
and O
nicotine B-drug
. O

May O
interact O
with O
cefamandole B-drug
naftate I-drug
, O
cephalothin B-drug
sodium I-drug
, O
magnesium B-drug
sulfate I-drug
, O
prednisolone B-drug
sodium I-drug
succinate I-drug
, O
and O
prochlorperazine B-drug
edisylate I-drug
. O

- O
Etretinate B-drug
( O
e.g. O
, O
Tegison B-brand
) O
or O

In O
patients O
taking O
furosemide B-drug
, O
nifedipine B-drug
, O
diltiazem B-drug
, O
ACE B-group
inhibitors I-group
, O
verapamil B-drug
, O
glyburide B-drug
, O
propranolol B-drug
, O
and O
various O
chemotherapy O
agents O
, O
no O
effect O
was O
shown O
on O
the O
clearance O
of O
hydrodolasetron B-drug_n
. O

The O
depression O
of O
cardiac O
contractility O
, O
conductivity O
, O
and O
automaticity O
as O
well O
as O
the O
vascular O
dilation O
associated O
with O
anesthetics B-group
may O
be O
potentiated O
by O
calcium B-group
channel I-group
blockers I-group
. O

Nifedipine B-drug
did O
not O
alter O
the O
plasma O
levels O
of O
Vardenafil B-drug
when O
taken O
in O
combination O
. O

No O
evidence O
of O
interaction O
of O
PROCRIT B-brand
with O
other O
drugs O
was O
observed O
in O
the O
course O
of O
clinical O
trials O
. O

The O
drug O
interaction O
between O
warfarin B-drug
and O
rifampin B-drug
is O
not O
well O
known O
. O

However O
, O
due O
to O
possible O
pharmacodynamic O
interactions O
, O
when O
co-administered O
with O
PRECEDEX B-brand
, O
a O
reduction O
in O
dosage O
of O
PRECEDEX B-brand
on O
the O
concomitant O
anesthetic B-group
, O
sedative B-group
, O
hypnotic B-group
or O
opioid B-group
may O
be O
required O
. O

Drugs O
which O
inhibit O
this O
metabolic O
pathway O
may O
have O
a O
profound O
effect O
on O
the O
clearance O
of O
alprazolam B-drug
. O

Enoxacin B-drug
does O
not O
affect O
the O
clearance O
of O
the O
active O
S-isomer O
, O
and O
changes O
in O
clotting O
time O
have O
not O
been O
observed O
when O
enoxacin B-drug
and O
warfarin B-drug
were O
coadministered O
. O

Anticoagulants B-group
( O
Oral O
) O
: O
In O
patients O
receiving O
oral O
anticoagulants B-group
, O
the O
coagulation O
times O
were O
increased O
in O
some O
cases O
. O

AUC O
for O
total O
nitrosoureas B-group
were O
about O
1.4-1.5 O
fold O
greater O
for O
the O
oral O
compared O
to O
the O
i.p O
. O

Because O
the O
tetracyclines B-group
have O
been O
shown O
to O
depress O
plasma O
prothrombin O
activity O
, O
patients O
who O
are O
on O
anticoagulant B-group
therapy O
may O
require O
downward O
adjustment O
of O
their O
anticoagulant B-group
dosage O
. O

Oxytocin B-drug
or O
other O
oxytocics B-group
( O
concurrent O
use O
with O
dinoprost B-drug
may O
result O
in O
uterine O
hypertonus O
, O
possibly O
causing O
uterine O
rupture O
or O
cervical O
laceration O
, O
especially O
in O
the O
absence O
of O
adequate O
cervical O
dilatation O
; O

The O
single-dose O
nature O
of O
this O
study O
and O
the O
lack O
of O
correlation O
between O
glyburide B-drug
blood O
levels O
and O
pharmaco-dynamic O
effects O
, O
makes O
the O
clinical O
significance O
of O
this O
interaction O
uncertain O
. O

The O
incidence O
of O
TBg O
deficiency O
approximates O
1 O
in O
9000 O
. O

If O
midazolam B-drug
is O
administered O
parenterally O
, O
special O
precaution O
is O
required O
since O
the O
sedative O
effect O
may O
be O
prolonged O
. O

Caffeine B-drug
: O
Enoxacin B-drug
is O
a O
potent O
inhibitor O
of O
the O
cytochrome O
P-450 O
isozymes O
responsible O
for O
the O
metabolism O
of O
methylxanthines B-group
. O

Poor O
metabolizers O
have O
higher O
than O
expected O
plasma O
concentrations O
of O
tricyclic B-group
antidepressants I-group
( O
TCAs B-group
) O
when O
given O
usual O
doses O
. O

Dexamethasone O
suppression O
test O
( O
DST O
) O
: O
False-negative O
results O
in O
the O
dexamethasone O
suppression O
test O
( O
DST O
) O
in O
patients O
being O
treated O
with O
indomethacin B-drug
have O
been O
reported O
. O

Use O
with O
Angiotensln B-group
Converting I-group
Enzyme I-group
Inhibitors I-group
: O
The O
use O
of O
angiotensin B-group
converting I-group
enzyme I-group
inhibitors I-group
to O
control O
hypertension O
in O
patients O
on O
azathioprine B-drug
has O
been O
reported O
to O
induce O
severe O
leukopenia O
. O

In O
addition O
, O
other O
quinolones B-group
have O
been O
reported O
to O
decrease O
the O
CYP3A4-mediated O
metabolism O
of O
cyclosporine B-drug
. O

Imipramine B-drug
and O
clonazepam B-drug
did O
not O
change O
fasting O
or O
overload O
glycemia O
. O

The O
concurrent O
administration O
of O
allopurinol B-drug
and O
ampicillin B-drug
increases O
substantially O
the O
incidence O
of O
rashes O
in O
patients O
receiving O
both O
drugs O
as O
compared O
to O
patients O
receiving O
ampicillin B-drug
alone O
. O

The O
initial O
dose O
of O
levorphanol B-drug
should O
be O
reduced O
by O
approximately O
50 O
% O
or O
more O
when O
it O
is O
given O
to O
patients O
along O
with O
another O
drug O
affecting O
respiration O
. O

Cerivastatin B-drug
plasma O
concentrations O
were O
also O
not O
affected O
by O
co-administration O
of O
digoxin B-drug
. O

Betaseron B-brand
administration O
to O
three O
cancer O
patients O
over O
a O
dose O
range O
of O
0.025 O
mg O
to O
2.2 O
mg O
led O
to O
a O
dose-dependent O
inhibition O
of O
antipyrine B-drug
elimination.14 O
The O
effect O
of O
alternate-day O
administration O
of O
0.25 O
mg O
of O
Betaseron B-brand
on O
drug O
metabolism O
in O
MS O
patients O
is O
unknown O
. O

- O
Acetohydroxamic B-drug
acid I-drug
( O
e.g. O
, O
Lithostat B-brand
) O
or O

Indinavir B-drug
is O
metabolized O
by O
CYP3A4 O
. O

Plasma O
was O
analyzed O
for O
tolbutamide B-drug
, O
and O
urine O
was O
analyzed O
for O
tolbutamide B-drug
and O
its O
two O
metabolites O
, O
4-hydroxytolbutamide B-drug_n
and O
carboxytolbutamide B-drug_n
by O
means O
of O
HPLC O
. O

No O
clinically O
relevant O
drug-drug O
interactions O
have O
been O
observed O
with O
drugs O
likely O
to O
be O
co-administered O
with O
anidulafungin B-drug
. O

Nelfinavir B-drug
is O
metabolized O
in O
proof O
by O
C.P.A O
. O

. O

Curariform B-brand
muscle I-brand
relaxants I-brand
( O
eg O
, O
tubocurarine B-drug
) O
and O
other O
drugs O
, O
including O
ether O
, O
succinylcholine B-drug
, O
gallamine B-drug
, O
decamethonium B-drug
and O
sodium B-drug
citrate I-drug
, O
potentiate O
the O
neuromuscular O
blocking O
effect O
and O
should O
be O
used O
with O
extreme O
caution O
in O
patients O
being O
treated O
with O
Coly-Mycin B-brand
M I-brand
Parenteral O
. O

The O
MPTP-induced B-drug
neuronal O
damage O
produced O
a O
tolerance O
to O
the O
disruptive O
effects O
of O
amphetamine B-drug
and O
a O
supersensitivity O
to O
the O
disruptive O
effects O
of O
apomorphine B-drug
in O
rats O
responding O
in O
a O
schedule O
controlled O
paradigm O
. O

Since O
chronic O
dosing O
is O
required O
for O
therapeutic O
efficacy O
of O
antipsychotics B-group
, O
future O
studies O
should O
focus O
on O
investigation O
of O
chronic O
dosing O
effects O
of O
these O
drugs O
in O
combination O
with O
PCP B-drug_n
. O

When O
carbamazepine B-drug
is O
added O
to O
aripiprazole B-drug
therapy O
, O
aripiprazole B-drug
dose O
should O
be O
doubled O
. O

Effect O
of O
Probenecid B-drug
: O
Probenecid B-drug
is O
a O
blocker O
of O
renal O
tubular O
secretion O
. O

Post-marketing O
reports O
of O
changes O
in O
prothrombin O
measures O
have O
been O
received O
among O
patients O
on O
concomitant O
warfarin B-drug
and O
esomeprazole B-drug
therapy O
. O

To O
determine O
whether O
probenecid B-drug
has O
a O
direct O
effect O
on O
the O
distribution O
of O
cloxacillin B-drug
, O
the O
elimination O
and O
distribution O
of O
cloxacillin B-drug
was O
studied O
in O
six O
patients O
, O
five O
lacking O
kidney O
function O
and O
one O
with O
a O
partially O
impaired O
renal O
function O
, O
in O
the O
presence O
or O
absence O
of O
probenecid B-drug
. O

Accordingly O
, O
diazepam B-drug
and O
fluvoxamine B-drug
should O
not O
ordinarily O
be O
co-administered O
. O

A O
potential O
interaction O
between O
oral O
miconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O

Calcium B-drug
Supplements/Antacids B-group

Fluoxetine B-drug
and O
its O
active O
metabolite O
, O
norfluoxe-tine O
, O
have O
long O
half-lives O
( O
4 O
to O
16 O
days O
for O
norfluoxetine B-drug_n
) O
, O
that O
may O
affect O
strategies O
during O
conversion O
from O
one O
drug O
to O
the O
other O
. O

In O
vitro O
displacement O
studies O
with O
highly O
protein-bound O
drugs O
such O
as O
furosemide B-drug
, O
propranolol B-drug
, O
captopril B-drug
, O
nicardipine B-drug
, O
pravastatin B-drug
, O
glyburide B-drug
, O
warfarin B-drug
, O
phenytoin B-drug
, O
acetylsalicylic B-drug
acid I-drug
, O
tolbutamide B-drug
, O
and O
metformin B-drug
showed O
no O
influence O
on O
the O
extent O
of O
nateglinide B-drug
protein O
binding O
. O

In O
those O
patients O
in O
whom O
renal O
insufficiency O
was O
documented O
, O
however O
, O
the O
recommendation O
to O
lower O
the O
dose O
of O
allopurinol B-drug
was O
not O
followed O
. O

Serum O
potassium O
levels O
and O
cardiac O
function O
should O
be O
closely O
monitored O
and O
any O
deficit O
promptly O
corrected O
. O

More O
specific O
applications O
of O
the O
assay O
of O
thio O
compounds O
in O
urine O
allow O
development O
of O
selective O
methods O
that O
may O
be O
useful O
for O
biological O
monitoring O
. O

. O

In O
a O
small O
( O
n=30 O
) O
combination O
study O
of O
ARAVA B-brand
with O
methotrexate B-drug
, O
a O
2- O
to O
3-fold O
elevation O
in O
liver O
enzymes O
was O
seen O
in O
5 O
of O
30 O
patients O
. O

In O
the O
absence O
of O
formal O
clinical O
drug O
interaction O
studies O
, O
caution O
should O
be O
exercised O
when O
administering O
TAXOL B-brand
concomitantly O
with O
known O
substrates O
or O
inhibitors O
of O
the O
cytochrome O
P450 O
isoenzymes O
CYP2C8 O
and O
CYP3A4 O
. O

pentoxifylline B-drug
; O

and O
clinical O
implications O
. O

Sedative/hypnotics B-group
: O
midazolam B-drug
, O
triazolam B-drug

Other O
kits O
, O
such O
as O
the O
Coat-A-Count O
RIA O
Kit O
, O
may O
be O
used O
. O

The O
effects O
, O
if O
any O
, O
on O
the O
pituitary-gonadal O
axis O
in O
premenopausal O
women O
are O
unknown O
. O

The O
clinical O
significance O
of O
this O
increase O
in O
doxazosin B-drug
AUC O
is O
unknown O
. O

Ketoconazole B-drug
: O
Potential O
interaction O
of O
Ketoconazole B-drug
and O
Isoniazid B-drug
may O
exist O
. O

Close O
supervision O
and O
careful O
adjustment O
of O
dosage O
are O
required O
when O
Anafranil B-brand
is O
administered O
with O
anticholinergic B-group
or O
sympathomimetic B-group
drugs I-group
. O

Prolonged O
recovery O
time O
may O
occur O
if O
barbiturates B-group
and/or O
narcotics B-group
are O
used O
concurrently O
with O
ketamine B-drug
. O

It O
was O
observed O
that O
contortrostatin B-drug_n
had O
a O
dramatic O
effect O
on O
the O
tyrosine O
phosphorylation O
status O
of O
several O
proteins O
in O
T24 O
human O
bladder O
cancer O
cells O
, O
including O
robust O
induction O
of O
phosphorylation O
of O
proteins O
in O
the O
range O
of O
120-140 O
kDa O
. O

The O
safety O
and O
efficacy O
of O
AMEVIVE B-brand
in O
pediatric O
patients O
have O
not O
been O
studied O
. O

Coadministration O
of O
glyburide B-drug
with O
doses O
higher O
than O
40 O
mg O
valdecoxib B-drug
( O
e.g. O
, O
40 O
mg O
BID O
) O
have O
not O
been O
studied O
. O

The O
dextrorotatory O
isomer O
, O
on O
the O
other O
hand O
, O
had O
effects O
similar O
to O
those O
of O
PCP B-drug_n
in O
both O
species O
. O

Antacids B-group
increase O
the O
rate O
of O
absorption O
of O
pseudoephedrine B-drug
, O
while O
kaolin B-drug
decreases O
it O
. O

Thyroid B-group
hormone I-group
activity O
may O
also O
be O
enhanced O
. O

Ritonavir B-drug

Methotrexate B-drug
Renal O
tubular O
transport O
of O
methotrexate B-drug
may O
be O
inhibited O
by O
concomitant O
administration O
of O
ciprofloxacin B-drug
, O
potentially O
leading O
to O
increased O
plasma O
levels O
of O
methotrexate B-drug
. O

A O
number O
of O
drugs O
, O
including O
ethacrynic B-drug
acid I-drug
, O
have O
been O
shown O
to O
displace O
warfarin B-drug
from O
plasma O
protein O
; O

Milk O
, O
milk O
products O
, O
and O
calcium-rich B-drug
foods O
or O
drugs O
may O
impair O
the O
absorption O
of O
EMCYT B-brand
. O

Anticoagulants B-group
: O
Combination O
hormonal B-group
contraceptives I-group
may O
increase O
or O
decrease O
the O
effects O
of O
coumarin B-group
derivatives I-group
. O

Concomitant O
administration O
of O
gemfibrozil B-drug
with O
Targretin B-brand
capsules O
is O
not O
recommended O
. O

No O
formal O
drug-drug O
interaction O
studies O
have O
been O
performed O
. O

Therefore O
, O
indomethacin B-drug
and O
diflunisal B-drug
should O
not O
be O
used O
concomitantly O
. O

Drug O
interaction O
studies O
with O
SUSTIVA B-brand
and O
these O
imidazole O
and O
triazole B-group
antifungals I-group
have O
not O
been O
conducted B-group
. I-group

In O
addition O
, O
administration O
of O
Sonata B-brand
to O
a O
patient O
taking O
another O
drug O
that O
is O
highly O
protein O
bound O
should O
not O
cause O
transient O
increase O
in O
free O
concentrations O
of O
the O
other O
drug O
. O

When O
taken O
orally O
, O
imidazole B-group
compounds I-group
like O
ketoconazole B-drug
may O
enhance O
the O
anticoagulant O
effect O
of O
coumarin-like B-group
drugs O
. O

Anticholinergic B-group
agents I-group
may O
affect O
gastrointestinal O
absorption O
of O
various O
drugs O
, O
such O
as O
slowly O
dissolving O
dosage O
forms O
of O
digoxin B-drug
; O

However O
, O
no O
clinically O
or O
statistically O
significant O
differences O
in O
prothrombin O
time O
ratio O
or O
warfarin B-drug
enantiomer O
pharmacokinetics O
were O
observed O
in O
a O
small O
study O
of O
7 O
healthy O
males O
who O
received O
both O
warfarin B-drug
and O
lomefloxacin B-drug
under O
steady-state O
conditions O
. O

All O
of O
these O
also O
resolved O
, O
2 O
with O
continuation O
of O
both O
drugs O
and O
3 O
after O
discontinuation O
of O
leflunomide B-drug
. O

Optimal O
designs O
for O
the O
individual O
and O
joint O
exposure O
general O
logistic O
regression O
models O
. O

The O
following O
drug O
interactions O
have O
been O
reported O
with O
etomidate B-drug
. O

The O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
and O
pulsatile O
choroidal O
blood O
flow O
were O
measured O
using O
the O
paraaminohippurate O
method O
, O
the O
inulin O
method O
and O
a O
laser O
interferometric O
measurement O
of O
fundus O
pulsation O
amplitude O
, O
respectively O
. O

Potassium-sparing B-group
diuretics I-group
such O
as O
spironolactone B-drug
, O
triamterene B-drug
, O
or O
amiloride B-drug
, O
or O
potassium B-drug
supplements O
should O
be O
given O
only O
for O
documented O
hypokalemia O
, O
and O
then O
with O
caution O
, O
since O
they O
may O
lead O
to O
a O
significant O
increase O
of O
serum O
potassium O
. O

Optimal O
conditions O
, O
kinetics O
, O
equilibrium O
, O
and O
the O
mechanism O
of O
this O
acid-catalyzed O
ethanolysis O
are O
reported O
. O

No O
formal O
drug O
interaction O
studies O
have O
been O
conducted O
. O

Dosage O
of O
the O
anticoagulant B-group
may O
require O
reduction O
in O
order O
to O
maintain O
satisfactory O
therapeutic O
hypoprothrombinemia O
. O

The O
histology O
of O
the O
liver O
was O
altered O
in O
the O
three O
groups O
which O
were O
submitted O
to O
treatment O
with O
the O
hydroalcoholic O
solutions O
, O
with O
quantitative O
and O
qualitative O
differences O
between O
the O
groups O
. O

The O
following O
laboratory O
tests O
have O
been O
found O
to O
be O
abnormal O
in O
a O
few O
patients O
receiving O
baclofen B-drug
: O
increased O
SGOT O
, O
elevated O
alkaline O
phosphatase O
, O
and O
elevation O
of O
blood O
sugar O
. O

Analgesic O
effects O
of O
antihistaminics B-group
. O

Combined O
effects O
may O
induce O
serious O
cardiac O
arrhythmias O
. O

Oral O
Hypoglycemic B-group
Agents I-group
: O
In O
one O
study O
, O
flurbiprofen B-drug
was O
given O
to O
adult O
diabetics O
who O
were O
already O
receiving O
glyburide B-drug
( O
n=4 O
) O
, O
metformin B-drug
( O
n=2 O
) O
chlorpropamide B-drug
with O
phenformin B-drug
( O
n= O
3 O
) O
or O
glyburide B-drug
with O
phenformin B-drug
( O
n=6 O
) O
. O

CELEBREX B-brand
should O
be O
introduced O
at O
the O
lowest O
recommended O
dose O
in O
patients O
receiving O
fluconazole B-drug
. O

The O
incidence O
of O
akathisia O
in O
clinical O
trials O
of O
the O
weekly O
dosage O
schedule O
was O
greater O
( O
8.5 O
% O
, O
4/47 O
patients O
) O
when O
prochlorperazine B-drug
was O
administered O
on O
the O
same O
day O
as O
CAMPTOSAR B-brand
than O
when O
these O
drugs O
were O
given O
on O
separate O
days O
( O
1.3 O
% O
, O
1/80 O
patients O
) O
. O

To O
avoid O
phenytoin B-drug
intoxication O
, O
appropriate O
adjustment O
of O
the O
anticonvulsant B-group
should O
be O
made O
. O

however O
, O
no O
significant O
difference O
in O
the O
maximum O
concentration O
in O
plasma O
or O
the O
area O
under O
the O
concentration-time O
curve O
from O
time O
zero O
to O
8 O
h O
was O
observed O
. O

Orlistat-Orlistat B-drug
may O
decrease O
the O
absorption O
of O
vitamin B-group
K I-group
. O

However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-drug
with O
vitamin B-group
D I-group
have O
not O
been O
investigated O
. O

Clinical O
Comment O

When O
used O
in O
therapeutic O
doses O
, O
azithromycin B-drug
had O
a O
modest O
effect O
on O
the O
pharmacokinetics O
of O
atorvastatin B-drug
, O
carbamazepine B-drug
, O
cetirizine B-drug
, O
didanosine B-drug
, O
efavirenz B-drug
, O
fluconazole B-drug
, O
indinavir B-drug
, O
midazolam B-drug
, O
rifabutin B-drug
, O
sildenafil B-drug
, O
theophylline B-drug
( O
intravenous O
and O
oral O
) O
, O
triazolam B-drug
, O
trimethoprim/sulfamethoxazole B-drug
or O
zidovudine B-drug
. O

HMG-CoA B-group
Reductase I-group
Inhibitors I-group
: O
lovastatin B-drug
, O
simvastatin B-drug
WARNING O
potential O
for O
serious O
reactions O
such O
as O
risk O
of O
myopathy O
including O
rhabdomyolysis O
. O

In O
addition O
to O
established O
drug O
interactions O
, O
there O
may O
be O
potential O
pharmacokinetic O
interactions O
between O
nevirapine B-drug
and O
other O
drug O
classes O
that O
are O
metabolized O
by O
the O
cytochrome O
P450 O
system O
. O

Drug/Laboratory O
Test O
Interaction O
After O
treatment O
with O
ampicillin B-drug
, O
a O
false-positive O
reaction O
for O
glucose O
in O
the O
urine O
may O
occur O
with O
copper B-drug_n
sulfate I-drug_n
tests O
( O
Benedicts O
solution O
, O
Fehlings O
solution O
, O
or O
Clinitest O
tablets O
) O
but O
not O
with O
enzyme O
based O
tests O
such O
as O
Clinistix O
and O
Glucose O
Enzymatic O
Test O
Strip O
USP O
. O

Lovastatin B-drug
therapy O
has O
not O
been O
associated O
with O
bleeding O
or O
with O
changes O
in O
prothrombin O
time O
in O
patients O
not O
taking O
anticoagulants B-group
. O

. O

Note O
: O

Olanzapine B-drug
, O
a O
thienobenzodiazepine B-group
derivative I-group
, O
is O
a O
second B-group
generation I-group
( I-group
atypical I-group
) I-group
antipsychotic I-group
agent I-group
which O
has O
proven O
efficacy O
against O
the O
positive O
and O
negative O
symptoms O
of O
schizophrenia O
. O

Other O
Drug O
Interaction O
Information O
Digoxin B-drug
: O
Studies O
in O
healthy O
volunteers O
have O
shown O
that O
TIKOSYN B-brand
does O
not O
affect O
the O
pharmacokinetics O
of O
digoxin B-drug
. O

Caution O
, O
however O
, O
is O
advised O
in O
patients O
taking O
tricyclic B-group
antidepressants I-group
which O
can O
affect O
the O
metabolism O
and O
uptake O
of O
circulating O
amines O
. O

Propanolol B-drug
: O
The O
pharmacokinetics O
of O
almotriptan B-drug
were O
not O
affected O
by O
coadministration O
of O
propranolol B-drug
. O

phase O
1 O
( O
days O
1-6 O
) O
: O
cisapride B-drug
10 O
mg O
4 O
times/day O
; O

Compared O
with O
risperidone B-drug
, O
olanzapine B-drug
has O
also O
been O
reported O
to O
decrease O
overall O
treatment O
costs O
, O
despite O
the O
several-fold O
higher O
daily O
acquisition O
cost O
of O
the O
drug O
. O

Alcohol B-drug
- O
Although O
LEXAPRO B-brand
did O
not O
potentiate O
the O
cognitive O
and O
motor O
effects O
of O
alcohol B-drug
in O
a O
clinical O
trial O
, O
as O
with O
other O
psychotropic B-group
medications I-group
, O
the O
use O
of O
alcohol B-drug
by O
patients O
taking O
LEXAPRO B-brand
is O
not O
recommended O
. O

- O
When O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
is O
used O
concurrently O
with O
anion-exchange B-group
resins I-group
( O
e.g O
. O
cholestryramine B-drug
) O
, O
an O
interval O
of O
at O
least O
2 O
hours O
should O
be O
maintained O
between O
the O
two O
medicines O
, O
since O
the O
absorption O
of O
Bezalip B-brand
or O
Bezalip B-brand
retard I-brand
is O
impaired O

However O
, O
initial O
dose O
modification O
is O
generally O
not O
necessary O
. O

4 O
. O

These O
behavioral O
changes O
may O
be O
related O
with O
the O
negative O
symptoms O
of O
schizophrenia O
. O

metronidazole B-drug
; O

Other O
quinolones B-group
have O
demonstrated O
moderate O
to O
marked O
interference O
with O
the O
metabolism O
of O
caffeine B-drug
, O
resulting O
in O
a O
reduced O
clearance O
, O
a O
prolongation O
of O
plasma O
half-life O
, O
and O
an O
increase O
in O
symptoms O
that O
accompany O
high O
levels O
of O
caffeine B-drug
. O

METHODS O
: O
From O
the O
beginning O
of O
the O
experiment O
, O
rats O
were O
given O
10 O
weekly O
subcutaneous O
injections O
of O
AOM B-drug_n
( O
7.4 O
mg/kg O
body O
weight O
) O
and O
subcutaneous O
injections O
of O
bombesin B-drug_n
( O
40 O
microg/kg O
body O
weight O
) O
every O
other O
day O
, O
and O
from O
week O
16 O
, O
intraperitoneal O
injections O
of O
verapamil B-drug
( O
10 O
or O
20 O
mg/kg O
body O
weight O
) O
every O
other O
day O
until O
the O
end O
fo O
the O
experiment O
in O
week O
45 O
. O

The O
exact O
length O
of O
time O
may O
vary O
and O
is O
dependent O
upon O
the O
particular O
MAO B-group
inhibitor I-group
being O
used O
, O
the O
length O
of O
time O
it O
has O
been O
administered O
, O
and O
the O
dosage O
involved O
. O

Saquinavir B-drug

Interaction O
between O
lomefloxacin B-drug
and O
cyclosporine B-drug
has O
not O
been O
studied O
. O

this O
effect O
is O
at O
least O
balanced O
by O
decreased O
metabolism O
of O
corticosteroids B-group
. O

Although O
metoclopramide B-drug
may O
increase O
the O
bioavailability O
of O
levodopa B-drug
by O
increasing O
gastric O
emptying O
, O
metoclopramide B-drug
may O
also O
adversely O
affect O
disease O
control O
by O
its O
dopamine O
receptor O
antagonistic O
properties O
. O

This O
increase O
may O
be O
clinically O
relevant O
as O
adverse O
experiences O
are O
related O
to O
dose O
and O
exposure O
; O

Increasing O
the O
indinavir B-drug
dose O
to O
1000 O
mg O
every O
8 O
hours O
does O
not O
compensate O
for O
the O
increased O
indinavir B-drug
metabolism O
due O
to O
efavirenz B-drug
. O

Internal O
application O
of O
InsP B-drug_n
( I-drug_n
3 I-drug_n
) I-drug_n
( O
100 O
microM O
) O
increased O
intracellular O
Ca O
( O
2+ O
) O
concentration O
( O
[ O
Ca O
( O
2+ O
) O
] O
( O
i O
) O
) O
and O
activated O
the O
Ca O
( O
2+ O
) O
-dependent O
K O
( O
+ O
) O
current O
. O

If O
treatment O
with O
inhibitors O
of O
CYP3A4 O
activity O
( O
such O
as O
ketoconazole B-drug
, O
intraconazole B-drug
, O
ritonavir B-drug
, O
indinavir B-drug
, O
saquinavir B-drug
, O
erythromycin B-drug
, O
etc O
. O
) O
is O
indicated O
, O
reduction O
of O
the O
budesonide B-drug
dose O
should O
be O
considered O
. O

The O
core O
temperature O
returned O
to O
normal O
300 O
minutes O
after O
ethanol B-drug
. O

St. O
Johns O
wort O
( O
Hypericum O
perforatum O
) O
may O
decrease O
SPRYCEL B-brand
plasma O
concentrations O
unpredictably O
. O

In O
a O
multiple O
dose O
study O
of O
theophylline B-drug
( O
400 O
mg O
once O
daily O
for O
3 O
days O
) O
and O
cetirizine B-drug
( O
20 O
mg O
once O
daily O
for O
3 O
days O
) O
, O
a O
16 O
% O
decrease O
in O
the O
clearance O
of O
cetirizine B-drug
was O
observed O
. O

Patients O
taking O
low-dose O
aspirin B-brand
plus O
ibuprofen B-drug
were O
not O
studied O
. O

These O
drugs O
include O
the O
thiazides B-group
and O
other O
diuretics B-group
, O
corticosteroids B-group
, O
phenothiazines B-group
, O
thyroid B-group
products I-group
, O
estrogens B-group
, O
oral O
contraceptives B-group
, O
phenytoin B-drug
, O
nicotinic B-drug
acid I-drug
, O
sympathomimetics B-group
, O
calcium B-group
channel I-group
blocking I-group
drugs I-group
, O
and O
isoniazid B-drug
. O

However O
, O
iloprost B-drug
has O
the O
potential O
to O
increase O
the O
hypotensive O
effect O
of O
vasodilators B-group
and O
antihypertensive B-group
agents I-group
. O

Specific O
drug O
interaction O
studies O
have O
not O
been O
conducted O
with O
Levofloxacin B-drug
. O

These O
reports O
are O
more O
frequent O
for O
women O
who O
use O
only O
a O
single O
method O
of O
contraception O
. O

Other O
medicines O
- O
Although O
certain O
medicines O
should O
not O
be O
used O
together O
at O
all O
, O
in O
other O
cases O
two O
different O
medicines O
may O
be O
used O
together O
even O
if O
an O
interaction O
might O
occur O
. O

Most O
cases O
of O
serious O
or O
fatal O
adverse O
events O
involving O
Levo-Dromoran B-brand
reported O
to O
the O
manufacturer O
or O
the O
FDA O
have O
involved O
either O
the O
administration O
of O
large O
initial O
doses O
or O
too O
frequent O
doses O
of O
the O
drug O
to O
nonopioid O
tolerant O
patients O
, O
or O
the O
simultaneous O
administration O
of O
levorphanol B-drug
with O
other O
drugs O
affecting O
respiration O
. O

The O
results O
demonstrate O
a O
high O
degree O
of O
stereoselectivity O
in O
the O
behavioral O
effects O
of O
NANM B-drug_n
. O

cimetidine B-drug
) O
and O
many O
that O
are O
substrates O
for O
P450 O
2D6 O
( O
many O
other O
antidepressants B-group
, O
phenothiazines B-group
, O
and O
the O
Type O
1C O
antiarrhythrnics O
propatenone O
and O
flecainide B-drug
) O
. O

The O
effect O
of O
ceftibuten B-drug
on O
the O
pharmacokinetics O
of O
theophylline B-drug
administered O
orally O
has O
not O
been O
investigated O
. O

Cimetidine B-drug

As O
a O
precursor O
to O
this O
effort O
, O
optimal O
and O
minimal O
experimental O
designs O
for O
the O
case O
in O
which O
a O
single O
compound O
is O
administered O
have O
also O
been O
developed O
. O

co-administration O
of O
phenobarbital B-drug
may O
produce O
a O
synergistic O
anticonvulsant O
action O
. O

If O
used O
in O
combination O
with O
saquinavir B-drug
hard O
gelatin O
capsules O
at O
the O
recommended O
dose O
of O
600 O
mg O
tid O
, O
no O
dose O
adjustments O
are O
needed O
. O

It O
is O
not O
known O
if O
REGRANEX B-brand
Gel O
interacts O
with O
other O
topical O
medications O
applied O
to O
the O
ulcer O
site O
. O

. O

Possible O
extrarenal O
mechanisms O
of O
action O
of O
cimetidine B-drug
on O
verografine B-drug
and O
iodamide B-drug
transport O
were O
also O
examined O
. O

[ O
Hippocampus O
as O
interaction O
sites O
between O
cerebral O
memory O
systems O
] O
Most O
of O
the O
current O
theories O
assume O
that O
there O
are O
multiple O
forms O
of O
memory O
that O
are O
supported O
by O
separate O
brain O
systems O
and O
have O
different O
characteristics O
. O

Concomitant O
medications O
should O
be O
carefully O
assessed O
. O

Periodic O
measurement O
of O
serum O
PSA O
levels O
may O
also O
be O
considered O
. O

Recovery O
of O
hoof O
twitch O
from O
50 O
% O
to O
75 O
% O
took O
7.7 O
+/- O
0.7 O
min O
for O
atracurium B-drug
alone O
and O
11.5 O
+/- O
2.7 O
min O
for O
atracurium B-drug
plus O
gentamycin B-drug
( O
P O
= O
0.03 O
) O
. O

Inducers O
and O
Inhibitors O
of O
Hepatic O
Metabolism O
: O
Rifampin B-drug
reduced O
plasma O
concentrations O
of O
carvedilol B-drug
by O
about O
70 O
% O
. O

The O
fluoroquinolones B-group
are O
a O
rapidly O
growing O
class O
of O
antibiotics B-group
with O
a O
broad O
spectrum O
of O
activity O
against O
gram-negative O
and O
some O
gram-positive O
aerobic O
bacteria O
. O

The O
mean O
minimum O
lithium B-drug
concentration O
increased O
15 O
% O
and O
the O
renal O
clearance O
of O
lithium B-drug
was O
decreased O
by O
19 O
% O
during O
this O
period O
of O
concomitant O
drug O
administration O
. O

Because O
escitalopram B-drug
is O
metabolized O
by O
multiple O
enzyme O
systems O
, O
inhibition O
of O
a O
single O
enzyme O
may O
not O
appreciably O
decrease O
escitalopram B-drug
clearance O
. O

Some O
drugs/substances B-drug
are O
known O
to O
accelerate O
the O
metabolism O
of O
amiodarone B-drug
by O
stimulating O
the O
synthesis O
of O
CYP3A4 B-drug
( O
enzyme O
induction O
) O
. O

Methotrexate B-drug
: O
HUMIRA B-brand
has O
been O
studied O
in O
rheumatoid O
arthritis O
patients O
taking O
concomitant O
MTX B-drug
. O

Some O
disorders O
unrelated O
to O
sexual O
dysfunction O
( O
eg O
, O
esophageal O
motility O
dysfunction O
) O
may O
also O
respond O
to O
sildenafil B-drug
. O

Co-administration O
of O
irbesartan B-drug
reduced O
aliskiren B-drug
Cmax O
up O
to O
50 O
% O
after O
multiple O
dosing O
. O

Disulfiram B-drug
alone O
in O
the O
rat O
s O
diet O
did O
not O
lead O
to O
such O
tumors O
. O

Platelet O
function O
studies O
in O
these O
patients O
have O
not O
demonstrated O
any O
significant O
platelet O
dysfunction O
. O

Paclitaxel B-drug
- O
In O
one O
report O
, O
L-glutamine B-drug
at O
a O
dose O
of O
10 O
grams O
three O
times O
daily O
, O
given O
24 O
hours O
after O
receiving O
paclitaxel B-drug
, O
appeared O
to O
prevent O
the O
development O
of O
myalgia O
and O
arthralgia O
, O
adverse O
reactions O
of O
paclitaxel B-drug
. O

METH B-drug
induced O
arc O
mRNA O
in O
layers O
IV O
and O
VI O
of O
the O
cortex O
which O
dopamine O
receptor O
are O
localized O
to O
. O

Carbamazepine B-drug
: O
Tiagabine B-drug
had O
no O
effect O
on O
the O
steady-state O
plasma O
concentrations O
of O
carbamazepine B-drug
or O
its O
epoxide O
metabolite O
in O
patients O
with O
epilepsy O
. O

Table O
4 O
Potential O
Drug O
Interactions O
: O
Use O
With O
Caution O
, O
Dose O
Adjustment O
of O
Co-administered O
Drug O
May O
Be O
Needed O
due O
to O
Possible O
Decrease O
in O
Clinical O
Effect O

Other O
concomitant O
therapies O
: O
In O
clinical O
trials O
, O
the O
safety O
profile O
in O
subjects O
treated O
with O
Acamprosate B-drug
concomitantly O
with O
anxiolytics B-group
, O
hypnotics B-group
and O
sedatives B-group
( O
including O
benzodiazepines B-group
) O
, O
or O
non-opioid B-group
analgesics I-group
was O
similar O
to O
that O
of O
subjects O
taking O
placebo O
with O
these O
concomitant O
medications O
. O

could O
not O
be O
confirmed O
for O
cloxacillin B-drug
in O
patients O
lacking O
kidney O
function O
. O

Drugs O
Metabolized O
by O
P450 O
2D6 O
- O
The O
biochemical O
activity O
of O
the O
drug O
metabolizing O
isozyme O
cytochrome O
P450 O
2D6 O
( O
debrisoquin O
hydroxylase O
) O
is O
reduced O
in O
a O
subset O
of O
the O
caucasian O
population O
( O
about O
7-10 O
% O
of O
caucasians O
are O
so O
called O
poor O
metabolizers O
) O
; O

Chapter O
3 O
covers O
pharmacology O
( O
pharmacokinetics O
, O
pharmacodynamics O
and O
potency O
, O
and O
clinical O
implications O
) O
. O

Slow-channel B-group
calcium I-group
blockers I-group
, O
such O
as O
verapamil B-drug
, O
diltiazem B-drug
and O
nifedipine B-drug
, O
inhibit O
platelet O
activation O
in O
vitro O
, O
and O
decrease O
platelet O
adhesion O
intravascularly O
. O

Magnesium- B-drug
and O
aluminum-containing B-drug
antacids B-group
, O
administered O
concomitantly O
with O
lomefloxacin B-drug
, O
significantly O
decreased O
the O
bioavailability O
( O
48 O
% O
) O
of O
lomefloxacin B-drug
. O

The O
regulation O
of O
topoisomerases O
is O
no O
doubt O
complex O
and O
multifaceted O
and O
is O
probably O
accomplished O
through O
redundancy O
at O
many O
control O
levels O
. O

clinical O
significance O
unknown O
. O

Narcotic B-group
analgesics I-group
may O
potentiate O
the O
hypotensive O
effects O
of O
clonidine B-drug
. O

Lithium B-drug
: O
Valdecoxib B-drug
40 O
mg O
BID O
for O
7 O
days O
produced O
significant O
decreases O
in O
lithium B-drug
serum O
clearance O
( O
25 O
% O
) O
and O
renal O
clearance O
( O
30 O
% O
) O
with O
a O
34 O
% O
higher O
serum O
exposure O
compared O
to O
lithium B-drug
alone O
. O

Clidinium B-drug
may O
decrease O
the O
effect O
of O
phenothiazines B-group
, O
levodopa B-drug
, O
and O
ketoconazole B-drug
. O

Coadministration O
of O
valdecoxib B-drug
( O
40 O
mg O
BID O
( O
day O
1 O
) O
and O
40 O
mg O
QD O
( O
days O
2-7 O
) O
) O
with O
glyburide B-drug
( O
10 O
mg O
glyburide B-drug
BID O
) O
resulted O
in O
21 O
% O
increase O
in O
glyburide B-drug
AUC0-12 O
and O
a O
16 O
% O
increase O
in O
glyburide B-drug
Cmax O
leading O
to O
a O
16 O
% O
decrease O
in O
glucose O
AUC0-24 O
. O

Nursing O
Mothers O
Fulvestrant B-drug
is O
found O
in O
rat O
milk O
at O
levels O
significantly O
higher O
( O
approximately O
12-fold O
) O
than O
plasma O
after O
administration O
of O
2 O
mg/kg O
. O

dose-dependently O
increased O
the O
number O
of O
defecation O
episodes O
and O
induced O
a O
soft O
and O
watery O
stool O
in O
cecectomized O
rats O
. O

Intermediate O
doses O
of O
( B-drug_n
+ I-drug_n
) I-drug_n
-NANM I-drug_n
or O
PCP B-drug_n
produced O
transient O
increases O
in O
FI O
responding O
in O
monkeys O
and O
sustained O
increases O
in O
FI O
responding O
in O
pigeons O
; O

The O
basal O
colonic O
fluid O
contents O
and O
transits O
were O
the O
same O
in O
cecectomized O
and O
in O
control O
rats O
. O

Co-administration O
of O
nelfinavir B-drug
at O
steady-state O
with O
a O
single O
dose O
of O
azithromycin B-drug
( O
2 O
x O
600 O
mg O
tablets O
) O
results O
in O
increased O
azithromycin B-drug
serum O
concentrations O
. O

Drug O
monitoring O
may O
be O
of O
assistance O
in O
detecting O
alterations O
in O
carbamazepine B-drug
plasma O
concentrations O
. O

Pharmacological/Pharmacodynamic O
Interactions O
with O
Carbamazepine B-drug
Concomitant O
administration O
of O
carbamazepine B-drug
and O
lithium B-drug
may O
increase O
the O
risk O
of O
neurotoxic O
side O
effects O
. O

The O
reaction O
after O
norepinephrine B-drug
remained O
the O
same O
in O
both O
groups O
of O
experiments O
. O

CONCLUSIONS O
: O
Olanzapine B-drug
demonstrated O
superior O
antipsychotic O
efficacy O
compared O
with O
haloperidol B-drug
in O
the O
treatment O
of O
acute O
phase O
schizophrenia O
, O
and O
in O
the O
treatment O
of O
some O
patients O
with O
first-episode O
or O
treatment-resistant O
schizophrenia O
. O

In O
clinical O
studies O
where O
patients O
were O
on O
chronic O
theophylline B-drug
therapy O
, O
lomefloxacin B-drug
had O
no O
measurable O
effect O
on O
the O
mean O
distribution O
of O
theophylline B-drug
concentrations O
or O
the O
mean O
estimates O
of O
theophylline B-drug
clearance O
. O

No O
cases O
of O
rhabdomyolysis O
were O
reported O
in O
this O
trial O
. O

No O
information O
is O
available O
about O
the O
use O
of O
butorphanol B-drug
concurrently O
with O
MAO B-group
inhibitors I-group
. O

Cromolyn B-drug
sodium I-drug
alone O
in O
doses O
up O
to O
540 O
mg/kg/day O
( O
approximately O
340 O
times O
the O
maximum O
recommended O
daily O
inhalation O
dose O
in O
adults O
on O
a O
mg/m2 O
basis O
) O
did O
not O
cause O
significant O
increases O
in O
resorptions O
or O
major O
malformations O
. O

Caution O
is O
advised O
in O
patients O
receiving O
chronic O
concomitant O
therapy O
. O

Methamphetamine B-drug
, O
like O
MPTP B-drug_n
, O
produced O
depletions O
of O
striatal O
dopamine O
but O
these O
actions O
were O
potentiated O
by O
pargyline B-drug
pretreatment O
. O

Amiodarone B-drug
is O
metabolized O
to O
desethylamiodarone B-drug
by O
the O
cytochrome O
P450 O
( O
CYP450 O
) O
enzyme O
group O
, O
specifically O
cytochromes O
P450 O
3A4 O
( O
CYP3A4 O
) O
and O
CYP2C8 O
. O

Tricyclic B-group
antidepressants I-group
have O
been O
reported O
to O
blunt O
the O
hypotensive O
effect O
of O
systemic O
clonidine B-drug
. O

Antagonism O
was O
never O
observed O
. O

When O
coadministered O
with O
SUSTIVA B-brand
in O
treatment-naive O
patients O
, O
the O
recommended O
dose O
of O
atazanavir B-drug
is O
300 O
mg O
with O
ritonavir B-drug
100 O
mg O
and O
SUSTIVA B-brand
600 O
mg O
( O
all O
once O
daily O
) O
. O

Vaccines B-group
: O
Patients O
on O
corticosteroid B-group
therapy O
may O
exhibit O
a O
diminished O
response O
to O
toxoids O
and O
live O
or B-group
inactivated I-group
vaccines I-group
due O
to O
inhibition O
of O
antibody O
response O
. O

In O
rats O
, O
simultaneous O
ingestion O
of O
disulfiram B-drug
and O
nitrite B-drug
in O
the O
diet O
for O
78 O
weeks O
has O
been O
reported O
to O
cause O
tumors O
, O
and O
it O
has O
been O
suggested O
that O
disulfiram B-drug
may O
react O
with O
nitrites B-group
in O
the O
rat O
stomach O
to O
form O
a O
nitrosamine O
, O
which O
is O
tumorigenic O
. O

Therophylline O
: O
A O
recent O
study O
has O
shown O
that O
concomitan O
administration O
of O
isoniazid B-drug
and O
theophylline B-drug
may O
cause O
elevated O
plasma O
levels O
of O
theophylline B-drug
, O
and O
in O
some O
instances O
a O
slight O
decrease O
in O
the O
elimination O
of O
isoniazid B-drug
. O

and O
( O
ii O
) O
the O
effects O
of O
filipin B-drug_n
were O
more O
efficiently O
inhibited O
by O
added O
cholesterol O
, O
the O
major O
membrane O
sterol O
in O
human O
cells O
, O
whereas O
the O
effects O
of O
amphotericin B-drug
B I-drug
were O
more O
efficiently O
inhibited O
by O
ergosterol O
, O
the O
major O
membrane O
sterol O
in O
yeast O
. O

Some O
of O
the O
cases O
of O
collapse/respiratory O
arrest/cardiac O
arrest O
during O
initial O
treatment O
occurred O
in O
patients O
who O
were O
being O
administered O
benzodiazepines B-group
; O

For O
comprehensive O
information O
concerning O
laboratory O
test O
alterations O
associated O
with O
ritonavir B-drug
, O
physicians O
should O
refer O
to O
the O
complete O
prescribing O
information O
for O
NORVIR B-brand
( O
ritonavir B-drug
) O
. O

The O
effects O
of O
ERGOMAR B-brand
may O
be O
potentiated O
by O
triacetyloleandomycin B-drug
which O
inhibits O
the O
metabolism O
of O
ergotamine B-drug
. O

In O
2 O
separate O
studies O
, O
fexofenadine B-drug
hydrochloride I-drug
120 O
mg O
twice O
daily O
( O
240 O
mg O
total O
daily O
dose O
) O
was O
co-administered O
with O
either O
erythromycin B-drug
500 O
mg O
every O
8 O
hours O
or O
ketoconazole B-drug
400 O
mg O
once O
daily O
under O
steady-state O
conditions O
to O
healthy O
volunteers O
( O
n=24 O
, O
each O
study O
) O
. O

HMG-CoA B-group
Reductase I-group
inhibitors I-group
: O
lovastatin B-drug
, O
simvastatin B-drug

Oral O
Anticoagulants B-group
CAUTION O
SHOULD O
BE O
EXERCISED O
WHEN O
COUMARIN B-group
ANTICOAGULANTS I-group
ARE O
GIVEN O
IN O
CONJUNCTION O
WITH O
TRICOR B-brand
. O

High-dose O
cisplatin B-drug
with O
sodium B-drug
thiosulfate I-drug
protection O
. O

There O
have O
been O
rare O
reports O
of O
significant O
respiratory O
depression O
, O
stupor O
and/or O
hypotension O
with O
the O
concomitant O
use O
of O
loxapine B-drug
and O
lorazepam B-drug
. O

The O
latter O
might O
arise O
from O
a O
hit O
in O
a O
genetically O
initiated O
cell O
, O
the O
result O
of O
which O
is O
a O
more O
rapid O
progression O
in O
tumor O
type O
. O

Coadministration O
of O
CRIXIVAN B-brand
and O
other O
drugs O
that O
inhibit O
CYP3A4 O
may O
decrease O
the O
clearance O
of O
indinavir B-drug
and O
may O
result O
in O
increased O
plasma O
concentrations O
of O
indinavir B-drug
. O

Probenecid B-drug
: O
As O
with O
other O
b-lactams B-group
, O
the O
renal O
excretion O
of O
cephalexin B-drug
is O
inhibited O
by O
probenecid B-drug
. O

Therefore O
, O
when O
using O
doses O
of O
Trileptal B-brand
greater O
than O
1200 O
mg/day O
during O
adjunctive O
therapy O
, O
a O
decrease O
in O
the O
dose O
of O
phenytoin B-drug
may O
be O
required O
. O

oxolinic B-drug
acid I-drug
; O

Cimetidine B-drug
: O
In O
the O
presence O
of O
cimetidine B-drug
at O
300 O
mg O
QID O
( O
N=12 O
) O
the O
mean O
apparent O
oral O
clearance O
of O
gabapentin B-drug
fell O
by O
14 O
% O
and O
creatinine O
clearance O
fell O
by O
10 O
% O
. O

The O
toxicity O
of O
cadmium O
, O
zinc B-drug
, O
and O
cadmium/zinc O
mixtures O
at O
concentrations O
ranging O
from O
10000 O
to O
10 O
microg/l O
was O
investigated O
. O

Vecuronium B-drug
: O
When O
used O
in O
the O
perioperative O
period O
, O
piperacillin B-drug
has O
been O
implicated O
in O
the O
prolongation O
of O
the O
neuromuscular O
blockade O
of O
vecuronium B-drug
. O

The O
agent O
was O
found O
to O
produce O
some O
inhibiting O
activity O
against O
hepatic O
microsomal O
7-ethoxycoumarine O
deethylase O
in O
male O
Wistar O
rats O
in O
vitro O
and O
in O
vivo O
experiments O
. O

Other O
strong O
inhibitors O
of O
CYP3A4 O
( O
itraconazole B-drug
) O
would O
be O
expected O
to O
have O
similar O
effects O
and O
need O
similar O
dose O
reductions O
; O

- O
a O
monoamine B-group
oxidase I-group
inhibitor I-group
( O
MAOI B-group
) O
such O
as O
isocarboxazid B-drug
( O
Marplan B-brand
) O
, O
tranylcypromine B-drug
( O
Parnate B-brand
) O
, O
or O
phenelzine B-drug
( O
Nardil B-brand
) O
; O

The O
mean O
percentage O
increase O
in O
the O
glipizide B-drug
AUC O
after O
fluconazole B-drug
administration O
was O
56.9 O
% O
( O
range O
: O
35 O
to O
81 O
) O
. O

A O
potential O
interaction O
between O
oral O
miconazole B-drug
and O
oral O
hypoglycemic B-group
agents I-group
leading O
to O
severe O
hypoglycemia O
has O
been O
reported O
. O

Additive O
adverse O
effects O
resulting O
from O
cholinergic O
blockade O
may O
occur O
when O
LEVSIN B-brand
is O
administered O
concomitantly O
with O
other O
antimuscarinics B-group
, O
amantadine B-drug
, O
haloperidol B-drug
, O
phenothiazines B-group
, O
monoamine B-group
oxidase I-group
( I-group
MAO I-group
) I-group
inhibitors I-group
, O
tricyclic B-group
antidepressants I-group
or O
some O
antihistamines B-group
. O

Additional O
drugs O
that O
are O
not O
recommended O
for O
coadministration O
with O
INVIRASE B-brand
and O
ritonavir B-drug
are O
included O
below O
. O

The O
physician O
is O
advised O
to O
monitor O
plasma O
levels O
of O
phenytoin B-drug
and O
to O
decrease O
the O
dose O
if O
necessary O
. O

Benazepril B-drug
, O
like O
other O
ACE B-group
inhibitors I-group
, O
has O
had O
less O
than O
additive O
effects O
with O
beta-adrenergic B-group
blockers I-group
, O
presumably O
because O
both O
drugs O
lower O
blood O
pressure O
by O
inhibiting O
parts O
of O
the O
renin-angiotensin O
system O

Fifteen O
to O
30 O
minutes O
of O
exposure O
to O
1.25 O
MAC O
isoflurane B-drug
or O
enflurane B-drug
had O
minimal O
effects O
on O
the O
duration O
of O
action O
of O
initial O
doses O
of O
NIMBEX B-brand
and O
therefore O
, O
no O
adjustment O
to O
the O
initial O
dose O
should O
be O
necessary O
when O
NIMBEX B-brand
is O
administered O
shortly O
after O
initiation O
of O
volatile O
agents O
. O

In O
vitro O
studies O
with O
several O
drugs O
which O
may O
be O
administered O
concomitantly O
showed O
that O
the O
extent O
of O
flecainide B-drug
binding O
to O
human O
plasma O
proteins O
is O
either O
unchanged O
or O
only O
slightly O
less O
. O

N-methyllevallorphan B-drug_n
( O
5 O
mg/kg O
, O
s.c. O
) O
completely O
antagonized O
the O
inhibitory O
effect O
of O
loperamide B-drug
and O
partly O
antagonized O
the O
effect O
of O
morphine B-drug
. O

At O
a O
median O
follow-up O
of O
33 O
months O
, O
the O
combination O
of O
ARIMIDEX B-brand
and O
tamoxifen B-drug
did O
not O
demonstrate O
any O
efficacy O
benefit O
when O
compared O
with O
tamoxifen B-drug
in O
all O
patients O
as O
well O
as O
in O
the O
hormone O
receptor-positive O
subpopulation O
. O

The O
effect O
of O
dofetilide B-drug
on O
the O
steady-state O
pharmacokinetics O
of O
digoxin B-drug
was O
evaluated O
in O
a O
randomized O
, O
double-blind O
study O
. O

increased O
platelet O
count O
; O

The O
effects O
of O
DCG-IV B-drug_n
and O
L-CCG-1 B-drug_n
upon O
phencyclidine B-drug_n
( O
PCP B-drug_n
) O
-induced O
locomotion O
and O
behavioral O
changes O
in O
mice O
. O

Serious O
anticholinergic O
symptoms O
( O
severe O
dry O
mouth O
, O
urinary O
retention O
, O
blurred O
vision O
) O
have O
been O
associated O
with O
elevations O
in O
the O
serum O
levels O
of O
tricyclic B-group
antidepressants I-group
when O
cimetidine B-drug
is O
added O
to O
the O
drug O
regimen O
. O

Concurrent O
use O
of O
butorphanol B-drug
with O
central B-group
nervous I-group
system I-group
depressants I-group
( O
e.g. O
, O
alcohol B-drug
, O
barbiturates B-group
, O
tranquilizers B-group
, O
and O
antihistamines B-group
) O
may O
result O
in O
increased O
central B-group
nervous I-group
system I-group
depressant I-group
effects O
. O

Atromid-S B-brand
may O
displace O
acidic O
drugs O
such O
as O
phenytoin B-drug
or O
tolbutamide B-drug
from O
their O
binding O
sites O
. O

- O
Corticosteroids B-group
, O
ACTH B-drug
: O
Intensified O
electrolyte O
depletion O
, O
particularly O
hypokalemia O

Because O
of O
the O
risk O
of O
serious O
ventricular O
arrhythmias O
and O
sudden O
death O
potentially O
associated O
with O
elevated O
plasma O
levels O
of O
thioridazine B-drug
, O
Duloxetine B-drug
and O
thioridazine B-drug
should O
not O
be O
co-administered O
. O

It O
is O
essentially O
completely O
metabolised O
, O
therefore O
little O
is O
excreted O
unchanged O
. O

Atazanavir B-drug

Alcohol B-drug
: O
In O
post-marketing O
experience O
, O
there O
have O
been O
rare O
reports O
of O
adverse O
neuropsychiatric O
events O
or O
reduced O
alcohol B-drug
tolerance O
in O
patients O
who O
were O
drinking O
alcohol B-drug
during O
treatment O
with O
WELLBUTRIN B-brand
. O

Such O
an O
interaction O
can O
potentially O
lead O
to O
higher O
free O
fractions O
of O
either O
tiagabine B-drug
or O
the O
competing O
drug O
. O

PROSTIN B-brand
E2 I-brand
may O
augment O
the O
activity O
of O
other O
oxytocic B-group
drugs I-group
. O

Single O
dose O
bioavailability O
studies O
in O
normal O
volunteers O
have O
failed O
to O
wshow O
an O
effect O
of O
aspirin B-brand
on O
ibuprofen B-drug
blood O
levels O
. O

Ergot O
derivatives O
: O
dihydroergotamine B-drug
, O
ergonovine B-drug
, O
ergotamine B-drug
, O
methylergonovine B-drug

fluoxetine B-drug
, O
fluvoxamine B-drug
, O
paroxetine B-drug
, O
sertraline B-drug
) O
. O

In O
vitro O
studies O
show O
significant O
inhibition O
of O
the O
formation O
of O
oxidized O
irbesartan O
metabolites O
with O
the O
known O
cytochrome O
CYP O
2C9 O
substrates/inhibitors O
sulphenazole B-drug
, O
tolbutamide B-drug
and O
nifedipine B-drug
. O

Other O
drugs O
that O
are O
specific O
substrates O
, O
inhibitors O
, O
or O
inducers O
of O
the O
enzyme O
system O
may O
have O
a O
significant O
impact O
on O
the O
efficacy O
and O
side O
effect O
profile O
of O
diltiazem B-drug
. O

[ O
Quantitative O
approach O
to O
treatment O
with O
incisive O
neuroleptics B-group
by O
therapeutic O
monitoring O
] O
; O
The O
problems O
encountered O
during O
the O
longterm O
treatment O
of O
psychotic O
patients O
with O
neuroleptics B-group
are O
illustrated O
by O
six O
typical O
case O
reports O
. O

The O
effect O
of O
BREVIBLOC B-drug
on O
the O
duration O
of O
succinylcholine-induced B-drug
neuromuscular O
blockade O
was O
studied O
in O
patients O
undergoing O
surgery O
. O

In O
treatment-experienced O
patients O
, O
available O
uncontrolled O
data O
suggest O
these O
agents O
contribute O
to O
regimen O
efficacy O
in O
NNRTI-na B-group
ve O
, O
treatment-experienced O
patients O
. O

While O
all O
the O
selective B-group
serotonin I-group
reuptake I-group
inhibitors I-group
( O
SSRIs B-group
) O
, O
e.g. O
, O
fluoxetine B-drug
, O
sertraline B-drug
, O
paroxetine B-drug
, O
and O
fluvoxamine B-drug
, O
inhibit O
P450 O
2D6 O
, O
they O
may O
vary O
in O
the O
extent O
of O
inhibition O
. O

Haloperidol B-drug
: O
Haloperidol B-drug
blocks O
dopamine O
receptors O
, O
thus O
inhibiting O
the O
central O
stimulant O
effects O
of O
amphetamines B-group
. O

No O
drug O
interactions O
have O
been O
reported O
between O
Prostin B-brand
VR I-brand
Pediatric I-brand
and O
the O
therapy O
standard O
in O
neonates O
with O
restricted O
pulmonary O
or O
systemic O
blood O
flow O
. O

Amiodarone B-drug
taken O
concomitantly O
with O
procainamide B-drug
for O
less O
than O
seven O
days O
increases O
plasma O
concentrations O
of O
procainamide B-drug
and O
n-acetyl O
procainamide B-drug
by O
55 O
% O
and O
33 O
% O
, O
respectively O
. O

In O
some O
patients O
, O
the O
administration O
of O
INDOCIN B-brand
can O
reduce O
the O
diuretic O
, O
natriuretic O
, O
and O
antihypertensive B-group
effects O
of O
loop O
, O
potassium-sparing O
, O
and O
thiazide B-group
diuretics I-group
. O

Improvements O
in O
general O
cognitive O
function O
seen O
with O
olanzapine B-drug
treatment O
in O
a O
1-year O
controlled O
study O
of O
patients O
with O
early-phase O
schizophrenia O
, O
were O
significantly O
greater O
than O
changes O
seen O
with O
either O
risperidone B-drug
or O
haloperidol B-drug
. O

Intravenous O
Pentamidine B-drug
: O
Treatment O
with O
HIVID B-drug
should O
be O
interrupted O
when O
the O
use O
of O
a O
drug O
that O
has O
the O
potential O
to O
cause O
pancreatitis O
is O
required O
. O

Studies O
to O
evaluate O
possible O
interactions O
between O
REVIA B-brand
and O
drugs O
other O
than O
opiates B-group
have O
not O
been O
performed O
. O

nalidixic B-drug
acid I-drug
; O

The O
findings O
suggest O
that O
the O
agent O
has O
slight O
effects O
on O
the O
tested O
activities O
. O

Drug O
Effect O

Aminosalicylic B-drug
acid I-drug
may O
decrease O
the O
amount O
of O
digoxin B-drug
( O
Lanoxin B-brand
, O
Lanoxicaps B-drug
) O
that O
gets O
absorbed O
into O
your O
body O
. O

Clinical O
Comment O

Quinidine B-drug
and O
procainamide O
doses O
should O
be O
reduced O
by O
one-third O
when O
either O
is O
administered O
with O
amiodarone B-drug
. O

However O
, O
halothane B-drug
anesthetic O
requirement O
( O
i.e. O
, O
MAC O
) O
was O
depressed O
in O
a O
dose-dependent O
fashion O
as O
much O
as O
56 O
% O
1-2 O
hours O
and O
as O
much O
as O
14 O
% O
5-6 O
hours O
after O
injection O
of O
ketamine B-drug
, O
50 O
mg/kg O
, O
im O
. O

CONCLUSIONS O
: O
The O
combination O
of O
CHOP O
plus O
HAART O
is O
feasible O
and O
may O
reduce O
the O
morbidity O
from O
OIs O
in O
HIV-NHL O
patients O
. O

The O
administration O
of O
local O
anesthetic B-group
solutions I-group
containing O
epinephrine B-drug
or O
norepinephrine B-drug
to O
patients O
receiving O
monoamine B-group
oxidase I-group
inhibitors I-group
or O
tricyclic B-group
antidepressants I-group
may O
produce O
severe O
, O
prolonged O
hypertension O
. O

Phenobarbital B-drug
: O
Decreases O
aspirin B-brand
effectiveness O
by O
enzyme O
induction O
. O

Orthostatic O
hypotension O
in O
patients O
taking O
clozapine B-drug
can O
, O
in O
rare O
cases O
( O
approximately O
1 O
case O
per O
3,000 O
patients O
) O
, O
be O
accompanied O
by O
profound O
collapse O
and O
respiratory O
and/or O
cardiac O
arrest O
. O

The O
use O
of O
dextromethorphan B-drug
hydrobromide I-drug
may O
result O
in O
additive O
CNS O
depressant O
effects O
when O
coadministered O
with O
alcohol B-drug
, O
antihistamines B-group
, O
psychotropics B-group
or O
other O
drugs O
that O
produce O
CNS O
depression O
. O

However O
, O
in O
vivo O
drug O
interaction O
studies O
of O
ketoconazole B-drug
with O
vitamin B-group
D I-group
have O
not O
been O
investigated O
. O

No O
inhibition O
of O
any O
of O
the O
other O
isoforms O
tested O
was O
observed O
at O
gabapentin B-drug
concentrations O
up O
to O
171 O
mg/mL O
( O
approximately O
15 O
times O
the O
Cmax O
at O
3600 O
mg/day O
) O
. O

Dose O
modification O
is O
recommended O
for O
patients O
who O
are O
also O
receiving O
a O
potent O
CYP O
3A4 O
inducer O
. O

Following O
a O
10 O
g O
bolus O
of O
AMICAR B-brand
, O
transient O
peak O
plasma O
concentrations O
of O
4.6 O
mMol/L O
or O
0.60 O
mg/mL O
have O
been O
obtained O
. O

Butalbital B-drug
, O
acetaminophen B-drug
and O
caffeine B-drug
may O
enhance O
the O
effects O
of O
: O
other O
narcotic B-group
analgesics O
, O
alcohol B-drug
, O
general O
anesthetics B-group
, O
tranquilizers B-group
such O
as O
chlordiazepoxide B-drug
, O
sedative-hypnotics B-group
, O
or O
other O
CNS B-group
depressants I-group
, O
causing O
increased O
CNS O
depression O
. O

Reduced O
efficacy O
and O
increased O
incidence O
of O
breakthrough O
bleeding O
and O
menstrual O
irregularities O
have O
been O
associated O
with O
concomitant O
use O
of O
rifampin B-drug
. O

Discontinuation O
of O
cimetidine B-drug
in O
well-controlled O
patients O
receiving O
tricyclic B-drug
antidepressants I-drug
and O
cimetidine B-drug
may O
decrease O
the O
plasma O
levels O
and O
efficacy O
of O
the O
antidepressants B-drug
. O

Nonsteroidal B-group
anti-inflammatory I-group
drugs I-group
have O
been O
reported O
to O
decrease O
the O
tubular O
secretion O
of O
methotrexate B-drug
and O
to O
potentiate O
its O
toxicity O
. O

Pharmacokinetic O
data O
indicate O
that O
oral O
ketoconazole B-drug
inhibits O
the O
metabolism O
of O
astemizole B-drug
, O
resulting O
in O
elevated O
plasma O
levels O
of O
astemizole B-drug
and O
its O
active O
metabolite O
desmethylastemizole B-drug_n
which O
may O
prolong O
QT O
intervals O
. O

Flurbiprofen B-drug
did O
not O
appear O
to O
affect O
the O
beta-blocker-mediated O
reduction O
in O
heart O
rate O
. O

In O
patients O
receiving O
HCTZ B-drug
alone O
, O
dofetilide B-drug
AUC O
increased O
by O
27 O
% O
and O
Cmax O
by O
21 O
% O
. O

descending O
epsilon O
and O
mu O
systems O
for O
beta-endorphin B-drug_n
and O
morphine B-drug
, O
respectively O
, O
are O
proposed O
. O

Both O
steady-state O
maximum O
concentration O
and O
AUC O
were O
dose O
proportional O
over O
the O
full O
dose O
range O
when O
assessed O
on O
day O
1 O
, O
as O
well O
as O
for O
the O
full O
duration O
of O
the O
study O
at O
steady O
state O
. O

Non-steroidal B-group
Anti-inflammatory I-group
Agents I-group
: O
In O
some O
patients O
with O
compromised O
renal O
function O
who O
are O
being O
treated O
with O
non-steroidal B-group
anti-inflammatory I-group
drugs I-group
, O
the O
co-administration O
of O
lisinopril B-drug
may O
result O
in O
a O
further O
deterioration O
of O
renal O
function O
. O

Drugs O
which O
may O
potentiate O
the O
release O
of O
neutrophils O
, O
such O
as O
lithium B-drug
, O
should O
be O
used O
with O
caution O
. O

bone O
density O
; O

Treatment O
with O
entacapone B-drug
coadministered O
with O
levodopa/dopa B-drug
decarboxylase B-group
inhibitor I-group
does O
not O
change O
these O
effects O
. O

Pimozide B-drug
and O
Celexa B-brand
- O
In O
a O
controlled O
study O
, O
a O
single O
dose O
of O
pimozide B-drug
2 O
mg O
co-administered O
with O
racemic O
citalopram B-drug
40 O
mg O
given O
once O
daily O
for O
11 O
days O
was O
associated O
with O
a O
mean O
increase O
in O
QTc O
values O
of O
approximately O
10 O
msec O
compared O
to O
pimozide B-drug
given O
alone O
. O

Oral O
Contraceptives B-group
: O
Multiple O
dose O
administration O
of O
tiagabine B-drug
( O
8 O
mg/day O
monotherapy O
) O
did O
not O
alter O
the O
pharmacokinetics O
of O
oral O
contraceptives B-group
in O
healthy O
women O
of O
childbearing O
age O
. O

The O
clinical O
significance O
of O
this O
property O
is O
unknown O
. O

Cephalosporins B-group
are O
known O
to O
occasionally O
induce O
a O
positive O
direct O
Coombs O
test O
. O

Loperamide B-drug
and O
morphine B-drug
( O
0.1 O
and O
1.0 O
mg/kg O
, O
s.c O
. O
) O

As O
with O
other O
cephalosporins B-group
, O
high O
concentrations O
of O
cefotetan B-drug
may O
interfere O
with O
measurement O
of O
serum O
and O
urine O
creatinine O
levels O
by O
Jaffe O
reaction O
and O
produce O
false O
increases O
in O
the O
levels O
of O
creatinine O
reported O
. O

Profound O
hypotensive O
episodes O
may O
occur O
when O
diazoxide B-drug
infection O
and O
hydralazine B-drug
are O
used O
concomitantly O
. O

However O
, O
concomitant O
administration O
of O
5 O
mg O
b.i.d O
. O
isradipine B-drug
and O
40 O
mg O
b.i.d O
. O

Two O
groups O
( O
SH/DA O
; O
SH/FA O
) O
were O
submitted O
to O
daily O
treatment O
with O
synthetic O
hydroalcoholic O
solutions O
containing O
ethanol B-drug
, O
methanol B-drug_n
, O
higher O
alcohols B-drug_n
and O
acetaldehyde B-drug_n
in O
the O
same O
proportions O
as O
those O
found O
in O
most O
common O
distilled O
and O
fermented O
alcoholic O
beverages O
; O

This O
interaction O
should O
be O
given O
consideration O
in O
patients O
taking O
VIOXX B-brand
concomitantly O
with O
ACE B-group
inhibitors I-group
. O

Esomeprazole B-drug
inhibits O
gastric O
acid O
secretion O
. O

Antihistamines B-group

Anesthetics B-group

Acetaminophen B-drug
: O
A O
report O
of O
severe O
acetaminophen B-drug
toxicity O
was O
reported O
in O
a O
patient O
receiving O
Isoniazid B-drug
. O

Interaction O
between O
glycine B-drug
and O
glutamate B-drug
in O
the O
development O
of O
spontaneous O
motility O
in O
chick O
embryos O
. O

The O
interaction O
was O
pharmacodynamic O
with O
no O
alteration O
of O
the O
pharmacokinetics O
of O
either O
drug O
. O

The O
pharmacokinetics O
of O
theophylline B-drug
were O
not O
altered O
. O

b O
This O
table O
is O
not O
all-inclusive O
. O

